

L10 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1301981 CAPLUS [Full-text](#)

DN 147:541713

TI Preparation of acylaminothiénylcarboxamides as insecticides, acaricides, nematocides, and molluscicides.

IN Jung, Pierre; Durieux, Patricia; Lutz, William; Maienfisch, Peter; Pitterna, Thomas; Renold, Peter; Zambach, Werner

PA Syngenta Participations A.-G., Switz.

SO PCT Int. Appl., 67pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007128410	A1	20071115	WO 2007-EP3626	20070425
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	GB 2006-8507	A	20060428		
	GB 2006-18907	A	20060925		
OS	MARPAT 147:541713				
GI					



I

AB Title compds. [I; A1, A2, A3 = CX, NX, N, O, S; X = H, halo, alkyl, CF3; R1, R2 = H, alkyl, alkylcarbonyl; G1, G2 = O, S; Q1 = (substituted) aryl, heteroaryl; Q2 = substituted Ph, 3-pyridyl], were prepared Thus, 5-aminothiophene-3-carboxylic acid [2,6-dimethyl-4-(1,2,2,2-tetrafluoro-1-trifluoromethylethyl)phenyl]amide (preparation given) and pyridine in THF at 0° were treated with 2-chloronicotinoyl chloride in CH2Cl2 and DMF followed by stirring to 45° to give 2-chloro-N-[4-[2,6-dimethyl-4-(1,2,2,2-tetrafluoro-1-trifluoromethylethyl)phenyl]carbamoyl]thiophen-2-yl]nicotinamide. The latter and other I at 200 ppm on cotton leaf disks gave >80% control of Spodoptera littoralis larvae after 3 days.

IT 956828-93-5P


RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylaminothiénylcarboxamides as insecticides, acaricides, nematocides, and molluscicides)

RN 956828-84-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[4-[[[2,6-dimethyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]-2-thienyl]-2,7-dimethyl- (CA INDEX NAME)



RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1176376 CAPLUS Full-text

DN 147:486429

TI Preparation of indazole compounds that inhibit one or more receptor, or non-receptor, tyrosine or serine/threonine kinase

IN Ericsson, Anna M.; Burchat, Andrew; Frank, Kristine E.; Calderwood, David J.; Abbott, Lily K.; Argiriadi, Maria A.; Borhani, David W.; Cusack, Kevin P.; Dixon, Richard W.; Gordon, Thomas D.; Mullen, Kelly D.; Talanian, Robert V.; Wu, Xiaoyun; Zhang, Xiaolei; Wang, Lu X.; Li, Biqin; Barberis, Claude E.; Wishart, Neil

PA Abbott Laboratories, USA

SO PCT Int. Appl., 266pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007117465	A2	20071018	WO 2007-US8307	20070402
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2007282101	A1	20071206	US 2007-731950	20070402
PRAI	US 2006-788553P	P	20060331		
OS	MARPAT 147:486429				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title indazoles I [R1 = H, benzyl substituted with OMe, (un)substituted alkyl, etc.; R3 = H, halo, NH2, OH, etc.; R4 = H or NH2; R5 = H, NH2, NO2, halo, etc.; R6 = H, alkoxy, alkyl, benzo[b]thienyl, etc.; R7 = H, halo, NH2, alkenyl, etc.] that inhibit one or more receptor, or non-receptor, tyrosine or S/T kinase, were prepared and formulated. Thus, reacting thiocarbamate II with 2-(pyridin-2-yl)ethylamine afforded 39% III. The exemplified compds. I inhibit either COT or MK2 at concns. of 50 µM or below.


IT 953401-99-5P 953402-03-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazoles that inhibit one or more receptor, or non-receptor, tyrosine or serine/threonine kinase)


RN 953401-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-amino-N-(7-benzo[b]thien-2-yl-1H-indazol-5-yl)-2-methyl- (CA INDEX NAME)



RN 953402-03-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(7-benzo[b]thien-2-yl-1H-indazol-5-yl)-2,7-dimethyl- (CA INDEX NAME)





L10 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1090237 CAPLUS Full-text

DN 147:406836

TI Preparation of pyridopyrimidine derivatives and their use as PDE4 inhibitors

IN Austin, Rupert; Bonnert, Roger; Hunt, Fraser; Nikitidis, Grigorios; Sangane, Hitesh; Sjö, Peter; Warner, Dan

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 21pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007/108750	A1	20070927	WO 2007-SE269	20070320
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2006-784855P	P	20060322		
	US 2007-884456P	P	20070111		
OS	MARPAT 147:406836				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [X = S, S(O), SO<sub>2</sub>, E = N, CE1; T = CO, SO<sub>2</sub>; W = (CH<sub>2</sub>)<sub>n</sub>; Y = (CH<sub>2</sub>)<sub>p</sub>; n, p = 0-1; m = 0-1; L = CH or N; when L = CH then J = NH; and when L = N then J is absent and T is bonded directly to L; R1 = (un)substituted alkyl, aryl, heteroaryl, etc.; G, E1 = H, halo, CN, etc.], useful in the treatment of a PDE4 mediated disease state, were prepared E.g., a multi-step synthesis of cis-II, starting from 2-chloro-5-fluoronicotinic acid, was given. Compds. I were tested in human PDE4B2 assay (data given for representative compds. I). For example, cis-II showed IC<sub>50</sub> of 4.59 nM. Pharmaceutical compns. comprising compound I alone or in combination with other therapeutic agents are claimed.

IT 950900-00-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridopyrimidine derivs. and their use as PDE4 inhibitors)

RN 950900-00-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[cis-4-[6-fluoro-1,4-dihydro-2,4-dioxo-1-(tetrahydro-2H-thiopyran-4-yl)pyrido[2,3-d]pyrimidin-3(2H)-yl]cyclohexyl]-2,7-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:733028 CAPLUS Full-text

DN 147:166332

TI Preparation of hetero-bicyclic carbamoyl pyrazolopyrimidine derivatives as metalloprotease inhibitors

IN Gallagher, Brian M.; Van Veldhuizen, Joshua; Wu, Xinyuan; Deng, Hongbo; Sucholeiki, Irving; Hochguertel, Matthias; Bluhm, Harald; Taveras, Arthur G.

PA Alantos Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 183pp., Cont.-in-part of U.S. Ser. No. 440,087.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007155737	A1	20070705	US 2006-602116	20061120
	US 2006293345	A1	20061228	US 2006-440087	20060522
	WO 2007139860	A2	20071206	WO 2007-US12343	20070522
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-683470P	P	20050520		
	US 2005-706465P	P	20050808		
	US 2005-734991P	P	20051109		
	US 2006-440087	A2	20060522		
	US 2006-602116	A	20061120		
OS	MARPAT 147:166332				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Hetero-bicyclic carbamoyl pyrazolopyrimidine derivs. I, wherein R1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, bicyclo-alkyl, hetero-bicyclo-alkyl, spiro-alkyl, spiro-heteroalkyl, aryl, heteroaryl, cycloalkyl fused aryl, heterocycloalkyl fused aryl, cycloalkyl fused heteroaryl, heterocycloalkyl fused heteroaryl, arylalkyl, heteroaryl-alkyl, cycloalkyl fused arylalkyl, heterocycloalkyl fused arylalkyl, cycloalkyl fused heteroaryl-alkyl, and heterocycloalkyl fused heteroaryl-alkyl; R2 is hydrogen, alkyl; R1 and R1 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S(O)<sub>x</sub>, (x = 0-2), substituted N; R3 is substituted N; and which is optionally substituted one or more times; Q is a 5- or 6-membered ring selected from the group consisting of aryl and heteroaryl; D is a member selected from the group consisting of substituted C and N; were prepared and used as metalloprotease inhibitors. Synthesis of compds. I is described in many examples. Thus, reacting the acid II with the corresponding amine (morpholine) afforded 60% III. Pharmaceutical

comps. comprising compound I in combination with therapeutic other agents are disclosed. Metalloprotease mediated disease is selected from the a MMP-3 mediated disease, a MMP-8 mediated disease, a MMP-12 mediated disease, a MMP-13 mediated disease, a ADAMTS-4 mediated disease and a ADAMTS-5 mediated disease. Hetero-bicyclic metalloprotease inhibiting compds. of the invention have ADAMTS-4 inhibitory activity of 1-20  $\mu$ M.

IT 943759-38-4P 943759-39-5P 943759-40-8P  
 943759-41-9P 943759-42-0P 943759-43-1P  
 943759-44-2P 943759-45-3P 943759-46-4P  
 943759-47-5P 943759-48-6P 943759-49-7P  
 943759-50-0P 943759-51-1P 943759-52-2P  
 943759-53-3P 943759-54-4P 943759-55-5P  
 943759-56-6P 943759-57-7P 943759-58-8P  
 943759-59-9P 943759-60-2P 943759-61-3P  
 943759-62-4P 943759-63-5P 943759-64-6P  
 943759-65-7P 943759-66-8P 943759-67-9P  
 943759-68-0P 943759-69-1P 943759-70-4P  
 943759-71-5P 943759-72-6P 943759-73-7P  
 943759-74-8P 943759-75-9P 943759-76-0P  
 943759-77-1P 943759-78-2P 943759-79-3P  
 943759-80-6P 943759-81-7P 943759-82-8P  
 943759-83-9P 943759-84-0P 943759-85-1P  
 943759-86-2P 943759-87-3P 943759-88-4P  
 943759-89-5P 943759-90-8P 943759-91-9P  
 943759-92-0P 943759-93-1P 943759-94-2P  
 943759-95-3P 943759-96-4P 943759-97-5P  
 943759-98-6P 943759-99-7P 943760-00-7P  
 943760-01-8P 943760-02-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterobicyclic carbamoyl pyrazolopyrimidine derivs. as metalloprotease inhibitors)

RN 943759-38-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(4-morpholinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943759-39-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[(cyclohexylamino)carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-

yl|carbonyl|amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-40-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[4-fluorophenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-41-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2,4-dichlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-42-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-43-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-44-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[4-methylphenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-45-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(3-pyridinylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-46-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[3-(hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-47-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-48-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 943759-49-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[4-methoxyphenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-50-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(2-thiazolylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-51-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(methylphenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-52-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(1H-pyrazol-3-ylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-53-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[4-(methoxycarbonyl)phenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-54-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(2,3-dihydro-1H-indol-1-yl)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-55-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-56-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-57-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-58-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(3-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-59-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methylphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-60-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(3-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-61-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-62-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-63-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943759-64-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(1,3-benzodioxol-5-yl)methyl]amino]carbonyl]-3-[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-65-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-66-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-aminophenyl)methyl]amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-67-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-pyridinylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-68-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 943759-69-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclopropylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-70-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclohexylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-71-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclohexylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-72-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-73-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-74-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-75-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dimethylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-76-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(1,2,3,4-tetrahydro-1-isoquinolinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-77-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943759-78-2 CAPLUS


CN Benzoic acid, 4-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)



RN 943759-79-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]sulfonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-80-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(benzoylamino)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-81-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylsulfonyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-82-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(phenylamino)carbonyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-83-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-84-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-85-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(1-pyrrolidinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-86-2 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943759-87-3 CAPLUS

CN Benzoic acid, 4-[3-[3-[[ (2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3-oxopropyl]- (CA INDEX NAME)




RN 943759-88-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-(aminosulfonyl)-N5-[[ (3,4-difluorophenyl)methyl]- (CA INDEX NAME)



RN 943759-89-5 CAPLUS

CN Benzoic acid, 4-[[[3-[[ (2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)






RN 943759-90-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(3-hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-91-9 CAPLUS

CN Benzoic acid, 4-[(1S)-1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-92-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]amino]carbonyl]-3-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-93-1 CAPLUS

CN Benzoic acid, 4-[(1S)-1-[[[3-[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-94-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3,5,7-tricarboxamide, N5-[(3,4-difluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-(2H-tetrazol-5-yl)-1H-inden-1-yl]-N3-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 943759-95-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3,5,7-tricarboxamide, N5-[(3,4-

difluorophenyl)methyl]-N3-(2-fluorophenyl)-N7-[(1S)-1-[3-methyl-4-(2H-tetrazol-5-yl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-96-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 2,3-dihydro-1-[[[5-[[[3-methoxyphenyl]amino]carbonyl]-3-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-97-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[2-chlorophenyl]amino]carbonyl]-5-[[[3-(trifluoromethoxy)phenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-98-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-99-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluoro-4-methylphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-00-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(cyclopentylmethyl)amino]carbonyl]-3-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-01-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[(cycloheptylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-02-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chloro-4-methoxyphenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 943760-02-0P 943760-04-1P 943760-05-2P  
 943760-07-4P 943760-08-5P 943760-09-6P  
 943760-10-9P 943760-11-0P 943760-12-1P  
 943760-13-2P 943760-14-3P 943760-15-4P  
 943760-16-5P 943760-17-6P 943760-19-8P  
 943760-21-2P 943760-27-8P 943760-29-0P  
 943760-31-4P 943760-33-6P 943760-35-8P  
 943760-38-1P 943760-40-5P 943760-42-7P  
 943760-44-9P 943760-46-1P 943760-48-3P  
 943760-49-4P 943760-50-7P 943760-51-8P  
 943760-52-9P 943760-53-0P 943760-54-1P  
 943760-55-2P 943760-56-3P 943760-58-5P  
 943760-60-9P 943760-61-0P 943760-62-1P  
 943760-63-2P 943760-64-3P 943760-65-4P  
 943760-66-5P 943760-67-6P 943760-68-7P  
 943760-69-8P 943760-70-1P 943760-71-2P  
 943760-72-3P 943760-73-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterobicyclic carbamoyl pyrazolopyrimidine derivs. as metalloprotease inhibitors)

RN 943760-03-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943760-04-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-

yl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-05-2 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(4-morpholinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943760-07-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-iodo-, methyl ester (CA INDEX NAME)



RN 943760-08-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-iodo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-09-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-10-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3,5-dicarboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, 5-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-11-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3,7-dicarboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-, 7-methyl ester (CA INDEX NAME)






RN 943760-12-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-[[2-(2-chlorophenyl)amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 943760-13-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-[[2-(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 943760-14-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(3-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-2,3-dihydro-4-methyl]-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-15-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methylphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-16-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-17-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(3-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-19-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943760-21-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-[[[2-chlorophenyl]amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]- (CA INDEX NAME)




RN 943760-27-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-methyl-, methyl ester (CA INDEX NAME)



RN 943760-29-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-2,7-dicarboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-, 2-methyl ester (CA INDEX NAME)



RN 943760-31-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-33-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-35-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-38-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-4-methyl-1H-inden-1-yl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943760-40-5 CAPLUS

CN Benzoic acid, 4-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943760-42-7 CAPLUS


CN Benzoic acid, 4-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 943760-44-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-46-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-48-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-49-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 943760-50-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-[[[(2-chlorophenyl)amino]sulfonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]- (CA INDEX NAME)




RN 943760-51-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]sulfonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.





RN 943760-52-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-sulfo-, 7-methyl ester (CA INDEX NAME)



RN 943760-53-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(1,1-dimethylethoxy)carbonyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-54-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-amino-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-55-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(benzoylamino)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-56-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(phenylsulfonyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-58-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylamino)carbonyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-60-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-61-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-62-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-aminophenyl)methyl]amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-63-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-pyridinylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-64-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-65-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclopropylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-66-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclohexylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-67-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[(cyclohexylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-68-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-69-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-70-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-71-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dimethylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-72-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(1,2,3,4-tetrahydro-1-isoquinolinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-73-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.





L10 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:733023 CAPLUS Full-text  
 DN 147:166331  
 TI Preparation of amide containing heterobicyclic metalloprotease inhibitors  
 IN Steeneck, Christoph; Gege, Christian; Richter, Frank; Kroth, Heiko;  
 Hochguertel, Matthias; Essers, Michael; Van Veldhuizen, Joshua; Nolte,  
 Bert; Gallagher, Brian; Feuerstein, Tim; Schneider, Matthias; Arndt,  
 Torsten; Deng, Hongbo; Biesinger, Ralf; Wu, Xinyuan; Bluhm, Harald;  
 Sucholeiki, Irving; Taveras, Arthur G.  
 PA Alantos Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 1030pp., Cont.-in-part of U.S. Ser. No. 440,087.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007155738	A1	20070705	US 2006-602140	20061120
	US 2006293345	A1	20061228	US 2006-440087	20060522
	WO 2007139856	A2	20071206	WO 2007-US12337	20070522
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-683470P	P	20050520		
	US 2005-706465P	P	20050808		
	US 2005-734991P	P	20051109		
	US 2006-440087	A2	20060522		
	US 2006-602140	A	20061120		
OS	MARPAT 147:166331				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl; or NR1R2 = 3-8 membered ring containing carbon atoms and optionally a heteroatom selected from O, S(O)x or (un)substituted NH (wherein x = 0-2); R3 = NR2OR21; R20 = H, alkyl; R21 = (un)substituted bicyclic or tricyclic fused ring system wherein at least one ring is partially saturated; Q = 5-6 membered ring selected from (un)substituted aryl or heteroaryl; D = CR22, N; R22 = H, OH, halo, etc.] that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors. Synthesis of compounds I is described in many examples. Thus, reacting the acid II with the corresponding amine (preparation of both intermediates is provided) afforded 40% III. Compounds I have a MMP-13 inhibition activity (IC50) ranging from below 0.1 nM to about 20 µM, and

typically, from about 0.2 nM to about 2  $\mu$ M. Pharmaceutical compns. comprising compound I alone or in combination with therapeutic other agents are disclosed.


IT 916204-53-0P 916204-59-6P 916205-05-5P  
 916205-09-9P 916205-16-8P 916205-17-9P  
 916205-22-6P 916205-23-7P 916205-24-8P  
 916205-25-9P 916205-52-2P 916205-53-3P  
 916205-54-4P 916205-55-5P 916205-56-6P  
 916205-57-7P 916205-58-8P 916205-63-5P  
 916205-64-6P 916205-65-7P 916206-24-1P  
 916206-25-2P 916206-26-3P 916206-27-4P  
 916206-28-5P 916206-29-6P 916206-41-2P  
 916206-46-7P 916206-47-8P 916206-50-3P  
 916206-51-4P 916206-52-5P 916206-53-6P  
 916206-64-9P 916206-65-0P 916206-66-1P  
 916206-71-3P 916206-73-0P 916206-81-0P  
 916206-86-5P 916206-87-6P 916206-88-7P  
 916206-89-8P 916206-90-1P 916206-91-2P  
 916206-92-3P 916207-04-0P 916207-05-1P  
 916207-06-2P 916207-07-3P 916207-33-5P  
 916207-34-6P 916207-35-7P 916207-51-7P  
 916207-52-8P 916207-53-9P 916207-54-0P  
 916207-97-1P 916208-94-1P 916209-70-6P  
 916209-74-0P 916209-75-1P 916209-76-2P  
 916209-77-3P 916209-78-4P 943760-03-0P  
 943760-04-1P 943760-05-2P 943760-09-6P  
 943760-14-3P 943760-15-4P 943760-16-5P  
 943760-17-6P 943760-31-4P 943760-35-8P  
 943760-38-1P 943760-44-9P 943760-46-1P  
 943760-48-3P 943760-49-4P 943760-54-1P  
 943837-36-3P 943837-95-4P 943838-18-4P  
 943838-19-5P 943838-21-9P 943838-22-0P  
 943838-51-5P 943838-53-7P 943839-01-6P  
 943839-04-1P 943839-10-9P 943841-59-6P  
 943841-60-9P 943841-61-0P 943841-64-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 916204-53-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrzolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916204-59-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-05-5 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916205-09-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916205-16-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916205-17-9 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl-, methyl ester (CA INDEX NAME)




RN 916205-22-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-(6-cyano-2,3-dihydro-1,1-dioxidobenzo[b]thien-3-yl)-3-fluoro- (CA INDEX NAME)



RN 916205-23-7 CAPLUS


CN Benzo[b]thiophene-6-carboxylic acid, 3-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, 1,1-dioxide (CA INDEX NAME)



RN 916205-24-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-cyano-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-25-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-52-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-53-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-54-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-55-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-56-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-57-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916205-58-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916205-63-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916205-64-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 916205-65-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-chloro-5-[[[3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-24-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-25-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-26-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-27-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-2-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-28-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-29-6 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916206-41-2 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-46-7 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]-, methyl ester (CA INDEX NAME)




RN 916206-47-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]-, methyl ester (CA INDEX NAME)




RN 916206-50-3 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]-, methyl ester (CA INDEX NAME)




RN 916206-51-4 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-52-5 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916206-53-6 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916206-64-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-65-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-66-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916206-71-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916206-73-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-bromo-N5,N7-bis[(4-fluoro-3-methylphenyl)methyl]- (CA INDEX NAME)



RN 916206-81-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-86-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyrimidinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-87-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-hydroxy-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-88-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-bromo-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916206-89-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(aminocarbonyl)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CH<sub>2</sub>

RN 916206-90-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-91-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-92-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-04-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 916207-05-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 916207-06-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(2,2,3,3-tetrafluoro-2,3-

dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-07-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-33-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-34-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-35-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-51-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-52-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-53-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A






RN 916207-54-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-97-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[4-fluoro-3-methylphenyl]methyl]amino]carbonyl]-3-nitropyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-94-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916209-70-6 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916209-74-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-bromo-3-hydroxyphenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-75-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(aminocarbonyl)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-76-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-dichloro-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-77-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-78-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-hydroxy-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-03-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-04-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-05-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(4-morpholinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-09-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-14-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(3-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-15-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methylphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-16-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-17-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(3-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-31-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[[[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-35-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[[[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-38-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-44-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 943760-46-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-methyl ester (CA INDEX NAME)




Absolute stereochemistry.



RN 943760-48-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-49-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-54-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[(3-amino-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl)carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 943837-36-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro-, hydrazide (CA INDEX NAME)




RN 943837-95-4 CAPLUS

CN Alanine, N-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl)carbonyl]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 943838-18-4 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl)carbonyl]amino]methyl-, methyl ester (CA INDEX NAME)




RN 943838-19-5 CAPLUS

CN Benzoic acid, 3-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 943838-21-9 CAPLUS

CN Benzoic acid, 4-[2-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]ethyl]-, methyl ester (CA INDEX NAME)



RN 943838-22-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943838-51-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-53-7 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(2-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943839-01-8 CAPLUS


CN Glycine, N-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-(CA INDEX NAME)



RN 943839-04-1 CAPLUS

CN L-Alanine, N-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 943839-10-9 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 7-[[[(1S)-5-carboxy-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-, 2-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN    943841-59-6    CAPLUS

CN    1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN    943841-60-9    CAPLUS

CN    1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943841-61-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Me

RN 943841-64-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-[[[5-[[[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-1-oxopropyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




—OBu-t

IT 916205-06-6P 916205-08-8P 916205-10-2P  
 916205-11-3P 916205-12-4P 916205-13-5P  
 916205-26-0P 916205-41-9P 916205-42-0P  
 916205-43-1P 916205-44-2P 916205-45-3P  
 916206-12-7P 916206-13-8P 916206-14-9P  
 916206-34-3P 916206-36-5P 916206-37-6P  
 916206-38-7P 916206-40-1P 916206-49-0P  
 916206-72-9P 916207-67-5P 916207-68-6P  
 916207-91-5P 916207-92-6P 916207-93-7P  
 916207-95-9P 916207-99-3P 916208-00-9P  
 916208-01-0P 916208-09-8P 916208-10-1P  
 916208-11-2P 916208-12-3P 916208-13-4P  
 916208-14-5P 916208-15-6P 916208-16-7P  
 916208-20-3P 916208-21-4P 916208-23-6P  
 916208-24-7P 916208-25-8P 916208-26-9P  
 916208-27-0P 916208-28-1P 916208-38-3P  
 916208-39-4P 916208-40-7P 916208-44-1P  
 916208-45-2P 916208-46-3P 916208-47-4P  
 916208-48-5P 916208-70-3P 916208-73-6P  
 916208-77-0P 916208-78-1P 916208-93-0P  
 916208-95-2P 916208-97-4P 916208-98-5P  
 916209-05-7P 916209-06-8P 916209-07-9P  
 916209-08-0P 916209-09-1P 916209-10-4P  
 916209-19-3P 916209-23-9P 916209-24-0P  
 916209-25-1P 916209-26-2P 916209-33-1P  
 916209-34-2P 916209-37-5P 916209-41-1P  
 916209-45-5P 916209-46-6P 916209-47-7P  
 916209-64-8P 916209-84-2P 916209-89-7P  
 916209-90-0P 916209-91-1P 916209-92-2P  
 916214-78-3P 916214-82-9P 916214-83-0P  
 916214-84-1P 916214-86-3P 916214-94-3P  
 916215-05-9P 916215-06-0P 916215-07-1P  
 916215-08-2P 916215-09-3P 916215-10-6P  
 916215-11-7P 916215-12-8P 916215-13-9P  
 916215-14-0P 916215-15-1P 916215-16-2P








RN 916205-08-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 916205-10-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916205-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclohexylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 916205-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-methyl- (CA INDEX NAME)



RN 916205-13-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7,N7-dimethyl- (CA INDEX NAME)



RN 916205-26-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2,3-dihydro-1H-inden-1-yl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-41-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-42-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-43-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[(trans-4-(5-methyl-1,3,4-oxadiazol-2-yl)cyclohexyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916205-44-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916205-45-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916206-12-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-(3-methyl-1,2,4-oxadiazol-5-yl)cyclohexyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916206-13-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]cyclohexyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916206-14-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-(2-thiazolyl)cyclohexyl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 916206-34-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[1-(hydroxymethyl)bicyclo[2.2.2]oct-4-ylmethyl]- (CA INDEX NAME)




RN 916206-36-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[(4-fluorobicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 916206-37-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[1-[[[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




RN 916206-38-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[1-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




PAGE 1-A






RN 916206-40-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[(1-hydroxybicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)



RN 916206-49-0 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-72-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-bromo-5-[[[(4-fluoro-3-

methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-67-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-68-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 916207-91-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-


(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916207-92-6 CAPLUS

CN Benzo[b]thiophene-6-carboxylic acid, 3-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, 1,1-dioxide (CA INDEX NAME)




RN 916207-93-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916207-95-9 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916207-99-3 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916208-00-9 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-01-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-09-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-10-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-11-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-12-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-13-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-14-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-15-6 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916208-16-7 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916208-20-3 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 916208-21-4 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916208-23-6 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916208-24-7 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916208-25-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916208-26-9 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916208-27-0 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 916208-28-1 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 916208-38-3 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-39-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-40-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-44-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyrimidinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-45-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-hydroxy-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-46-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-bromo-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-47-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(aminocarbonyl)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-48-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-70-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-73-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-77-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-78-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-93-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-95-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-97-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916208-98-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-05-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-06-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-07-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-08-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-2-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-09-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-10-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-19-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-23-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916209-24-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-

(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-25-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-26-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-33-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-34-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,5-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-37-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-chloro-5-[[[3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-41-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-amino-7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916209-45-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[2,3-dihydro-1,1-dioxido-6-(2H-tetrazol-5-yl)benzo[b]thien-3-yl]-3-fluoro- (CA INDEX NAME)



RN 916209-46-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-4-methyl-5-(2H-tetrazol-5-yl)-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-47-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-(2H-tetrazol-5-yl)-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 916209-64-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)



RN 916209-84-2 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 916209-89-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-bromo-3-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-90-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(aminocarbonyl)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916209-91-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-dichloro-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-



yl|carbonyl|amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-92-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-hydroxy-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-78-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-82-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-83-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-84-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-86-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-[(2-amino-3,4-dioxo-1-cyclobuten-1-yl)amino]methyl]phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-94-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-fluoro-3-methylphenyl]methyl]amino]carbonyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-05-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-[(cyanoamino)iminomethyl]amino]phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-06-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-07-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-08-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-09-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-10-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-11-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-12-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-13-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-

(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-14-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-15-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-16-2 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(2-fluoro-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916215-17-3 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-18-4 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916215-19-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-[[[(cyanoamino)iminomethyl]amino]phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-20-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-21-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-22-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-23-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-24-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-25-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-26-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-27-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-28-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-29-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-30-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-fluoro-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-31-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[2-cyano-4-

pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-32-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-53-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-[[[(cyanoamino)iminomethyl]amino]phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-54-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-55-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-56-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-57-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(2-fluoro-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916215-69-5 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-[[[(cyanoamino)iminomethyl]amino]phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916215-70-8 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3,4-difluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)






RN 916215-72-0 CAPLUS

CN Bicyclo[2.2.1]heptane-1-carboxylic acid, 4-[[[5-[[[3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-73-1 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-fluoro-5-[[[4-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-74-2 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[(2-fluoro-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916215-75-3 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-76-4 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-77-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[1-[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-ylmethyl)- (CA INDEX NAME)




RN 916215-78-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-fluoro-N5-[(4-fluoro-3-methylphenyl)methyl]-N7-[1-[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-ylmethyl)- (CA INDEX NAME)




RN 916215-79-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-fluoro-N5-[(4-fluorophenyl)methyl]-N7-[[1-[[[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-yl]methyl]- (CA INDEX NAME)




RN 916215-97-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclohexylmethyl)-3-fluoro-N5-[(4-fluoro-3-methylphenyl)methyl]- (CA INDEX NAME)



RN 916215-98-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-(cyclohexylmethyl)-3-fluoro- (CA INDEX NAME)




RN 916216-15-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-16-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-17-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-18-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-19-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-20-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-21-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916216-22-3 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916216-23-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluorophenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)






RN 916216-24-5 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-25-6 CAPLUS

CN Benzoic acid, 4-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-26-7 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-27-8 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-28-9 CAPLUS

CN Benzoic acid, 4-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-29-0 CAPLUS

CN Benzoic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl-  
(CA INDEX NAME)




RN 916216-30-3 CAPLUS

CN Benzoic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl-  
(CA INDEX NAME)



RN 916216-31-4 CAPLUS


CN Benzoic acid, 4-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)



RN 943759-38-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(4-morpholinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-39-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[(cyclohexylamino)carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-40-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-41-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2,4-dichlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-42-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-43-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-44-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-methylphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-46-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(3-hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

O=C1C(=O)N2C(=O)N(C(=O)Nc3ccc(O)cc3)C(=O)N2C(=O)N1Cc1ccc(F)c(F)c1


CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[4-chlorophenyl]amino]carbonyl]-5-  
[[[3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-  
yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Cc1ccc(C(=O)Nc2ccc(Cl)cc2)c3c4c(c1)sc(=O)[nH]4c5nc6c(ncn6C(=O)NCCc7cc(F)c(F)cc7)c8ccccc85

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 943759-50-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(2-thiazolylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-51-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(methylphenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943759-52-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[2-oxo-2-phenylpropanamido]methyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

rbonyl]-3-[(1H-pyrazol-3-ylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-53-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-54-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-55-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-56-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-57-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-58-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(3-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-59-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methylphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-60-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(3-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-61-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-62-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-63-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-64-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(1,3-benzodioxol-5-yl)methyl]amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-65-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-68-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-69-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclopropylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-70-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclohexylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943759-71-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclohexylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 943759-72-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-73-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-74-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-75-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dimethylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-77-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943759-78-2 CAPLUS


CN Benzoic acid, 4-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)



RN 943759-79-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]sulfonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-80-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(benzoylamino)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-81-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(phenylsulfonyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-82-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylamino)carbonyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-83-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-84-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-85-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(1-pyrrolidinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943759-86-2 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943759-88-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-(aminosulfonyl)-N5-[[[(3,4-difluorophenyl)methyl]- (CA INDEX NAME)



RN 943759-90-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(3-hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-19-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943760-40-5 CAPLUS

CN Benzoic acid, 4-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943760-42-7 CAPLUS

CN Benzoic acid, 4-[[[3-[[2-chlorophenyl]amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 943760-51-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[2-chlorophenyl]amino]sulfonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.






RN 943760-55-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-(benzoylamino)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-56-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(phenylsulfonyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-58-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(phenylamino)carbonyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-60-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[(methylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-61-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-62-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-aminophenyl)methyl]amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-63-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-pyridinylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-64-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-65-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclopropylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-66-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(cyclohexylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-67-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[(cyclohexylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-68-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-69-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-70-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-71-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-dimethylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943760-72-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(1,2,3,4-tetrahydro-1-isoquinolinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-73-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-33-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-amino-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 943837-34-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-(dimethylamino)-2-oxoethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-35-2 CAPLUS




CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5,N7-bis[(3,4-difluorophenyl)methyl]-2-(2-thienyl)- (CA INDEX NAME)




RN    943837-37-4    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro-, 2-(2,2,2-trifluoroacetyl)hydrazide (CA INDEX NAME)



RN    943837-38-5    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro-, 2-(2,2,2-trifluoroethyl)hydrazide (CA INDEX NAME)




RN    943837-39-6    CAPLUS

CN    1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-

(CA INDEX NAME)


Absolute stereochemistry.



RN 943837-53-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-54-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[1H-indazol-5-ylmethyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943837-56-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[1H-indazol-6-ylmethyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-

dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-57-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-bis(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-59-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[1,3-benzodioxol-5-ylmethyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 943837-60-3P 943837-61-4P 943837-62-5P  
943837-64-7P 943837-65-8P 943837-66-9P  
943837-67-0P 943837-69-2P 943837-70-5P

943831-71-6F	943831-72-7F	943831-73-8F
943831-74-9F	943831-75-0F	943831-76-1F
943831-77-2F	943831-78-3F	943831-79-4F
943831-82-9F	943831-83-0F	943831-84-1F
943831-85-2F	943831-86-3F	943831-87-4F
943831-91-6F	943831-92-1F	943831-93-2F
943831-94-3F	943831-96-5F	943831-97-6F
943831-98-7F	943831-99-8F	943838-00-4F
943838-02-6F	943838-03-7F	943838-04-8F
943838-05-9F	943838-06-0F	943838-07-1F
943838-08-2F	943838-09-3F	943838-10-6F
943838-11-7F	943838-12-8F	943838-13-9F
943838-14-0F	943838-15-1F	943838-16-2F
943838-22-1F	943838-24-2F	943838-25-3F
943838-26-4F	943838-27-5F	943838-28-7F
943838-36-6F	943838-37-7F	943838-38-6F
943838-39-9F	943838-40-2F	943838-41-5F
943838-42-4F	943838-43-5F	943838-44-6F
943838-46-8F	943838-47-9F	943838-48-0F
943838-49-1F	943838-54-6F	943838-55-9F
943838-56-0F	943838-58-2F	943838-59-3F
943838-60-6F	943838-61-7F	943838-62-8F
943838-63-9F	943838-64-0F	943838-65-1F
943838-66-2F	943838-68-4F	943838-69-5F
943838-70-8F	943838-71-9F	943838-73-1F
943838-74-2F	943838-75-3F	943838-76-4F
943838-78-6F	943838-81-1F	943838-83-3F
943838-85-5F	943838-87-7F	943838-90-2F
943838-93-9F	943838-94-6F	943838-95-7F
943838-99-1F	943838-00-7F	943838-02-9F
943838-03-0F	943838-06-3F	943838-07-4F
943838-08-5F	943838-09-6F	943838-11-0F
943838-12-1F	943838-13-2F	943838-14-3F
943838-15-4F	943838-22-3F	943838-23-4F
943838-24-5F	943838-25-6F	943838-26-7F
943838-27-8F	943840-59-1F	943841-00-7F
943841-01-8F	943841-02-9F	943841-05-2F
943841-06-3F	943841-07-4F	943841-08-5F
943841-09-6F	943841-10-9F	943841-11-0F
943841-12-1F	943841-13-2F	943841-14-3F
943841-15-4F	943841-16-5F	943841-17-6F
943841-18-7F	943841-19-8F	943841-20-1F
943841-21-2F	943841-22-3F	943841-23-4F
943841-24-5F	943841-25-6F	943841-26-7F
943841-27-8F	943841-28-9F	943841-29-0F
943841-30-3F	943841-31-4F	943841-32-5F
943841-33-6F	943841-34-7F	943841-35-8F
943841-36-9F	943841-42-8F	943841-45-0F
943841-47-2F	943841-49-4F	943841-51-8F
943841-53-0F	943841-56-3F	943841-57-4F
943841-62-1F	943841-66-2F	943841-65-4F
943841-66-5F	943841-67-6F	943841-68-7F
943841-68-9F	943841-70-1F	943841-71-2F
943841-73-4F	943841-74-5F	943841-75-6F
943841-76-7F	943841-77-8F	943841-78-9F
943841-79-0F	943841-80-3F	943841-81-4F
943841-82-5F	943841-83-6F	943841-85-8F
943841-88-9F	943841-90-3F	943841-91-4F
943841-92-5F	943841-93-6F	943841-94-7F
943841-95-8F	943841-96-9F	943841-97-0F

943847-49-2P 943847-53-6P 943847-56-1P  
 943847-57-2P 943847-58-3P 943847-59-4P  
 943847-60-7P 943847-61-8P 943848-59-7P  
 943848-60-0P 943848-61-1P 943848-62-2P  
 943848-63-3P 943848-64-4P 943848-65-5P  
 943848-66-6P 943848-67-7P 943848-68-8P  
 943848-69-9P 943848-70-2P 943848-71-3P  
 943848-72-4P 943848-73-5P 943848-74-6P  
 943848-75-7P 943848-76-8P 943848-77-9P  
 943848-78-0P 943848-79-1P 943848-80-4P  
 943848-81-5P 943848-82-6P 943848-83-7P  
 943848-84-8P 943848-85-9P 943848-86-0P  
 943848-87-1P 943848-88-2P 943848-89-3P  
 943848-90-6P 943848-91-7P 943848-92-6P  
 943848-93-9P 943848-94-0P 943848-95-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 943837-60-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(2-oxo-1-  
 pyrrolidinyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-  
 yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA  
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

$\equiv \text{CH}_2$

RN 943837-61-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(4-morpholinyl)-4-  
 pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-  
 yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 943837-62-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(4-morpholinyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 943837-64-7 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-methyl-1,2-benzisothiazol-5-yl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943837-65-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 943837-66-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)phenyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943837-67-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)bicyclo[2.2.2]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943837-69-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]bicyclo[2.2.2]oct-1-yl]methyl]- (CA INDEX NAME)



RN 943837-70-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]bicyclo[2.2.2]oct-1-yl]methyl]- (CA INDEX NAME)






RN 943837-71-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 943837-72-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-fluorobicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943837-73-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-hydroxybicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943837-74-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)- (CA INDEX NAME)




RN 943837-75-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-2-propyn-1-yl- (CA INDEX NAME)




RN 943837-76-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclopropylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943837-77-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(phenylmethyl)- (CA INDEX NAME)



RN 943837-78-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 943837-80-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3-fluoro-N7-(phenylmethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-82-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5,N7-bis[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943837-83-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)methyl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 943837-84-1 CAPLUS

CN Pentacyclo[4.2.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester  
(CA INDEX NAME)




RN 943837-85-2 CAPLUS

CN Pentacyclo[4.2.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester  
(CA INDEX NAME)




RN 943837-86-3 CAPLUS

CN Pentacyclo[4.2.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
4-[[[5-[[[3-(4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943837-87-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-([1,2,4]triazolo[1,5-a]pyridin-6-ylmethyl)- (CA INDEX NAME)



RN 943837-91-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methoxyphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943837-92-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[6-(difluoromethoxy)-3-pyridinyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943837-93-2 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 943837-94-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[2-(dimethylamino)ethyl]-3-fluoro- (CA INDEX NAME)




RN 943837-96-5 CAPLUS

CN Glycine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 943837-97-6 CAPLUS


CN β-Alanine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 943837-98-7 CAPLUS

CN D-Alanine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943837-99-8 CAPLUS

CN L-Alanine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-00-4 CAPLUS

CN Glycine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-methyl ester (CA INDEX NAME)






RN 943838-02-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(3S)-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-03-7 CAPLUS


CN L-Valine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 943838-04-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[2-(methylamino)-2-oxoethyl]- (CA INDEX NAME)



RN 943838-05-9 CAPLUS

CN Butanoic acid, 2-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-06-0 CAPLUS


CN L-Serine, N-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 943838-07-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[1-cyano-2-[(1-methylethyl)amino]-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943838-08-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(2-oxo-3-piperidinyl)- (CA INDEX NAME)



RN 943838-09-3 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943838-10-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[2-(1,1-dimethylethoxy)ethyl]-3-fluoro- (CA INDEX NAME)



RN 943838-11-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(2-bromoethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943838-12-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethyl)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-13-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-2,2-dimethyl-5-benzofuranyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-14-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,2-dimethyl-1,3-benzodioxol-5-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943838-15-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(3S)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 943838-20-8 CAPLUS


CN Benzoic acid, 2-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943838-23-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[(3,4-difluorophenyl)amino]carbonyl]-2-phenylpyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]methyl]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-24-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[(3,4-difluorophenyl)amino]carbonyl]-2-(2-thienyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]methyl]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-25-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-26-4 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(2-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943838-27-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)




RN 943838-29-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-2H-tetrazol-5-yl-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 943838-28-6

CMF C18 H13 F N10 O4



CM 2

CRN 7087-68-5


CMF C8 H19 N



RN 943838-36-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 943838-37-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943838-38-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-ethyl-2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943838-39-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-3-(1-methylethyl)-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943838-40-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(acetylamino)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-41-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-[(methylsulfonyl)amino]phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-42-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-amino-1-methyl-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-43-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(1S)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-44-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(3S)-1-ethyl-2-oxo-3-pyrrolidinyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943838-46-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 943838-47-9 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(4-ethyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 943838-48-0 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-dihydro-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943838-49-1 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 943838-54-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 943838-55-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 943838-56-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-58-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 7-[[[(1S)-5-carboxy-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943838-59-3 CAPLUS

CN Pentacyclo[4.2.0.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943838-60-6 CAPLUS

CN Pentacyclo[4.2.0.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943838-61-7 CAPLUS

CN Pentacyclo[4.2.0.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
4-[[[5-[[[3-(4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943838-62-8 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 943838-63-9 CAPLUS

CN Benzoic acid, 3-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943838-64-0 CAPLUS

CN Benzoic acid, 2-[2-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-




yl]carbonyl]amino]ethyl]- (CA INDEX NAME)



RN 943838-65-1 CAPLUS


CN Benzoic acid, 4-[2-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]ethyl]- (CA INDEX NAME)



RN 943838-66-2 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(2-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943838-68-4 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943838-69-5 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(4-ethyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943838-70-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3,4-dihydro-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 943838-71-9 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[1,3-benzodioxol-5-ylmethyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 943838-73-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[1,3-benzodioxol-5-ylmethyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-74-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(2-oxo-1-pyrrolidinyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-75-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(4-morpholinyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-76-4 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(4-morpholinyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943838-78-6 CAPLUS


CN Alanine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-2-methyl- (CA INDEX NAME)



RN 943838-81-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-83-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1H-indazol-5-ylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-85-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[1H-indazol-6-ylmethyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-87-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-bis(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943838-90-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-methyl-1,2-benzisothiazol-5-yl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943838-93-5 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-aminophenyl)methyl]amino]carbonyl]-3-[[[(2-chlorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 943759-66-8

CMF C33 H28 Cl N7 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 943838-94-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3-pyridinylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-


yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-, 2,2,2-trifluoroacetate  
(1:1) (CA INDEX NAME)

CM 1

CRN 943759-67-9

CMF C32 H26 Cl N7 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 943838-95-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(1,2,3,4-tetrahydro-1-isoquinolinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 943759-76-0

CMF C36 H32 Cl N7 O5

Absolute stereochemistry.





CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 943838-99-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methoxyphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-00-7 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[6-(difluoromethoxy)pyridinyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943839-02-9 CAPLUS


CN  $\beta$ -Alanine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-  
(CA INDEX NAME)



RN 943839-03-0 CAPLUS

CN D-Alanine, N-[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 943839-06-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-fluoro-5-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-07-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethyl)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-08-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[2,3-dihydro-2,2-dimethyl-5-benzofuranyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-09-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[2,2-dimethyl-1,3-benzodioxol-5-yl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-11-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[(3,4-difluorophenyl)amino]carbonyl]-2-phenylpyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]methyl]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-12-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[(3,4-difluorophenyl)amino]carbonyl]-2-(2-thienyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]methyl]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-13-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-phenylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-14-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(2-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-15-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 7-[[[(1S)-5-carboxy-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-, 3-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 943839-22-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-2-oxo-5-

benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-23-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-24-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-ethyl-2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943839-25-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-3-(1-methylethyl)-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-

7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-26-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(acetamido)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943839-27-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(methylsulfonyl)amino]phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943840-99-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-3,5,7-tricarboxamide, N3-(2-chlorophenyl)-N5-[(3,4-difluorophenyl)methyl]- (CA INDEX NAME)



RN 943841-00-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-[(butylamino)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-01-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2,3-dihydro-4-methyl-5-[(octylamino)carbonyl]-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943841-02-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-[(dodecylamino)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 943841-05-2 CAPLUS

CN L-Proline, 1-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-06-3 CAPLUS

CN D-Proline, 1-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-07-4 CAPLUS

CN L-Leucine, N-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-08-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, hexadecyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-09-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-difluorophenyl]methyl]amino]carbonyl]-3-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-10-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-11-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-methoxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-12-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-thiazolylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-13-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(methylphenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-14-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(3-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-15-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-16-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(1H-pyrazol-3-ylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-17-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[4-(methoxycarbonyl)phenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-18-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(2,3-dihydro-1H-indol-1-yl)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-19-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-20-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-21-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-(4-morpholinyl)ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-22-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[(cyclohexylamino)carbonyl]-5-[[[3,4-difluorophenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-23-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(4-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-24-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2,4-dichlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.






RN 943841-25-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(2-fluorophenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-26-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-27-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[4-methylphenyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-28-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(3-pyridinylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-29-0 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[4-(4-hydroxyphenyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 943841-30-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[2-[(1,1-dimethylethyl)amino]-2-oxoethyl]-3-fluoro- (CA INDEX NAME)



RN 943841-31-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-32-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-(tricyclo[3.3.1.1.3,7]dec-1-ylamino)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-33-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-[(ethylamino)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-34-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-N7-[(1S)-5-(hexylamino)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943841-35-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-

[[decylamino)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-36-9 CAPLUS

CN Glycine, N-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-43-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-(1,1-dimethylethoxy)-2-oxoethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-45-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[(phenylmethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-47-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(1-pyrrolidinylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-49-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[(phenylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-51-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[[[(2-hydroxyethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 943841-53-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3,5,7-tricarboxamide, N3,N7-bis(2-chlorophenyl)-N5-[(3,4-difluorophenyl)methyl]- (CA INDEX NAME)



RN 943841-56-3 CAPLUS


CN Glycine, N-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 943841-57-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-62-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(cyclopentylamino)-1-methyl-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943841-63-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[(4-



methylbicyclo[2.2.2]oct-1-yl)amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-65-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-[(4-pyridinylmethyl)amino]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-66-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-[(4-morpholinylcarbonyl)amino]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-67-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-[(4-fluorophenyl)methyl]amino]-1-methyl-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-68-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[[4-methyl-1-piperazinyl]carbonyl]amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-69-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-[(1-methylpiperidinyl)carbonyl]amino]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-70-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-[(4-piperidinylmethyl)amino]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 943841-71-2 CAPLUS

CN 1H-indene-5-carboxylic acid, 1-[[[3-[[[2-chlorophenyl]amino]methyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 943841-73-4 CAPLUS

CN L-Proline, 1-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-74-5 CAPLUS

CN D-Proline, 1-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-75-6 CAPLUS

CN L-Leucine, N-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943841-76-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-[[[4-chlorophenyl]amino]carbonyl]-5-

[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943841-77-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[(3-pyridinylamino)carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 943759-45-3

CMF C32 H25 F2 N7 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 943841-78-9 CAPLUS

CN Glycine, N-[[[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-79-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, carboxymethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-80-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-[[[(2-hydroxyethyl)amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-81-4 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]methyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943841-82-5 CAPLUS


CN Glycine, N-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]- (CA INDEX NAME)



RN 943841-83-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943841-85-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2,3-dihydroxypropyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-38-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, octyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 943847-40-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-ethyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-41-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-amino-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-42-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,4)triazolo[1,5-a]pyridin-6-ylmethyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-43-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-44-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-5-chloro-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro-N5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-45-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-46-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinazolinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-47-0 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2-(difluoromethoxy)-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943847-49-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (CA INDEX NAME)




RN 943847-53-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3,4-dihydro-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-2-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 943847-56-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(2-oxo-3-pyrrolidinyl)- (CA INDEX NAME)



CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-pyrrolidinyl]-3-fluoro-    (CA INDEX NAME)

O=C1OC(=O)c2ccc(cc2)CCNC(=O)C3=CC=C4C(=C3)N=CN=C4FNC(=O)N5C(=O)N(C(C)(C)C)CC5

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-piperidinyl]-3-fluoro-    (CA INDEX NAME)

Chemical structure of compound 10: A 2,4-difluorophenyl ring is connected via a methylene group to a carbonyl group, which is further connected to a 6-membered ring containing a sulfur atom and a tert-butyl group. The 6-membered ring is also connected to a carbonyl group, which is further connected to a 2,4-difluorophenyl ring.


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-1-(chloromethyl)-2-[(1,1-dimethylethyl)amino]-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-    (CA INDEX NAME)

CC(C)(C)NC(=O)[C@H](Cl)CNC(=O)Nc1nc2c(ncn2C3=CC=C(C=C3)C4=CC(=O)NCC4=O)C(=O)NCC5=CC=CC=C5C6=CC(=O)NCC6=O

RN 943847-60-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-(1-piperidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943847-61-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943848-59-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3-chloro-4-fluorophenyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(3-fluorophenyl)methyl]- (CA INDEX NAME)




RN 943848-61-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 943848-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(aminocarbonyl)phenyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943848-63-3 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3-(aminocarbonyl)-4-fluorophenyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943848-64-4 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)-3-fluorophenyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)






RN 943848-65-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(difluoromethoxy)phenyl]methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-66-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(difluoromethoxy)phenyl]methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-67-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[2-(difluoromethoxy)phenyl]methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-68-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[2-(aminocarbonyl)phenyl]methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-69-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[4-(trifluoromethoxy)phenyl)methyl]-  
(CA INDEX NAME)




RN 943848-70-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[3-(trifluoromethoxy)phenyl)methyl]-  
(CA INDEX NAME)




RN 943848-71-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[2-(trifluoromethoxy)phenyl)methyl]-  
(CA INDEX NAME)




RN 943848-72-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1,3-benzodioxol-5-ylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-73-5 CAPLUS

CN Benzoic acid, 2-chloro-4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943848-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 943848-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 943848-76-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(5-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943848-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-78-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(2-(trifluoromethyl)-4-pyridinyl)methyl]- (CA INDEX NAME)




RN 943848-79-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 943848-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(4-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943848-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[2-(trifluoromethyl)-4-pyrimidinylmethyl]- (CA INDEX NAME)




RN 943848-82-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(2-pyrazinylmethyl)- (CA INDEX NAME)



RN 943848-83-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1-methyl-4-piperidiny)methyl]- (CA INDEX NAME)



RN 943848-84-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[1-(methylsulfonyl)-4-piperidiny)methyl]- (CA INDEX NAME)






RN 943848-85-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclobutylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943848-86-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(2-pyrimidinylmethyl)- (CA INDEX NAME)



RN 943848-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-

benzoxazin-6-yl)methyl]-3-fluoro-N7-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 943848-88-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1-acetyl-4-piperidinyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-89-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclopentylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-90-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4,4-difluorocyclohexyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(bicyclo[2.2.2]oct-1-ylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943848-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(tricyclo[3.3.1.1.3,7]dec-2-ylmethyl)-  
(CA INDEX NAME)




RN 943848-93-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cycloheptylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-  
(CA INDEX NAME)




RN 943848-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1-azabicyclo[2.2.2]oct-4-ylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-  
(CA INDEX NAME)



RN 943848-95-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-aminobicyclo[2.2.2]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



IT 943848-96-2P 943848-97-3P 943848-98-4P  
 943848-99-5P 943849-00-1P 943849-01-2P  
 943849-02-3P 943849-03-4P 943849-04-5P  
 943849-05-6P 943849-06-7P 943849-07-8P  
 943849-08-9P 943849-09-0P 943849-11-4P  
 943849-12-5P 943849-13-6P 943849-14-7P  
 943849-15-8P 943849-16-9P 943849-17-0P  
 943849-18-1P 943849-19-2P 943849-21-6P  
 943849-23-8P 943849-25-0P 943849-26-1P  
 943849-28-3P 943849-30-7P 943849-32-5P  
 943849-34-1P 943850-47-3P 943850-48-4P  
 943850-49-5P 943850-51-9P 943850-52-0P  
 943850-53-1P 943850-54-2P 943850-55-3P  
 943850-56-4P 943850-57-5P 943850-58-6P  
 943850-59-7P 943850-60-0P 943850-61-1P  
 943850-62-2P 943850-63-3P 943850-64-4P  
 943850-65-5P 943850-66-6P 943850-67-7P  
 943850-68-8P 943850-69-9P 943850-70-2P  
 943850-71-3P 943850-72-4P 943850-73-5P  
 943850-74-6P 943850-75-7P 943850-76-8P  
 943850-77-9P 943850-78-0P 943850-79-1P  
 943850-80-4P 943850-81-5P 943850-82-6P  
 943850-83-7P 943850-84-8P 943850-85-9P  
 943850-86-0P 943850-87-1P 943850-88-2P  
 943850-89-3P 943850-90-6P 943850-91-7P  
 943850-92-8P 943850-93-9P 943850-94-0P  
 943850-95-1P 943850-96-2P 943850-97-3P  
 943850-98-4P 943850-99-5P 943851-00-1P  
 943851-01-2P 943851-02-3P 943851-03-4P  
 943851-04-5P 943851-05-6P 943851-06-7P  
 943851-07-8P 943851-08-9P 943851-09-0P  
 943851-10-3P 943851-11-4P 943851-12-5P  
 943851-13-6P 943851-14-7P 943851-15-8P  
 943851-16-9P 943851-17-0P 943851-18-1P


943851-19-2P 943851-20-5P 943851-21-6P  
 943851-22-7P 943851-23-6P 943851-24-9P  
 943851-25-0P 943851-26-1P 943851-27-2P  
 943851-28-3P 943851-29-4P 943851-30-7P  
 943851-31-8P 943851-32-9P 943851-33-0P  
 943851-34-1P 943852-22-0P 943852-23-1P  
 943852-24-2P 943852-25-3P 943852-26-4P  
 943852-27-5P 943852-28-6P 943852-29-7P  
 943852-30-0P 943852-31-1P 943852-32-2P  
 943852-33-3P 943852-34-4P 943852-35-5P  
 943852-36-6P 943852-37-7P 943852-38-8P  
 943852-39-9P 943852-40-2P 943852-41-3P  
 943852-42-4P 943852-43-5P 943852-44-6P  
 943852-45-7P 943852-46-8P 943852-47-9P  
 943852-48-0P 943852-49-1P 943852-50-4P  
 943852-51-5P 943852-52-6P 943852-53-7P  
 943852-54-8P 943852-55-9P 943852-56-0P  
 943852-57-1P 943852-58-2P 943852-59-3P  
 943852-60-6P 943852-61-7P 943852-63-9P  
 943852-64-0P 943852-65-1P 943852-66-2P  
 943852-67-3P 943852-68-4P 943852-69-5P  
 943852-70-8P 943852-71-9P 943852-72-0P  
 943852-73-1P 943852-74-2P 943852-75-3P  
 943852-76-4P 943852-77-5P 943852-78-6P  
 943852-79-7P 943852-80-0P 943852-81-1P  
 943852-82-2P 943852-83-3P 943852-84-4P  
 943852-85-5P 943852-86-6P 943852-87-7P  
 943852-88-8P 943852-89-9P 943852-90-2P  
 943852-91-3P 943852-92-4P 943852-93-5P  
 943852-94-6P 943852-95-7P 943852-96-8P  
 943852-97-9P 943852-98-0P 943852-99-1P  
 943853-00-7P 943853-01-8P 943853-02-9P  
 943853-03-0P 943853-04-1P 943853-05-2P  
 943853-06-3P 943853-07-4P 943853-08-5P  
 943853-09-6P 943853-11-0P 943853-12-1P  
 943853-13-2P 943853-14-3P 943853-15-4P  
 943853-16-5P 943853-17-6P 943853-18-7P  
 943853-19-8P 943853-20-1P 943853-21-2P  
 943853-22-3P 943853-23-4P 943853-24-5P  
 943853-25-6P 943853-26-7P 943853-27-8P  
 943853-28-9P 943853-29-0P 943853-30-3P  
 943853-31-4P 943853-32-5P 943853-33-6P  
 943853-34-7P 943853-36-9P 943853-37-0P  
 943853-38-1P 943853-39-2P 943853-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of amide containing heterobicyclic metalloprotease inhibitors)


RN 943848-96-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-  
 benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-  
 yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 943848-97-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[4-[(methylamino)carbonyl]cyclohexyl]methyl)- (CA INDEX NAME)



RN 943848-98-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(3S)-1-(1-methylethyl)-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 943848-99-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)cyclohexyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943849-00-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(1-azetidiny)-1-methyl-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943849-01-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(3S)-1-methyl-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 943849-02-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(3S)-1-(1-methylethyl)-2-oxo-3-azetidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-03-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-azetidinyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943849-04-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-

benzoxazin-6-yl)methyl]-3-fluoro-N7-[ (1S)-1-methyl-2-oxo-2-(1-piperazinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-05-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(3S)-1-methyl-2-oxo-3-azetidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-06-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(3-azetidinylamino)-1-methyl-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-07-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-[(1-acetyl-3-azetidinyl)amino]-1-methyl-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-08-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-09-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[(1S)-2-[4-(dimethylamino)-1-piperidinyl]-1-methyl-2-oxoethyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-11-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[(1-methyl-3-azetidinyl)amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943849-12-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[[1-(methylsulfonyl)-3-azetidinyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943849-13-6 CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN    943849-14-7    CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-ylmethyl)- (CA INDEX NAME)




RN    943849-15-8    CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-hydroxypentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN    943849-16-9    CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-fluoropentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943849-17-0 CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-(methylamino)pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943849-18-1 CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N7-[(4-chloropentacyclo[4.2.0.0<sup>2,5</sup>.0<sup>3,8</sup>.0<sup>4,7</sup>]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-    (CA INDEX NAME)




RN 943849-19-2 CAPLUS

CN    Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[[4-[(dimethylamino)carbonyl]pentacyclo[4.2.0.0.02,5.03,8.04,7]oct-1-yl)methyl]-3-fluoro-    (CA INDEX NAME)




RN 943849-21-6 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[[4-(dimethylamino)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943849-23-8 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943849-25-0 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N7-[[4-aminopentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943849-26-1 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-[(methylsulfonyl)amino]pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943849-28-3 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[4-(2H-tetrazol-5-yl)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943849-30-7 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N7-[[4-(acetylamino)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943849-32-9 CAPLUS


CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N7-[[4-(cyanopentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)






RN 943849-34-1 CAPLUS

CN Pyrazolo[1,5-a][1,3]diazine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(aminocarbonyl)phenyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 943850-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluoro-3-methylphenyl)methyl]- (CA INDEX NAME)




RN 943850-51-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 943850-52-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3,4-difluorophenyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943850-53-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 943850-54-2 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluorobicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943850-55-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4,4-difluorocyclohexyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-56-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(tricyclo[3.3.1.1.3,7]dec-2-ylmethyl)- (CA INDEX NAME)




RN 943850-57-5 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cycloheptylmethyl)-N5-  
 [(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-    (CA INDEX NAME)



RN    943850-58-6    CAPLUS


CN    Pentacyclo[4.2.0.02,5.03,8.04,7]octane-1-carboxylic acid,  
 4-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-  
 fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-    (CA INDEX  
 NAME)



RN    943850-59-7    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-  
 benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-(4-methyl-1-piperazinyl)-  
 2-oxoethyl]-    (CA INDEX NAME)


Absolute stereochemistry.



RN    943850-60-0    CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-  
 benzoxazolyl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-azetidiny]-3-

Absolute stereochemistry.




CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-N7-[(1S)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]-3-fluoro-    (CA INDEX NAME)

Absolute stereochemistry.




CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-N7-[[4-[(dimethylamino)carbonyl]pentacyclo[4.2.0.0<sup>2,5</sup>.0<sup>3,8</sup>.0<sup>4,7</sup>]oct-1-yl)methyl]-3-fluoro-    (CA INDEX NAME)




CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)pentacyclo[4.2.0.0<sup>2,5</sup>.0<sup>3,8</sup>.0<sup>4,7</sup>]oct-1-yl)methyl]-N5-[(2,3-

dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-(methylamino)pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)



RN 943850-65-5 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-aminopentacyclo[4.2.0.0<sup>2,5</sup>.0<sup>3,8</sup>.0<sup>4,7</sup>]oct-1-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-    (CA INDEX NAME)



RN 943850-66-6 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 943850-67-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-chloropentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943850-68-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[[1-(methylsulfonyl)-3-azetidiny]amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-69-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-ylmethyl)- (CA INDEX NAME)






RN 943850-70-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluoropentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943850-71-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-hydroxypentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943850-72-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-[(methylamino)carbonyl]pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943850-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-N7-[[4-(dimethylamino)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-cyanopentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-(acetylamino)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-76-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-N7-[(4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylsulfonyl)amino]pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl]methyl]- (CA INDEX NAME)



RN 943850-78-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-(2H-tetrazol-5-yl)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl]methyl]- (CA INDEX NAME)



RN 943850-79-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[(1-methyl-3-azetidiny]amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-N7-[(1S)-2-[4-(dimethylamino)-1-piperidinyl]-1-methyl-2-oxoethyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(3-azetidinylamino)-1-methyl-2-oxoethyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943850-82-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-methyl-2-oxo-3-azetidiny]- (CA


INDEX NAME)

Absolute stereochemistry.



RN 943850-83-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]cyclohexyl]methyl]- (CA INDEX NAME)



RN 943850-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-[(1-acetyl-3-azetidinyl)amino]-1-methyl-2-oxoethyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-85-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-(1-piperazinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(1-azetidiny)-1-methyl-2-oxoethyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-87-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-methyl-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943850-88-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-(1-methylethyl)-2-oxo-3-azetidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943850-89-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)cyclohexyl]methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-90-6 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-(1-methylethyl)-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943850-91-7 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-pyrrolidinyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943850-92-8 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)






RN 943850-93-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(bicyclo[2.2.2]oct-1-ylmethyl)-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]bicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943850-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclohexylmethyl)-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-96-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)- (CA INDEX NAME)




RN 943850-97-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1-azabicyclo[2.2.2]oct-4-ylmethyl)-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-98-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-aminobicyclo[2.2.2]oct-1-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943850-99-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)bicyclo[2.2.2]oct-1-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-00-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(aminocarbonyl)-4-fluorophenyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-01-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclopentylmethyl)-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-02-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclopropylmethyl)-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-03-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1-acetyl-4-piperidinyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-04-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 943851-05-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943851-06-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclobutylmethyl)-N5-  
[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-07-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-  
benzoxazolyl)methyl]-3-fluoro-N7-[[1-(methylsulfonyl)-4-  
piperidinyl)methyl]- (CA INDEX NAME)




RN 943851-08-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-  
benzoxazolyl)methyl]-3-fluoro-N7-[(1-methyl-4-piperidinyl)methyl]- (CA  
INDEX NAME)




RN 943851-09-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2-pyrazinylmethyl)- (CA INDEX NAME)




RN 943851-10-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[2-(trifluoromethyl)-4-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 943851-11-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 943851-12-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 943851-13-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[2-(trifluoromethyl)-4-pyridinyl]methyl]- (CA INDEX NAME)






RN 943851-14-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(4-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943851-15-8 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 943851-16-9 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-    (CA INDEX NAME)




RN    943851-17-0    CAPLUS

CN    Benzoic acid, 2-chloro-4-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-    (CA INDEX NAME)




RN    943851-18-1    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2-pyridinylmethyl)-    (CA INDEX NAME)




RN 943851-19-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 943851-20-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(5-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943851-21-6 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943851-22-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1,3-benzodioxol-5-ylmethyl)-N5-[(2,3-dihydro-2-oxo-5-fluoropyrazolo[1,5-a]pyrimidin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-23-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)phenyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-fluoropyrazolo[1,5-a]pyrimidin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-24-9 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[4-(trifluoromethoxy)phenyl)methyl]-  
(CA INDEX NAME)




RN    943851-25-0    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[2-(trifluoromethoxy)phenyl)methyl]-  
(CA INDEX NAME)




RN    943851-26-1    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[3-(trifluoromethoxy)phenyl)methyl]-  
(CA INDEX NAME)




RN 943851-27-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(2-aminocarbonyl)phenyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943851-28-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3-fluorophenyl)methyl]- (CA INDEX NAME)




RN 943851-29-4 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(difluoromethoxy)phenyl]methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-    (CA INDEX NAME)




RN    943851-30-7    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[2-(difluoromethoxy)phenyl]methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-    (CA INDEX NAME)




RN    943851-31-8    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(difluoromethoxy)phenyl]methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-    (CA INDEX NAME)



RN 943851-32-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)-3-fluorophenyl]methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943851-33-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 943851-34-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3-chloro-4-fluorophenyl)methyl]-N5-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-22-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 943852-23-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluoro-3-methylphenyl)methyl]- (CA INDEX NAME)



RN 943852-24-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3-fluorophenyl)methyl]- (CA INDEX NAME)



RN 943852-25-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-methyl-2-oxo-3-azetidiny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-26-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-azetidinyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-27-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-28-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-oxo-2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943852-29-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[[4-[(dimethylamino)carbonyl]pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-30-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-cyanopentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-31-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(acetylaminopentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-32-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl]methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-33-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-(methylsulfonyl)amino]pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl]methyl]- (CA INDEX NAME)




RN 943852-34-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-(2H-tetrazol-5-yl)pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl]methyl]- (CA INDEX NAME)




RN 943852-35-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[4-(dimethylamino)pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-36-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluoropentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943852-37-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl)- (CA INDEX NAME)




RN 943852-38-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-(methylamino)pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943852-39-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl]methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-40-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-chloropentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl]methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-41-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]pentacyclo[4.2.0.0.2,5.0.3,8.0.4,7]oct-1-yl]methyl]- (CA INDEX NAME)




RN 943852-42-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-aminopentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-43-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-hydroxypentacyclo[4.2.0.02,5.03,8.04,7]oct-1-yl)methyl]- (CA INDEX NAME)



RN 943852-44-6 CAPLUS

CN Pentacyclo[4.2.0.02,5.03,8.04,7]octane-1-carboxylic acid, 4-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943852-45-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 943852-46-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[(3S)-1-(1,1-dimethylethyl)-2-oxo-3-pyrrolidinyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-47-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[(1-(methylsulfonyl)-3-azetidinyl)amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-48-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-methyl-2-[(1-methyl-3-azetidinyl)amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-49-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(3-azetidinylamino)-1-methyl-2-oxoethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-50-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[(1S)-2-[4-(dimethylamino)-1-piperidinyl]-1-methyl-2-oxoethyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 943852-51-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]cyclohexyl)methyl]- (CA INDEX NAME)



RN 943852-52-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-[(1-acetyl-3-azetidiny)amino]-1-methyl-2-oxoethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-53-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2-(1-azetidiny)-1-methyl-2-oxoethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-54-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[(1S)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-55-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-methyl-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 943852-56-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-(1-methylethyl)-2-oxo-3-azetidiny]- (CA INDEX NAME)

Absolute stereochemistry.



RN 943852-57-1 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)cyclohexyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943852-58-2 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(3S)-1-(1-methylethyl)-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943852-59-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[2-[(1,1-dimethylethyl)amino]-2-oxoethyl]-3-fluoro- (CA INDEX NAME)




RN 943852-60-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4,4-difluorocyclohexyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-61-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclohexylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-63-9 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943852-64-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cycloheptylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-65-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1-azabicyclo[2.2.2]oct-4-ylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-  
(CA INDEX NAME)




RN 943852-66-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)- (CA INDEX NAME)



RN 943852-67-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-ylmethyl)- (CA INDEX NAME)






RN 943852-68-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(4-aminobicyclo[2.2.2]oct-1-yl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-69-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(bicyclo[2.2.2]oct-1-ylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-70-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(4-fluorobicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 943852-71-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)bicyclo[2.2.2]oct-1-yl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-72-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]bicyclo[2.2.2]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-73-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2-pyrazinylmethyl)- (CA INDEX NAME)




RN 943852-74-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(2-(trifluoromethyl)-4-pyrimidinyl)methyl]- (CA INDEX NAME)




RN 943852-75-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1-methyl-4-piperidiny)methyl]-(CA INDEX NAME)




RN 943852-76-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1,3-benzodioxol-5-ylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-(CA INDEX NAME)




RN 943852-77-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 943852-78-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943852-79-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclopentylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-80-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclopropylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-81-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1-acetyl-4-piperidinyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-82-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclobutylmethyl)-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-83-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[2-(aminocarbonyl)phenyl]methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-84-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 943852-85-5 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[1-(methylsulfonyl)-4-piperidinyl)methyl]- (CA INDEX NAME)



RN 943852-86-6 CAPLUS


CN Benzoic acid, 2-chloro-4-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)






RN 943852-87-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943852-88-8 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 943852-89-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[2-(trifluoromethyl)-4-pyridinyl)methyl]- (CA INDEX NAME)



RN 943852-90-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943852-91-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-

oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 943852-92-4 CAPLUS

CN Benzoic acid, 4-[[[5-[[[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 943852-93-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(5-pyrimidinylmethyl)- (CA INDEX NAME)




RN 943852-94-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)phenyl]methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-95-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 943852-96-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 943852-97-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 943852-98-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminocarbonyl)-3-fluorophenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943852-99-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[2-(difluoromethoxy)phenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-00-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(difluoromethoxy)phenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-01-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(difluoromethoxy)phenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-02-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(aminocarbonyl)-4-fluorophenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-03-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(aminocarbonyl)phenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-04-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)






RN 943853-05-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(2-fluorophenyl)methyl]- (CA INDEX NAME)



RN 943853-06-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3,4-difluorophenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-07-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 943853-08-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3-chloro-4-fluorophenyl)methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-09-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1-methyl-3-azetidiny)methyl]- (CA INDEX NAME)




RN 943853-11-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[4-[(dimethylamino)carbonyl]phenylmethyl]-3-fluoro- (CA INDEX NAME)




RN 943853-12-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[4-[(methylamino)carbonyl]phenylmethyl]- (CA INDEX NAME)




RN 943853-13-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(1-methyl-3-azetidiny)- (CA INDEX NAME)




RN 943853-14-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-3-azetidiny-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-15-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[3-[(methylamino)carbonyl]phenyl]methyl)- (CA INDEX NAME)



RN 943853-16-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[2-(aminocarbonyl)-4-fluorophenyl]methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-17-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943853-18-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943853-19-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1R)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943853-20-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1R)-2-amino-2-oxo-1-phenylethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-

fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943853-21-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1R)-2-amino-2-oxo-1-phenylethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 943853-22-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[[4-[(methylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)



RN 943853-23-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1R)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 943853-24-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[[3-[(dimethylamino)carbonyl]phenyl]methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-25-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[[3-[(dimethylamino)carbonyl]phenyl]methyl]-3-fluoro- (CA INDEX NAME)






RN 943853-26-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[3-[(methylamino)carbonyl]phenyl]methyl)- (CA INDEX NAME)



RN 943853-27-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-(1-methylethyl)- (CA INDEX NAME)



RN 943853-28-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-

benzoxazin-6-yl)methyl]-3-fluoro-N7-(2-methylpropyl)- (CA INDEX NAME)




RN 943853-29-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(6-(trifluoromethyl)-3-pyridinyl)methyl]- (CA INDEX NAME)



RN 943853-30-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 943853-31-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[(4-(dimethylamino)carbonyl)cyclohexyl)methyl]- (CA INDEX NAME)

yl]-3-fluoro- (CA INDEX NAME)



RN 943853-32-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[3-(aminosulfonyl)phenyl]methyl]-N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-33-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943853-34-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 943853-36-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-3-fluoro-N7-[(6-(trifluoromethyl)-2-pyridinyl)methyl]- (CA INDEX NAME)



RN 943853-37-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[[4-(aminosulfonyl)phenyl)methyl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-

yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-38-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[[4-[(dimethylamino)carbonyl]bicyclo[2.2.2]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 943853-39-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[[4-[(dimethylamino)carbonyl]cyclohexyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-40-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



IT 943853-41-6P 943853-42-7P 943853-43-8P


943853-55-2P 943853-83-6P 943853-84-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 943853-41-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[5-(trifluoromethyl)-2-pyridinyl]methyl]- (CA INDEX NAME)



RN 943853-42-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]methyl]-3-fluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me


RN 943853-43-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-N7-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-55-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(3-azetidinylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943853-83-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.





RN 943853-84-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[[2-(2-amino-3,4-dioxo-1-cyclobuten-1-yl)-1,2,3,4-tetrahydro-7-isoquinoliny]methyl]-3-fluoro-N7-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



IT 916214-55-6 943760-13-2 943760-21-2

943760-33-6 943843-26-3 943843-41-2

943843-58-1 943843-78-5 943843-97-3


943867-27-4 943867-28-5 943867-29-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amide containing heterobicyclic metalloprotease inhibitors)


RN 916214-55-6 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 943760-13-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-[[{(2-chlorophenyl)amino]carbonyl]-5-[[{(3,4-difluorophenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 943760-21-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]- (CA INDEX NAME)



RN 943760-33-6 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[(2-(aminocarbonyl)-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943843-26-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 943843-41-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-sulfo-, 7-methyl ester, ammonium salt (1:1) (CA INDEX NAME)



● NH3


RN 943843-58-1 CAPLUS

CN Benzoic acid, 2-[2-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]ethyl]-, methyl ester (CA INDEX NAME)



RN 943843-78-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-3,7-dicarboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]- (CA INDEX NAME)



RN 943843-97-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-[[[(2-chlorophenyl)amino]carbonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 943867-27-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-5-benzoxazolyl)methyl]-3-fluoro-N7-(4-pyrimidinylmethyl)- (CA INDEX NAME)



RN 943867-28-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-5-

benzoxazolyl)methyl]-N7-[4-[(dimethylamino)carbonyl]phenyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 943867-29-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]-N7-[4-[(dimethylamino)carbonyl]bicyclo[2.2.2]oct-1-yl)methyl]-3-fluoro- (CA INDEX NAME)



IT 916212-36-7P 916212-39-0P 916212-40-3P  
 916212-41-4P 916212-42-5P 916212-47-0P  
 916212-49-2P 916212-58-3P 916212-61-8P  
 916212-62-9P 916212-64-1P 916212-65-2P  
 916212-66-3P 916212-67-4P 916212-72-1P  
 916212-80-1P 916212-81-2P 916212-83-4P  
 916212-94-7P 916212-97-0P 916212-98-1P  
 916212-99-2P 916213-03-1P 916213-05-3P  
 916213-07-5P 916213-17-7P 916213-18-8P  
 916213-21-3P 916213-24-6P 916213-25-7P  
 916213-26-8P 916213-29-1P 916213-31-6P  
 943760-08-5P 943760-10-9P 943760-12-1P  
 943760-27-8P 943760-29-0P 943760-50-7P  
 943760-52-9P 943760-53-0P 943843-21-8P  
 943843-24-1P 943843-37-6P 943843-38-7P  
 943843-39-8P 943843-40-1P 943843-89-8P  
 943843-91-2P 943845-99-6P 943846-04-6P  
 943846-05-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 916212-36-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 916212-39-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 916212-40-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitro-, methyl ester (CA INDEX NAME)



RN 916212-41-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-bromo-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 916212-42-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-3-nitro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 916212-47-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)



RN 916212-49-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 916212-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)




RN 916212-61-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 2-chloro-7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 916212-62-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 916212-64-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-(acetyloxy)-7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 916212-65-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-(acetyloxy)-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 916212-66-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 916212-67-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 916212-72-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-fluoro-7-[[[1-(methoxycarbonyl)bicyclo[2.2.2]oct-4-yl]methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 916212-80-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]- (CA INDEX NAME)




RN 916212-81-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-fluoro-5-[[[4-fluorophenyl]methyl]amino]carbonyl]- (CA INDEX NAME)



RN 916212-83-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 916212-94-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 916212-97-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916212-98-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(4-fluoro-3-nitrophenyl)methyl]amino]carbonyl]-3-nitro- (CA INDEX NAME)



RN 916212-99-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-3-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 916213-03-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-bromo-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]- (CA INDEX NAME)



RN 916213-05-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 916213-07-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 916213-17-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 916213-18-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 2-chloro-7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 916213-21-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916213-24-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxy- (CA INDEX NAME)



RN 916213-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-3-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 916213-26-8 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-3-fluoro-    (CA INDEX NAME)

Absolute stereochemistry.




RN    916213-29-1    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-    (CA INDEX NAME)



RN    916213-34-8    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-fluoro-7-[[[1-(methoxycarbonyl)bicyclo[2.2.2]oct-4-yl]methyl]amino]carbonyl]-    (CA INDEX NAME)




RN    943760-08-5    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-5-[(1,1-



dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-iodo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-10-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3,5-dicarboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, 5-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-12-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-[[[(2-chlorophenyl)amino]carbonyl]-7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943760-27-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-2-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-7-methyl-, methyl ester (CA INDEX NAME)

NAME)




RN 943760-29-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2,7-dicarboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-, 2-methyl ester (CA INDEX NAME)




RN 943760-50-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-[[[(2-chlorophenyl)amino]sulfonyl]-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]- (CA INDEX NAME)



RN 943760-52-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-sulfo-, 7-methyl ester (CA INDEX NAME)



RN 943760-53-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-[[[(1,1-dimethylethoxy)carbonyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943843-21-8 CAPLUS

CN Carbamic acid, N-[(1S)-1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-1H-inden-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 943843-24-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 943843-37-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-phenyl- (CA INDEX NAME)




RN 943843-38-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(2-thienyl)- (CA INDEX NAME)




RN 943843-39-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-phenyl- (CA INDEX NAME)



RN 943843-40-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(2-thienyl)- (CA INDEX NAME)



RN 943843-89-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-(hydroxymethyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 943843-91-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-formylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 943845-99-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]-3-fluoro-, 1,1-dimethylethyl ester


(CA INDEX NAME)

Absolute stereochemistry.




RN 943846-04-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-phenyl-, methyl ester (CA INDEX NAME)



RN 943846-05-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-(2-thienyl)-, methyl ester (CA INDEX NAME)



L10 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:726515 CAPLUS Full-text

DN 147:143271

TI Preparation of pyrrolidine derivatives as Cannabinoid receptor (CB1) antagonists

IN Moritani, Yasunori; Kokubo, Shigeru; Tsuboi, Yasunori; Okagaki, Chieko; Oku, Akira; Hirano, Naomitsu

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 222pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 2007169270	A	20070705	JP 2006-316427	20061124
PRAI	JP 2005-339547	A	20051125		
OS	MARPAT 147:143271				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; R1 and R2 independently = (un)substituted aryl, heteroaryl or together they may form benzocycloheptane; R3 and R4 independently = H, OH, hydroxyalkyl, etc. or together they may form an oxo group; R5 = H or alkyl; Y = single bond, O or -NR7-; R6 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R7 = alkyl or alkyloxycarbonylalkyl with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of CB1 receptor. Thus, e.g., compound (II) was prepared by benzylation of (3R)-1-[bis-(4-chlorophenyl)methyl]-3- aminopyrrolidine (preparation given) with 4-(trifluoromethoxy)benzoyl chloride. I as antagonists of CB1 receptor should prove useful in the treatment of diseases such as but not limited to depression, migraine and obesity. Pharmaceutical compns. comprising I are disclosed.


IT 870625-46-0E

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrrolidine derivs. as Cannabinoid receptor (CB1) antagonists)

RN 870625-46-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[1-[bis(4-chlorophenyl)methyl]-3-pyrrolidinyl]-2,7-dimethyl- (CA INDEX NAME)




GI




I

CN    Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(2-methoxyethyl)-3-(4-methoxyphenyl)-7-methyl- (CA INDEX NAME)




CN    Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(2-chloro-6-fluorophenyl)-N,N,7-trimethyl- (CA INDEX NAME)






RN 923537-81-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N,N,7-trimethyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 923550-42-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(2-chloro-6-fluorophenyl)-N,N-diethyl-7-methyl- (CA INDEX NAME)




RN 924560-80-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(2-fluorophenyl)-N-[2-[(2-furanylmethyl)thio]ethyl]-7-methyl- (CA INDEX NAME)




RN 924565-66-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(2-methoxyphenyl)-7-methyl-N-(2-phenoxyethyl)- (CA INDEX NAME)




RN 924572-27-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-methyl-3-[(4-(1-methylethyl)phenyl)-N-(2-phenoxyethyl)-] (CA INDEX NAME)




RN 924585-78-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-[(2-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]-7-methyl-] (CA INDEX NAME)




RN 941573-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(2,2-dimethylpropyl)-7-methyl-3-[(4-(1-methylethyl)phenyl)-] (CA INDEX NAME)



RN 941573-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-methyl-N-(1-phenylethyl)-3-(2-thienyl)- (CA INDEX NAME)



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:257211 CAPLUS Full-text  
 DN 146:316926

TI Heterocyclic dihydropyrimidine compounds as potassium channel inhibitors and their preparation, pharmaceutical composition and use in the treatment of arrhythmia and IKur-associated conditions

IN Han, Wei; Hu, Zilun

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 121pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007027454	A1	20070308	WO 2006-US32382	20060818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2007203157	A1	20070830	US 2006-511154	20060828
PRAI	US 2005-712497P	P	20050830		
OS	MARPAT 146:316926				
GI					



AB Heterocyclic dihydropyrimidine compds. of useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra rapidly activating delayed rectifier), which have the structure of formula I, stereoisomers including enantiomers thereof and diastereomers thereof, or a pharmaceutically acceptable salt thereof. Compds. of formula I wherein Q is (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl and (un)substituted (hetero)aryl; R3 is (un)substituted carbonylamino, sulfonyl, (un)substituted sulfonyl, (un)substituted sulfonylamino, etc.; R4 is (un)substituted alkyl; R5 is H and (un)substituted

alkyl; R6 and R7 are independently H, (un)substituted alkyl, and polyhaloalkyl; and their pharmaceutically acceptable salts, and stereoisomers thereof, are claimed. Methods of using such compds. in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compns. containing such compds. are also provided. Example compound (-)- and (+)-II was prepared by substitution of chloroacetone with 4-fluorothiophenol followed by oxidation to give 1-(4-fluorophenylsulfonyl)propan-2-one which underwent cyclization with 3-methyl-1H-pyrazol-5-amine and 3,4-dichlorobenzaldehyde to give compound II, which underwent chiral separation to give (-)- and (+)-II. All the invention compds. were evaluated for their Kv1.5 inhibitory activity. From the assay, it was determined that one of the enantiomers of II showed 98 % inhibition at 0.3  $\mu$ M and the other showed 48% inhibition at 0.3  $\mu$ M.


IT 928619-27-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic dihydropyrimidine compds. as inhibitors of potassium channel function useful alone or in combination with other agents for treatment and prevention of diseases)

RN 928619-27-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-(3,4-dichlorophenyl)-N,5-dimethyl-N-(phenylsulfonyl)-2-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1252740 CAPLUS Full-text

DN 146:27854

TI Preparation of amide containing heterobicyclic metalloprotease inhibitors  
IN Steeneck, Christoph; Gege, Christian; Richter, Frank; Hochguertel, Matthias; Feurstein, Tim; Bluhm, Harald; Sucholeiki, Irving; Boer, Jurgen; Wu, Xinyuan; Schneider, Matthias; Nolte, Bert; Gallagher, Brian; Van Veldhuizen, Joshua; Deng, Hongbo; Essers, Michael; Kroth, Heiko; Kiely, Andrew; Powers, Timothy; Taveras, Arthur G.

PA Alantos-Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 744pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006128184	A2	20061130	WO 2006-US20970	20060522
	WO 2006128184	A3	20070308		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006251989	A1	20061130	AU 2006-251989	20060522
	CA 2608890	A1	20061130	CA 2006-2608890	20060522
	IN 2007DN09935	A	20080118	IN 2007-DN9935	20071220
PRAI	US 2005-683470P	P	20050520		
	US 2005-706465P	P	20050808		
	US 2005-734991P	P	20051109		
	WO 2006-US20970	W	20060522		
OS	MARPAT 146:27854				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl; or NR1R2 = 3-8 membered ring containing carbon atoms and optionally a heteroatom; R3 = NR2OR21; R20 = H, alkyl; R21 = (un)substituted bicyclic or tricyclic fused ring system wherein at least one ring is partially saturated; Q = 5-6 membered ring selected from (un)substituted aryl or heteroaryl; D = CR22, N; R22 = H, OH, halo, etc.] that exhibit an increased potency in relation to currently known MMP-13 inhibitors. Synthesis of compds. I is described in many examples. Thus, reacting the acid II with the corresponding amine (preparation of both intermediates is provided) afforded 40% III. Compds. I have a MMP-13 inhibition activity (IC50) ranging from below 0.1 nM to about 20  $\mu$ M, and typically, from about 0.2

nM to about 2  $\mu$ M. Pharmaceutical compns. comprising compound I in combination with therapeutic other agents are disclosed.


IT 916204-53-0P 916204-59-6P 916205-05-5P  
 916205-09-9P 916205-16-8P 916205-17-9P  
 916205-22-6P 916205-23-7P 916205-24-8P  
 916205-25-9P 916205-52-2P 916205-53-3P  
 916205-54-4P 916205-55-5P 916205-56-6P  
 916205-57-7P 916205-58-8P 916205-63-5P  
 916205-64-6P 916205-65-7P 916206-24-1P  
 916206-25-2P 916206-26-3P 916206-27-4P  
 916206-28-5P 916206-29-6P 916206-41-2P  
 916206-46-7P 916206-47-8P 916206-50-3P  
 916206-51-4P 916206-52-5P 916206-53-6P  
 916206-64-9P 916206-65-0P 916206-66-1P  
 916206-71-8P 916206-73-0P 916206-81-0P  
 916206-96-5P 916206-87-6P 916206-89-7P  
 916206-99-8P 916206-90-1P 916206-91-2P  
 916206-92-3P 916207-04-0P 916207-05-1P  
 916207-06-2P 916207-07-3P 916207-33-5P  
 916207-34-6P 916207-35-7P 916207-51-7P  
 916207-52-8P 916207-53-9P 916207-54-0P  
 916207-97-1P 916209-70-6P 916209-74-0P  
 916209-75-1P 916209-76-2P 916209-77-3P  
 916209-78-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 916204-53-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrzolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916204-59-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-05-5 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916205-09-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916205-16-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916205-17-9 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916205-22-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-(6-cyano-2,3-dihydro-1,1-dioxidobenzo[b]thien-3-yl)-3-fluoro- (CA INDEX NAME)





RN 916205-23-7 CAPLUS


CN Benzo[b]thiophene-6-carboxylic acid, 3-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, 1,1-dioxide (CA INDEX NAME)



RN 916205-24-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-cyano-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-25-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-52-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-53-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-54-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-55-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-56-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-57-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-58-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-63-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916205-64-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 916205-65-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-24-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-25-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-26-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-27-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-2-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-28-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-29-6 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916206-41-2 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)






RN 916206-46-7 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-47-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-50-3 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-51-4 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-52-5 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916206-53-6 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 916206-64-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-65-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-66-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-71-8 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916206-73-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-bromo-N5,N7-bis[(4-fluoro-3-methylphenyl)methyl]- (CA INDEX NAME)



RN 916206-81-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-86-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyrimidinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-87-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-hydroxy-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-88-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-bromo-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916206-89-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(aminocarbonyl)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CH<sub>2</sub>

RN 916206-90-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916206-91-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916206-92-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, methyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916207-04-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-05-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916207-06-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(2,2,3,3-tetrafluoro-2,3-

dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-07-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-33-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-34-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-35-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-51-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-52-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 1,1-dimethylethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-53-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



RN 916207-54-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-97-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[4-(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916209-70-6 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl-, methyl ester (CA INDEX NAME)



RN 916209-74-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-bromo-3-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-75-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(aminocarbonyl)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-76-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-dichloro-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-77-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-78-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-hydroxy-4-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, 2-propen-1-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 916205-06-6P 916205-06-8P 916205-10-2F  
 916205-11-3P 916205-12-4P 916205-13-5F  
 916205-25-0P 916205-41-9P 916205-42-0P  
 916205-43-1P 916205-44-2P 916205-45-3P  
 916206-12-7P 916206-13-8P 916206-14-9P  
 916206-34-3P 916206-35-5P 916206-37-6P  
 916206-38-7P 916206-40-1P 916206-49-0P  
 916206-72-9P 916207-67-5P 916207-68-6P  
 916207-91-5P 916207-92-6P 916207-93-7P  
 916207-95-9P 916207-99-3P 916208-00-9P  
 916208-01-0P 916208-09-8P 916208-10-1P  
 916208-11-2P 916208-12-3P 916208-13-4P  
 916208-14-5P 916208-15-6P 916208-16-7P  
 916208-20-3P 916208-21-4P 916208-23-6P  
 916208-24-7P 916208-25-8P 916208-26-9P  
 916208-27-0P 916208-28-1P 916208-38-3P  
 916208-39-4P 916208-40-7P 916208-44-1P  
 916208-45-2P 916208-46-3P 916208-47-4P  
 916208-48-5P 916208-70-3P 916208-73-6P  
 916208-77-0P 916208-78-1P 916208-93-0P  
 916208-94-1P 916208-95-2P 916208-97-4P  
 916208-98-5P 916209-05-7P 916209-06-6P  
 916209-07-9P 916209-08-0P 916209-09-1P  
 916209-10-4P 916209-13-3P 916209-23-9P  
 916209-24-0P 916209-25-1P 916209-26-2P  
 916209-33-1P 916209-34-2P 916209-37-5P  
 916209-41-1P 916209-45-5P 916209-46-6P  
 916209-47-7P 916209-64-8P 916209-84-2P  
 916209-89-7P 916209-90-0P 916209-91-1P  
 916209-9C-2P 916214-78-3P 916214-82-9P  
 916214-83-0P 916214-84-1P 916214-86-3P  
 916214-94-3P 916215-05-9P 916215-06-0P  
 916215-07-1P 916215-08-2P 916215-09-3P  
 916215-10-6P 916215-11-7P 916215-12-8P  
 916215-13-9P 916215-14-0P 916215-15-1P  
 916215-16-2P 916215-17-3P 916215-18-4P  
 916215-19-5P 916215-20-8P 916215-21-9P  
 916215-22-0P 916215-23-1P 916215-24-2P  
 916215-25-3P 916215-26-4P 916215-27-5P  
 916215-28-6P 916215-29-7P 916215-30-0P  
 916215-31-1P 916215-32-2P 916215-53-7P  
 916215-54-8P 916215-55-9P 916215-56-0P  
 916215-57-1P 916215-69-5P 916215-70-8P  
 916215-72-0P 916215-73-1P 916215-74-2P  
 916215-75-3P 916215-76-4P 916215-77-5P  
 916215-78-6P 916215-79-7P 916215-97-3P  
 916215-98-0P 916216-15-4P 916216-16-5P  
 916216-17-6P 916216-18-7P 916216-19-8P  
 916216-20-1P 916216-21-2P 916216-22-3P  
 916216-23-4P 916216-24-5P 916216-25-6P  
 916216-26-7P 916216-27-8P 916216-28-9P  
 916216-29-0P 916216-30-3P 916216-31-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 916205-06-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(1-azabicyclo[2.2.2]oct-4-




ylmethyl)-N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro- (CA INDEX NAME)



RN 916205-08-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)



RN 916205-10-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916205-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclohexylmethyl)-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)




RN 916205-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-methyl- (CA INDEX NAME)



RN 916205-13-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7,N7-dimethyl- (CA INDEX NAME)



RN 916205-26-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-[(1S)-2,3-dihydro-1H-inden-1-yl]-N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-41-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-42-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-5-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2,3-dihydro-4-methyl-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916205-43-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[(trans-4-(5-methyl-1,3,4-oxadiazol-2-yl)cyclohexyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916205-44-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916205-45-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916206-12-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-(3-methyl-1,2,4-oxadiazol-5-yl)cyclohexyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916206-13-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]cyclohexyl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 916206-14-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[trans-4-(2-thiazolyl)cyclohexyl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 916206-34-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[1-(hydroxymethyl)bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




RN 916206-36-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[(4-fluorobicyclo[2.2.2]oct-1-yl)methyl]- (CA INDEX NAME)




RN 916206-37-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[1-[[[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




RN 916206-38-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[1-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




PAGE 1-A




RN 916206-40-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-3-fluoro-N7-[(1-hydroxybicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)



RN 916206-49-0 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 916206-72-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-bromo-5-[[[(4-fluoro-3-



methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, methyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-67-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916207-68-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 916207-91-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-


(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916207-92-6 CAPLUS

CN Benzo[b]thiophene-6-carboxylic acid, 3-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, 1,1-dioxide (CA INDEX NAME)




RN 916207-93-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916207-95-9 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 916207-99-3 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916208-00-9 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-01-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-09-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-10-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxypyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-11-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-12-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-13-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-14-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-15-6 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916208-16-7 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916208-20-3 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916208-21-4 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916208-23-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-24-7 CAPLUS


CN   Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)






RN 916208-25-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916208-26-9 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916208-27-0 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 916208-28-1 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 916208-38-3 CAPLUS  
 CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-39-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-40-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-44-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyrimidinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-45-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-hydroxy-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-46-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-bromo-4-hydroxyphenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-47-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(aminocarbonyl)phenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-48-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-[(methylamino)carbonyl]phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-70-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-73-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-77-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-78-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-93-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-94-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-95-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-97-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-fluoro-5-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916208-98-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-05-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916209-06-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-07-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-08-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[6-(trifluoromethyl)-2-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-09-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-10-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-19-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-chloro-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916209-23-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-

fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-24-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-25-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-26-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-33-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-34-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-37-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-41-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-amino-7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916209-45-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[2,3-dihydro-1,1-dioxido-6-(2H-tetrazol-5-yl)benzo[b]thien-3-yl]-3-fluoro- (CA INDEX NAME)



RN 916209-46-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-4-methyl-5-(2H-tetrazol-5-yl)-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-47-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-[(1S)-2,3-dihydro-5-(2H-tetrazol-5-yl)-1H-inden-1-yl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 916209-64-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)



RN 916209-84-2 CAPLUS


CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[2-(trifluoromethyl)-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)



RN 916209-89-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-bromo-3-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-90-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(aminocarbonyl)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-91-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,5-dichloro-4-hydroxyphenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916209-92-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-hydroxy-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 916214-78-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[7-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-82-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-83-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-84-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[2-chloro-5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-86-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-[(2-amino-3,4-dioxo-1-cyclobuten-1-yl)amino]methyl]phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916214-94-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[4-fluoro-3-methylphenyl]methyl]amino]carbonyl]-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-05-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-[[[(cyanoamino)iminomethyl]amino]phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-06-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-07-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-08-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-09-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-10-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-11-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-12-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-

(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-13-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-14-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-15-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-16-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-fluoro-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-17-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[2-cyano-4-pyridinyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-18-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-19-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3-[[[5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-20-8 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-



benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-21-9 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-22-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(1,2,3,4-tetrahydro-2-oxo-7-quinoliny)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-23-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-24-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-25-3 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-26-4 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-27-5 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-28-6 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-29-7 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-30-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-fluoro-4-

pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-31-1 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 916215-32-2 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-2-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 916215-56-0 CAPLUS

CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 916215-57-1 CAPLUS


CN 1H-Indene-5-carboxylic acid, 1-[[[3-fluoro-5-[[[2-fluoro-4-pyridinyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]-2,3-dihydro-4-methyl-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 916215-69-5 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-[[[(cyanoamino)iminomethyl]amino]phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-70-8 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916215-72-0 CAPLUS


CN Bicyclo[2.2.1]heptane-1-carboxylic acid, 4-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)






RN 916215-73-1 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-74-2 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[(2-fluoro-4-pyridinyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-75-3 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[(2-cyano-4-pyridinyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-76-4 CAPLUS

CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[3-fluoro-5-[[[(3-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916215-77-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]-3-fluoro-N7-[[1-[(methanesulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-yl]methyl]- (CA INDEX NAME)




RN 916215-78-6 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-fluoro-N5-[(4-fluoro-3-methylphenyl)methyl]-N7-[1-[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




RN 916215-79-7 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, 3-fluoro-N5-[(4-fluorophenyl)methyl]-N7-[[1-[(methylsulfonyl)amino]carbonyl]bicyclo[2.2.2]oct-4-yl)methyl]- (CA INDEX NAME)




RN 916215-97-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N7-(cyclohexylmethyl)-3-fluoro-N5-[(4-fluoro-3-methylphenyl)methyl]- (CA INDEX NAME)




RN 916215-98-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-dicarboxamide, N5-[(3-chloro-4-fluorophenyl)methyl]-N7-(cyclohexylmethyl)-3-fluoro- (CA INDEX NAME)




RN 916216-15-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-16-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-17-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-18-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[3-(difluoromethoxy)-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 916216-19-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethoxy)phenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino)methyl]- (CA INDEX NAME)




RN 916216-20-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-21-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-22-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 916216-23-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-fluoro-5-[[[4-fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 916216-24-5 CAPLUS


CN Benzoic acid, 4-[[[5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)






RN 916216-25-6 CAPLUS

CN Benzoic acid, 4-[[[(3-fluoro-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-26-7 CAPLUS

CN Benzoic acid, 4-[[[[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-27-8 CAPLUS

CN Benzoic acid, 4-[[[[5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-28-9 CAPLUS

CN Benzoic acid, 4-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-29-0 CAPLUS

CN Benzoic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-30-3 CAPLUS

CN Benzoic acid, 4-[[[3-fluoro-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)




RN 916216-31-4 CAPLUS

CN Benzoic acid, 4-[[[3-fluoro-5-[[[4-(fluorophenyl)methyl]amino]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-2-methyl- (CA INDEX NAME)



IT 916214-55-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of amide containing heterobicyclic metalloprotease inhibitors)  
 RN 916214-55-6 CAPLUS  
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[[[5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoropyrazolo[1,5-a]pyrimidin-7-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




IT 916212-36-7P 916212-39-0P 916212-40-3P  
 916212-41-4P 916212-42-5P 916212-47-0P  
 916212-49-2P 916212-58-3P 916212-61-6P  
 916212-62-9P 916212-64-1P 916212-65-2P  
 916212-66-3P 916212-67-4P 916212-72-1P  
 916212-80-1P 916212-81-2P 916212-83-4P  
 916212-94-7P 916212-97-0P 916212-98-1P  
 916212-99-2P 916213-03-1P 916213-05-3P  
 916213-07-5P 916213-17-7P 916213-18-8P  
 916213-21-3P 916213-24-6P 916213-25-7P  
 916213-26-8P 916213-29-1P 916213-31-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of amide containing heterobicyclic metalloprotease inhibitors)

RN 916212-36-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 916212-39-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 916212-40-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-nitro-, methyl ester (CA INDEX NAME)



RN 916212-41-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-bromo-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 916212-42-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-3-nitro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 916212-47-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)



RN 916212-49-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 916212-58-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)



RN 916212-61-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 2-chloro-7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 916212-62-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 916212-64-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-(acetyloxy)-7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 916212-65-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-(acetyloxy)-7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 916212-66-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-3-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 916212-67-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 916212-72-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-fluoro-7-[[[1-(methoxycarbonyl)bicyclo[2.2.2]oct-4-yl]methyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 916212-80-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-fluoro-5-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]- (CA INDEX NAME)




RN 916212-81-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-fluoro-5-[[[4-fluorophenyl]methyl]amino]carbonyl]- (CA INDEX NAME)



RN 916212-83-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[3-(difluoromethoxy)phenyl]methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 916212-94-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 916212-97-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 916212-98-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(4-fluoro-3-nitrophenyl)methyl]amino]carbonyl]-3-nitro- (CA INDEX NAME)



RN 916212-99-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-3-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 916213-03-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-bromo-5-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]- (CA INDEX NAME)



RN 916213-05-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 916213-07-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-5-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-4-methyl-1H-inden-1-yl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 916213-17-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 5-[[[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)



RN 916213-18-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 2-chloro-7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 916213-21-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 916213-24-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-3-hydroxy- (CA INDEX NAME)



RN 916213-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-5-(methoxycarbonyl)-1H-inden-1-yl]amino]carbonyl]-3-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 916213-26-8 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[[(1S)-2,3-dihydro-4-methyl-5-[(2-propen-1-yloxy)carbonyl]-1H-inden-1-yl]amino]carbonyl]-3-fluoro-    (CA INDEX NAME)

Absolute stereochemistry.




RN    916213-29-1    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-7-carboxylic acid, 3-chloro-5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]-    (CA INDEX NAME)



RN    916213-34-8    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-fluoro-7-[[[1-(methoxycarbonyl)bicyclo[2.2.2]oct-4-yl]methyl]amino]carbonyl]-    (CA INDEX NAME)



L10 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1097667 CAPLUS Full-text

DN 145:432167

TI Pharmaceutical compositions and methods using replicase complex defect inducers for inhibiting hepatitis C virus (HCV) replication

IN Huang, Mingjun

PA Achillion, USA

SO PCT Int. Appl., 550pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006110762	A2	20061019	WO 2006-US13503	20060411
	WO 2006110762	A3	20070503		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006235438	A1	20061019	AU 2006-235438	20060411
	CA 2604442	A1	20061019	CA 2006-2604442	20060411
	EP 1874952	A2	20080109	EP 2006-749774	20060411
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRAI	US 2005-669872P	P	20050411		
	WO 2006-US13503	W	20060411		

OS MARPAT 145:432167


AB The invention relates generally to replicase complex defect inducers and pharmaceutical compns. containing such inducers. Methods for developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods for screening test compds. for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.

IT 698985-11-4 870143-56-3 870143-86-5  
912634-94-7

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(replicase complex defect inducers for inhibiting hepatitis C virus replication)

RN 698985-11-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]phenyl]amino]thioxomethyl]-2,7-dimethyl- (CA INDEX NAME)






RN 870143-56-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[[[3-fluoro-4-(pentyloxy)phenyl]amino]thioxomethyl]-2,7-dimethyl- (CA INDEX NAME)




RN 870143-86-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[[[6-(pentyloxy)-3-pyridinyl]amino]thioxomethyl]- (CA INDEX NAME)



RN 912634-94-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[[[3-(phenylmethoxy)phenyl]amino]thioxomethyl]- (CA INDEX NAME)



L10 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:471911 CAPLUS [Full-text](#)

DN 144:488660

TI Preparation of benzimidazole-1-propanoic acids as integrin antagonists and anticancer agents

IN Bloxham, Jason; Borzillo, Gary, V.; Collington, Eric, William; Sadiq, Shazia; Sambrook Smith, Colin Peter; Waller, Chris, L.; Wynne, Graham, M.

PA Osi Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 112 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006053342	A2	20060518	WO 2005-US42048	20051109
	WO 2006053342	A3	20060928		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006116383	A1	20060601	US 2005-270088	20051109
	EP 1828144	A2	20070905	EP 2005-825865	20051109
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-627775P	P	20041112		
	WO 2005-US42048	W	20051109		
OS	MARPAT 144:488660				
GI					



I



II



III

AB Title compds. I [wherein a = single bond or double bond; A = direct bond, (un)substituted NH, C(O), etc.; X1 = (un)substituted carboxyalkyl; X2 = H, (un)substituted alkyl, alkenyl, etc.; X4 = H, alkyl, etc.; X5 = alkyl, alkenyl, oxo, etc.] and pharmaceutically acceptable salts and solvates thereof, which are useful as integrin antagonists, anticancer drugs and so on (no data), were prepared For instance, acylation of Et 3-(5-amino-1H-benzimidazol-1-yl)-3-phenylpropanoate (preparation given) with 4-nitrobenzoyl chloride in dichloromethane followed by ester hydrolysis under acidic conditions gave benzimidazolepropanoic acid II.


IT 887271-27-4P 887272-95-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazolepropanoic acids as integrin antagonists for treating such as cancer)


RN 887271-27-4 CAPLUS

CN 1H-Benzimidazole-1-propanoic acid, 5-[[[(2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl)carbonyl]amino]-β-phenyl- (CA INDEX NAME)



RN 887272-95-9 CAPLUS

CN 1H-Benzimidazole-1-propanoic acid, 6-[[[(2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl)carbonyl]amino]-β-phenyl- (CA INDEX NAME)



L10 ANSWER 12 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:470227 CAPLUS Full-text

DN 144:488673

TI Preparation of pyrazolo[1,5-a]pyrimidines as inhibitors of protein kinases

IN Jimenez, Juan-Miguel; Knegt, Ronald; Charrier, Jean-Damien; Stamos, Dean; Li, Pan; Come, Jon, R.; Aronov, Alex

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 293 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006052913	A1	20060518	WO 2005-US40344	20051104
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005304784	A1	20060518	AU 2005-304784	20051104
	CA 2586375	A1	20060518	CA 2005-2586375	20051104
	US 2006135537	A1	20060622	US 2005-266935	20051104
	EP 1812440	A1	20070801	EP 2005-816516	20051104
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101094853	A	20071226	CN 2005-80045025	20051104
	IN 2007KN01724	A	20070727	IN 2007-KN1724	20070515
	KR 2007090172	A	20070905	KR 2007-712308	20070531
	NO 2007002795	A	20070601	NO 2007-2795	20070601
FRAI	US 2004-625446P	P	20041104		
	WO 2005-US40344	W	20051104		
OS	MARPAT 144:488673				
GI					



I



II

AB The title compds. I [R = (un)substituted C(:Q)R<sub>2</sub>a, Y (wherein Y = 5-10 membered monocyclic or bicyclic heterocyclyl, aryl, or heteroaryl; Q = O, N, or S; R<sub>2</sub>a = alkyl, aryl, heteroaryl, etc.); R<sub>1</sub> = H, alkyl; Z = a bond, alkylene wherein up to two methylene units of the aliphatic chain are optionally and independently replaced by a heteroatom selected from O, N, or S; R<sub>3</sub>, R<sub>4</sub> = H, halo, alkyl, etc.], useful as inhibitors of protein kinases, were prepared E.g., a 3-step synthesis of II, starting from 2-pyridylacetonitrile, was given. Compds. I were tested against various protein kinases such as Aurora A, Aurora B, ITK, JAK3, c-Met, RIK (biol. data given for selected compds. I). The invention also provides pharmaceutically acceptable compns. comprising compds. I and methods of using the compns. in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing the compds. I.


IT 887363-22-6P 887363-24-8P 887363-26-6P  
887363-27-1P 887363-33-9P 887363-35-1P  
887363-37-3P 887363-39-5P 887365-45-9P  
887365-47-1P 887365-48-2P 887365-49-3P  
887365-50-6P 887365-51-7P 887365-52-8P  
887365-53-9P 887365-56-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidines as inhibitors of protein kinases useful in treatment of various diseases)


RN 887363-22-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-(2-phenylethyl)-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887363-24-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[(4-aminophenyl)methyl]-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887363-26-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-3-(2-pyridinyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 887363-27-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-amino-3-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-6-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 887363-33-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-methyl-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887363-35-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-(2-methylpropyl)-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887363-37-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-3-piperidinyl-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887363-39-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-(phenylmethyl)-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887365-45-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 887365-47-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[3-(4-morpholinyl)propyl]-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887365-48-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-(2-pyridinyl)- (CA INDEX NAME)




RN 887365-49-3 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[2-(diethylamino)ethyl]-  
N-methyl-3-(2-pyridinyl)-    (CA INDEX NAME)




RN 887365-50-6 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[2-(dimethylamino)ethyl]-3-(2-pyridinyl)-    (CA INDEX NAME)



RN 887365-51-7 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-(4-piperidinylmethyl)-3-(2-pyridinyl)- (CA INDEX NAME)



RN 887365-52-8 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[3-(dimethylamino)propyl]-3-(2-pyridinyl)- (CA INDEX NAME)






RN 887365-53-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-[3-(4-methyl-1-piperazinyl)propyl]-3-(2-pyridinyl)- (CA INDEX NAME)



RN 887365-56-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-amino-N-cyclopropyl-3-(2-pyridinyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1290266 CAPLUS [Full-text](#)

DN 144:22804

TI Preparation of pyrrolidine derivatives as CB1 receptor antagonists

IN Moritani, Yasunori; Furukubo, Shigeru; Tsuboi, Yasunori; Okagaki, Chieko;  
Oku, Akira; Hirano, Naomitsu

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 205 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115977	A1	20051208	WO 2005-JP10197	20050527
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2006219472	A	20060824	JP 2005-155309	20050527
	EP 1748980	A1	20070207	EP 2005-745829	20050527
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1960970	A	20070509	CN 2005-80017310	20050527
	US 2007167440	A1	20070719	US 2006-579950	20061109
PRAI	JP 2004-160059	A	20040528		
	US 2004-575409P	P	20040601		
	JP 2005-7833	A	20050114		
	US 2005-644992P	P	20050121		
	WO 2005-JP10197	W	20050527		
OS	MARPAT 144:22804				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 and R2 independently = (un)substituted aryl, heteroaryl or together they may form benzocycloheptane; R3 and R4 independently = H, OH, hydroxyalkyl, etc. or together they may form an oxo group; R5 = H or alkyl; Y = single bond, O or -NR7-; R6 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R7 = alkyl or alkyloxycarbonylalkyl with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of CB1 receptor. Thus, e.g., II was prepared by benzylation of (3R)-1-[bis-(4-chlorophenyl)methyl]-3-aminopyrrolidine (preparation given) with 4-(trifluoromethoxy)benzoyl chloride. I as antagonists of CB1 receptor should prove useful in the treatment of diseases such as but not limited to depression, migraine and obesity. Pharmaceutical compns. comprising I are disclosed.


IT 870625-46-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidine derivs. as CB1 receptor antagonists)

RN 870625-46-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[1-(bis(4-chlorophenyl)methyl)-3-pyrrolidinyl]-2,7-dimethyl- (CA INDEX NAME)



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:1262794 CAPLUS Full-text  
 DN 144:6680

TI Preparation of substituted (arylacetyl)thioureas, their use as antiviral agents, and method for prophylactic or therapeutic treatment of hepatitis C

IN Phadke, Avinashi; Chen, Dawei; Deshpande, Milind; Thurkauf, Andrew; Wang, Xiangzhu; Shen, Yiping; Liu, Cuixian; Quinn, Jesse; Okanda, Junko; Lee, Shouming

PA Achillion Pharmaceuticals, Inc., USA

SO Jpn. Kokai Tokkyo Koho, 186 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005330284	A	20051202	JP 2005-144790	20050517
	US 2006025416	A1	20060202	US 2005-131013	20050517
	AU 2005326813	A1	20060810	AU 2005-326813	20050517
	CA 2566809	A1	20060810	CA 2005-2566809	20050517
	WO 2006083271	A2	20060810	WO 2005-US17308	20050517
	WO 2006083271	A3	20061026		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	EP 1747196	A2	20070131	EP 2005-856726	20050517
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	BR 2005011283	A	20071204	BR 2005-11283	20050517
	CN 101087755	A	20071212	CN 2005-80016081	20050517
	JP 2006225394	A	20060831	JP 2006-51358	20060227
	IN 2006DN06690	A	20070831	IN 2006-DN6690	20061110
	KR 2007010183	A	20070122	KR 2006-724219	20061117
	MX 2006PA13374	A	20070301	MX 2006-PA13374	20061117
	NO 2006005736	A	20070208	NO 2006-5736	20061212
PRAI	US 2004-572156P	P	20040518		
	JP 2005-144790	A3	20050517		
	WO 2005-US17308	W	20050517		
OS	MARPAT 144:6680				

AB A1XYZNRIC(:Q)NR2VWA2 [A1, A2 = C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, (un)saturated heterocyclyl, etc.; Q = S, etc.; X, W = O, S, NH, bond, etc.; V = C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, bond, etc.; Y = (un)substituted C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, bond, etc.; Z = CO, CS, NH, etc.; R1, R2 = H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, etc.], e.g. 1-(4-pentylphenyl)-3-(1,2,3-thiadiazole-4-carbonyl)thiourea, 1-[3-(4-phenylbenzyloxy)phenyl]-3-(2-morpholinoacetyl)thiourea, 1-(3-cyanobenzoyl)-3-(3-benzyloxyphenyl)thiourea, or their pharmacol. acceptable salts, strongly and/or selectively inhibit replication of hepatitis C virus (HCV). Thus, nicotinoyl chloride HCl salt

treated with  $\text{NH}_4\text{SCN}$  and 3-PhOC6H4NH<sub>2</sub> to give 1-(3-phenoxyphenyl)-3-(pyridine-3-carbonyl)thiourea, which inhibited replication of HCV replicon with EC<sub>50</sub> value of <10  $\mu\text{M}$ .


IT 870143-23-0P 870143-56-9P 870143-86-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (arylacyl)thioureas as antiviral agents for treatment of hepatitis C)


RN 870143-23-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[[[4-(pentyloxy)-3-(trifluoromethyl)phenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 870143-56-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[[[3-fluoro-4-(pentyloxy)phenyl]amino]thioxomethyl]-2,7-dimethyl- (CA INDEX NAME)



RN 870143-86-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[[[6-(pentyloxy)-3-pyridinyl]amino]thioxomethyl]- (CA INDEX NAME)



L10 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:612293 CAPLUS Full-text

DN 143:133389

TI Preparation of pyrazolopyrimidines as CRF receptor antagonists

IN Luo, Zhiyong; Slee, Deborah; Tellaw, John Edward; Williams, John; Zhang, Xiahou

PA SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063755	A1	20050714	WO 2004-IB4234	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004309168	A1	20050714	AU 2004-309168	20041220
	CA 2550948	A1	20050714	CA 2004-2550948	20041220
	EP 1697374	A1	20060906	EP 2004-820857	20041220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	CN 1938309	A	20070328	CN 2004-80042012	20041220
	BR 2004017943	A	20070417	BR 2004-17943	20041220
	JP 2007515472	T	20070614	JP 2006-546391	20041220
	IN 2006DN03246	A	20070824	IN 2006-DN3246	20060606
	KR 2007009537	A	20070118	KR 2006-712368	20060621
	MX 2006PA07283	A	20060907	MX 2006-PA7283	20060622
	NO 2006003230	A	20060912	NO 2006-3230	20060711
	US 2007287705	A1	20071213	US 2007-596648	20070529
PRAI	US 2003-532031P	P	20031222		
	WO 2004-IB4234	W	20041220		
OS	MARPAT 143:133389				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = H, (un)substituted alkyl, heteroaryl, etc.; R2 = (un)substituted alkyl, aryl, aryloxyalkyl, etc.; R3 = H, alkyl or absent if double bond is present; Y = CO, =(CR4)-; R4 = H, thioalkyl, (un)substituted alkyl, etc.; Ar = (un)substituted Ph or pyridyl; Het = (un)substituted heteroaryl] and their pharmaceutically acceptable salts, are prepared and disclosed as CRF receptor antagonists. Thus, e.g., II was prepared by cyclization of III (preparation given) with Et acetoacetate followed by chlorination and subsequent Suzuki coupling with 2-methoxyphenylboronic acid. The CRF receptor binding activity of I was evaluated using radioligand binding assay (no data). I as CRF receptor antagonists should prove useful in the

treatment of stroke, depression and anxiety. Pharmaceutical compns. comprising I are disclosed.

IT 859159-61-8P 859159-62-9P 859159-63-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 859159-61-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxamide, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,N,2,5-tetramethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859159-60-7

CMF C21 H22 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 859159-62-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxamide, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 859159-63-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-7-carboxamide, N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (CA INDEX NAME)



RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:564644 CAPLUS Full-text

DN 143:97280

TI Preparation of benzazepine derivatives as histamine H3 antagonists

IN Bailey, Nicholas; Bamford, Mark James; Dean, David Kenneth; Pickering, Paula Louise; Wilson, David Matthew; Witherington, Jason

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 68 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058837	A1	20050630	WO 2004-EP14380	20041215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1713778	A1	20061025	EP 2004-803989	20041215
	EP 1713778	B1	20080116		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	JP 2007514690	T	20070607	JP 2006-544347	20041215
	AT 384050	T	20080215	AT 2004-803989	20041215
	US 2007060566	A1	20070315	US 2006-596503	20060615
PRAI	GB 2003-29214	A	20031217		
	WO 2004-EP14380	W	20041215		
OS	CASREACT 143:97280; MARPAT 143:97280				
GI					



AB Title compds. I [R1 = (un)substituted cycloalkyl; R2 = H, alkyl, cycloalkyl, etc.; X = a bond, CO, CO2, etc.; R3 = halo, alkoxy, CN, etc.; R4 = H, aryl, heteroaryl, etc.; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of histamine H3. Thus, e.g., II was prepared by reductive amination of N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-morpholinecarboxamide (preparation given) with cyclobutanone. The activity of I was evaluated in the histamine H3 functional antagonist assay and it was revealed that numerous compds. of the invention possessed antagonism > 6.5 pKb. I as histamine H3 antagonists should prove useful in the treatment of neurol. disorders. Pharmaceutical compns. comprising I are disclosed.

IT 856904-24-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzazepine derivs. as histamine H3 antagonists)


RN 856904-24-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,7-dimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 856904-23-9

CMF C23 H27 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:1011018 CAPLUS [Full-text](#)  
 DN 142:355243  
 TI A convenient route to pyridones, pyrazolo[2,3-a]pyrimidines and  
 pyrazolo[5,1-c]triazines incorporating antipyrine moiety  
 AU Farag, Ahmad M.; Dawood, Kamal M.; Elmenoufy, Hanan A.  
 CS Department of Chemistry, Faculty of Science, Cairo University, Giza,  
 12613, Egypt  
 SO Heteroatom Chemistry (2004), 15(7), 508-514  
 CODEN: HETCE8; ISSN: 1042-7163  
 PB John Wiley & Sons, Inc.  
 DT Journal  
 LA English  
 OS CASREACT 142:355243  
 GI




I



II


AB Condensation of 4-aminoantipyrine with Et acetoacetate, Et benzoylacetate, and Et cyanoacetate furnished the corresponding Et 3-(1,2-dihydro-1,5-dimethyl-2-phenyl-3-oxo-3H-pyrazol-4-yl)aminoacrylate and 2-cyano-N-[(1,2-dihydro-1,5-dimethyl-2-phenyl-3-oxo-3H-pyrazol-4-yl)]acetamide derivs. The aminoacrylates derivs. react with acetonitrile and sodium hydride to give 2-amino-6-methyl-1-(1,2-dihydro-1,5-dimethyl-2-phenyl-3-oxo-3H-pyrazol-4-yl)-4-pyridone. Reaction of the cyanoacetamide derivative with dimethylformamide-dimethylacetal (DMF-DMA) afforded 2-cyano-N-[(1,2-dihydro-1,5-dimethyl-2-phenyl-3-oxo-pyrazol-4-yl)-2-(N,N-dimethylamino)methylene]acetamide in high yield. Treatment of the latter with 5-aminopyrazole derivs. afforded the corresponding pyrazolo[2,3-a]pyrimidines I (R = Ph, p-ClC6H4). 2-Cyano-N-[(1,2-dihydro-1,5-dimethyl-2-phenyl-3-oxo-3H-pyrazol-4-yl)]acetamide also reacts with heterocyclic diazonium salts to give the corresponding pyrazolo[5,1-c]-1,2,4-triazine derivative II.

IT 848996-69-0P 848996-64-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (convenient route to pyridones, pyrazolo[2,3-a]pyrimidines and  
 pyrazolo[5,1-c]triazines incorporating antipyrine moiety)  
 RN 848996-69-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-amino-N-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-2-phenyl- (CA INDEX NAME)



RN 848996-84-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-amino-2-(4-chlorophenyl)-N-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:857603 CAPLUS Full-text  
 DN 141:332189  
 TI Pyrazolopyrimidine compounds and their use in medicine  
 IN Parratt, Martin; Bower, Justin Fairfield; Williamson, Douglas; Cansfield, Andrew  
 PA Vernalis Cambridge Limited, UK  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087707	A1	20041014	WO 2004-GB1214	20040318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1608652	A1	20051228	EP 2004-721593	20040318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	US 2007179161	A1	20070802	US 2006-551177	20061206
PRAI	GB 2003-7389	A	20030331		
	GB 2003-12296	A	20030529		
	GB 2003-19028	A	20030813		
	GB 2003-25854	A	20031105		
	WO 2004-GB1214	W	20040318		
OS	MARPAT 141:332189				
GI					



I



II

AB Compds. of formula (I) or salts, N-oxides, hydrates or solvates thereof are disclosed as inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical; n is 0 or 1. Q represents a radical of formula  $-(Alk1)_p(X)r-(Alk2)_s-Z$  wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a -O-, -S- or -NRA- link, wherein RA is hydrogen or C1-C6 alkyl; X represents -O-, -S-,  $-(C=O)-$ ,  $-(C=S)-$ ,  $-SO_2-$ ,  $-SO-$ ,  $-(C=O)O-$ ,  $-OC(=O)-$ ,  $-C(=O)NRA-$ ,  $-NRAC(=O)-$ ,  $-C(=S)NRA-$ ,  $-NRAC(=S)-$ ,  $-SO_2NRA-$ ,  $-NRASO_2-$ ,  $-OC(=O)NRA-$ ,  $-NRAC(=O)O-$ , or -NRA- wherein RA is hydrogen or C1-C6 alkyl; p, r and s are independently 0 or 1. R1 represents a radical  $-(Alk3)a-(Y)b-(Alk4)d-B$  wherein a, b and d are independently 0 or 1; Alk3 and Alk4 are optionally substituted divalent C1-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -O-, -S-, or -NRA- wherein RA is hydrogen or C1-C6 alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -NRA- and b is 1, then RA and the radical  $-(Alk4)d-B$  taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents H, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, Ph, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms. Preparation of I is also disclosed; thus, e.g., the HCl salt of II was prepared from 5,7-dichloropyrazolo[1,5-a]pyrimidine via substitution with 4-fluoroaniline followed by N-protection with di-t-Bu dicarbonate, coupling with Ph boronic acid, and deprotection. I were assayed for CDK2 inhibition and were identified to possess IC50 values ranging from 0.004-24.866  $\mu M$ . Data for assays of CHK1 kinase activity and PDK dependent kinase activity were given as well as growth inhibition assay data for select example compds.


IT 771504-58-6P 771504-77-9P 771505-00-1P  
771505-08-9P 771507-02-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrazolopyrimidines with kinase inhibitory activity)


RN 771504-58-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-N-ethyl-3-(1-methylethyl)- (CA INDEX NAME)




RN 771504-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-(2-aminoethyl)-7-[[4-(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)- (CA INDEX NAME)




RN 771505-00-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 7-[[4-(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 771505-08-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(dimethylamino)ethyl]-7-[[4-(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)- (CA INDEX NAME)



RN 771507-02-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 7-[[4-  
[(dimethylamino)sulfonyl]phenyl]amino]-N-[2-(methylamino)ethyl]-3-(1-  
methylethyl)- (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 19 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:817666 CAPLUS Full-text

DN 141:309638

TI Inhibitors of cathepsin S for use in disease treatment

IN Liu, Hong; Tully, David; Epple, Robert; Bursulaya, Badry; Williams, Jennifer; Chatterjee, Arnab; Harris, Jennifer Leslie; Li, Jun

PA IRM LLC, Bermuda

SO PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004084842	A2	20041007	WO 2004-US9218	20040324
	WO 2004084842	A3	20041125		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
	US 2004198780	A1	20041007	US 2004-807612	20040323
	US 7109243	B2	20060919		
PRAI	US 2003-457595P	P	20030324		
	US 2004-807612	A	20040323		

OS MARPAT 141:309638

AB The present invention provides WC(:O)NHCH2CH2NHAr [W = R1X(C:O)NHCHR2; R1 = (substituted)phenyl, pyridyl, or pyridinium N-oxide; X = furan, NHCH2, OCH2, phenylene, etc.; R2 = (substituted)phenyl, etc.; Ar = (substituted phenyl)] compds. and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isoenzyme (e.g., cathepsin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

IT 768364-02-9P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitors of cathepsin S for use in disease treatment)

RN 768364-02-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[12-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-2,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:648505 CAPLUS Full-text

DN 141:190794

TI Preparation of arylcarboxamides as dipeptidyl peptidase IV inhibitors

IN Kakigami, Takuji; Oka, Mitsuru; Katoh, Noriyasu; Yoshida, Masahiro;

Shirai, Masahiro; Murase, Toru; Sakairi, Masao; Yamamoto, Takayo;

Takeuchi, Mitsunori; Hayashi, Yuji; Takeda, Motohiro; Makino, Mitsunori

PA Sanwa Kagaku Kenkyusho Co., Ltd., Japan

SO PCT Int. Appl., 84 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067509	A1	20040812	WO 2004-JP886	20040130
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	AU 2004207731	A1	20040812	AU 2004-207731	20040130
	CA 2514191	A1	20040812	CA 2004-2514191	20040130
	EP 1595866	A1	20051116	EP 2004-706796	20040130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1745063	A	20060308	CN 2004-80003342	20040130
	US 2006229286	A1	20061012	US 2006-541108	20060201
	US 7345180	B2	20080318		
PRAI	JP 2003-23077	A	20030131		
	WO 2004-JP886	A	20040130		
OS	MARPAT 141:190794				
GI					



AB The title compds. I [wherein R1 and R2 = independently H, (un)substituted alkyl, CO<sub>2</sub>H, etc.; R3 = H or (un)substituted aryl; R4 = H or CN; D = CONR<sub>6</sub>, CO, or NR<sub>6</sub>CO; R6 = H or (un)substituted alkyl; E = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, or SCH<sub>2</sub>; n = 0-3; A = (un)substituted bicyclo(hetero)cyclyl] or pharmaceutically acceptable salts thereof are prepared as dipeptidyl peptidase (DPP) IV inhibitors. For example, the compound II•HCl was prepared in a multi-step synthesis. I inhibited DPP IV with IC<sub>50</sub> of 0.002 to 0.094 μM.

IT 739366-1/-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of arylcarboxamides as dipeptidyl peptidase IV inhibitors)

RN 739366-17-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 739366-19-9P 739366-20-2P 739366-21-3P

739366-22-4P 739366-23-5P 739366-24-6P

739366-25-7P 739366-26-8P 739366-27-9P

739366-28-0P 739366-29-1P 739366-30-4P

739366-31-5P 739366-32-6P 739366-78-0P

739367-01-2P 739367-02-3P 739367-03-4P

739367-04-5P 739367-05-6P 739367-48-7P

739367-49-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of arylcarboxamides as dipeptidyl peptidase IV inhibitors)

RN 739366-19-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2,7-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 739366-20-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-21-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-([2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino)-2-methylpropyl]-2,5,7-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-22-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-([2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino)-2-methylpropyl]-7-methoxy-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-23-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-([2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino)-2-methylpropyl]-5,7-dimethyl-2-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-24-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methyl-7-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-(1,1-dimethylethyl)-5,7-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-26-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-(1,1-dimethylethyl)-7-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-7-methyl-2-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-28-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-7-methoxy-5-methyl-2-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-29-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-4,5-dihydro-2-methyl-5-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-30-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-7-hydroxy-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-31-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-(hydroxymethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-32-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-(methoxymethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 739366-78-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-N,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 739367-01-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2R)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 739367-02-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(4R)-4-cyano-3-thiazolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739367-03-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-azetidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739367-04-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[1-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]cyclopentyl]methyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739367-05-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[4-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methylpentyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 739367-48-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]ethyl]-2,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-49-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[2-[(2-oxo-2-(3-thiazolidinyl)ethyl]amino)ethyl]- (CA INDEX NAME)



IT 739365-56-1P 739365-57-2P 739365-58-3P


739365-75-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of arylcarboxamides as dipeptidyl peptidase IV inhibitors)


RN 739365-56-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(2-amino-2-methylpropyl)-2-methyl- (CA INDEX NAME)




RN 739365-57-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[(1-aminocyclopentyl)methyl]-2-methyl- (CA INDEX NAME)




RN 739365-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(4-amino-4-methylpentyl)-2-methyl- (CA INDEX NAME)





RN 739365-76-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(2-aminoethyl)-2,7-dimethyl- (CA INDEX NAME)



L10 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:453172 CAPLUS Full-text  
 DN 141:23305  
 TI Preparation of substituted aryl thioureas as inhibitors of viral replication  
 IN Chen, Dawei; Deshpande, Milind; Thurkauf, Andrew; Phadke, Avinash; Wang, Xiangzhu; Shen, Yiping; Liu, Cuixian; Quinn, Jesse; Ohkanda, Junko; Li, Shouming  
 PA Achillion Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 218 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046095	A1	20040603	WO 2003-US36809	20031118
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506415	A1	20040603	CA 2003-2506415	20031118
	AU 2003295605	A1	20040615	AU 2003-295605	20031118
	US 2004138205	A1	20040715	US 2003-716175	20031118
	US 7094807	B2	20060822		
	EP 1562895	A1	20050817	EP 2003-786803	20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016397	A	20050927	BR 2003-16397	20031118
	CN 1738797	A	20060222	CN 2003-80108710	20031118
	JP 2006506439	T	20060223	JP 2004-553861	20031118
	NZ 540033	A	20070531	NZ 2003-540033	20031118
	US 2006014836	A1	20060119	US 2004-15300	20041217
	MX 2005PA05379	A	20060217	MX 2005-PA5379	20050519
	NO 2005002546	A	20050718	NO 2005-2546	20050526
	JP 2007084548	A	20070405	JP 2006-272359	20061003
FRAI	US 2002-427634P	P	20021119		
	JP 2004-553861	A3	20031118		
	US 2003-716175	A1	20031118		
	WO 2003-US36809	W	20031118		
OS	MARPAT 141:23305				
GI					



II

AB The title compds. [I; A1 = (un)substituted aryl, 5-6 membered heteroaryl; etc.; A2 = (un)substituted Ph, 2-pyridyl, 5-pyrimidinyl, etc.; X, W = O, S, NR, absent (wherein R = H, alkyl, arylalkyl); V = alkyl, alkenyl, cycloalkyl, absent; Y = alkyl, cycloalkylalkyl, alkenyl, etc.; when V is absent, W is absent; Z = carbonyl, thiocarbonyl, imino, alkylimino; R1, R2 = substituted alkyl, alkenyl, alkynyl; or R1 and R2 are joined to form (un)substituted 5-7 membered saturated or mono-unsatd. ring containing one addnl. heteroatom chosen from N, S and O] which possess potent antiviral activity, were prepared and formulated. Thus, treating 2-naphthoyl chloride with ammonium thiocyanate in acetone followed by addition of Bu 4-aminobenzoate afforded II which was found to inhibit replication of the HCV replicon with EC50 of < 30  $\mu$ M. The invention particularly provides compds. I that are potent and/ or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compns. containing one or more compound I, or a salt, solvate, or acylated prodrug of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with one or more other therapeutic agent.


IT 698985-03-4P 698985-11-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aryl thioureas as inhibitors of viral replication)


RN 698985-03-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[[[3-(2-phenylethoxy)phenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 698985-11-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[[[3-[(2,3-dihydro-1H-inden-2-yl)oxy]phenyl]amino]thioxomethyl]-2,7-dimethyl- (CA INDEX NAME)



L10 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:182661 CAPLUS Full-text  
 DN 140:235616  
 TI Preparation of 4-amino-azepan-3-ones as cathepsin S inhibitors  
 IN Bondinelli, William E.; Hall, Ralph F.; Jin, Qi; Kerns, Jeffrey K.; Nie,  
 Hong; Widdowson, Katherine L.  
 PA SmithKline Beecham Corporation, USA  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004017911	A2	20040304	WO 2003-US26358	20030822
	WO 2004017911	A3	20040701		
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003269984	A1	20040311	AU 2003-269984	20030822
	EP 1539178	A2	20050615	EP 2003-751880	20030822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505526	T	20060216	JP 2004-529860	20030822
	US 2006052365	A1	20060309	US 2005-525114	20050927
PRAI	US 2002-405227P	P	20020822		
	WO 2003-US26358	W	20030822		
OS	MARPAT 140:235616				
GI					



AB 4-Amino-azepan-3-ones of formula I [R1 = (substituted) aminomethylcarbonyl, acyl, etc.; R2 = H, alkyl, arylalkyl, etc.; R3 = H, alkyl, cycloalkyl-alkyl, acyl, etc.; R4 = alkyl, etc.] are prepared. The compds. are useful as protease

inhibitors, particularly of cathepsin S, and as such are useful for preventing a number of diseases amongst which are atherosclerotic lesions and pulmonary diseases such as asthma and allergic reactions (no data). Thus, II was prepared from 4-fluorophenylboronic acid and 5-bromofuran-2-carboxylic acid [(S)-2-cyclopentyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridin-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl]-amide (preparation given) in 24% yield.

IT 666725-25-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino-azepanones as cathepsin S inhibitors)

RN 666725-25-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[(1S)-1-(cyclopentylmethyl)-2-[[[(4S,7R)-hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]-2-oxoethyl]-2,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:875291 CAPLUS Full-text

DN 139:350751

TI Preparation of pyrazolo[1,5-a]pyrimidine derivatives as NAD(P)H oxidase inhibitors

IN Seno, Kaoru; Nishi, Koichi; Matsuo, Yoshiyuki; Fujishita, Toshio

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 240 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091256	A1	20031106	WO 2003-JP5024	20030418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2483306	A1	20031106	CA 2003-2483306	20030418
	AU 2003227437	A1	20031110	AU 2003-227437	20030418
	EP 1505068	A1	20050209	EP 2003-717663	20030418
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009475	A	20050301	BR 2003-9475	20030418
	CN 1662537	A	20050831	CN 2003-814483	20030418
	MX 2004PA10441	A	20050214	MX 2004-PA10441	20041022
	US 2006089362	A1	20060427	US 2005-511840	20050923
PRAI	JP 2002-121519	A	20020423		
	WO 2003-JP5024	W	20030418		
OS	MARPAT 139:350751				
GI					



I

AB Title compds. I (R1, R2, R3, R4, R5 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, , aryl, heteroaryl, etc.) and their pharmaceutically acceptable salts, useful in the prevention of or treatments for diseases relating to NAD(P)H, are prepared Thus, N-2-cyclohexylphenyl 3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amide was prepared in several steps from Et 7-chloropyrazolo[1,5-a]pyrimidine-5-carboxylate.

IT 619305-38-3 619305-39-4 619305-40-7  
 619305-41-8 619305-42-9 619305-43-0  
 619305-44-1 619305-45-2 619305-46-3  
 619305-47-4 619305-48-5 619305-49-6  
 619305-50-9 619305-51-0 619305-52-1  
 619305-53-2 619305-54-3 619305-55-4  
 619305-56-5 619305-57-6 619305-58-7  
 619305-59-8 619305-60-1 619305-61-2  
 619305-65-6 619305-66-7 619305-67-8




619305-66-9 619305-69-0 619305-70-3  
 619305-71-4 619305-72-5 619305-73-6  
 619305-74-7 619305-75-8 619305-76-9  
 619305-77-0 619305-78-1 619305-79-2  
 619305-80-5 619305-81-6 619305-82-7  
 619305-83-8 619305-84-9 619305-85-0  
 619305-86-1 619305-87-2 619305-88-3  
 619305-89-4 619305-90-7 619305-91-8  
 619305-92-9 619305-93-0 619305-94-1  
 619305-95-2 619305-96-3 619305-97-4  
 619305-98-5 619305-99-6 619306-00-2  
 619306-01-3 619306-02-4 619306-03-5  
 619306-04-6 619306-05-7 619306-06-8  
 619306-07-9 619306-08-0 619306-09-1  
 619306-10-4 619306-11-5 619306-12-6  
 619306-13-7 619306-14-8 619306-15-9  
 619306-16-0 619306-17-1 619306-18-2  
 619306-19-3 619306-20-6 619306-21-7  
 619306-22-8 619306-23-9 619306-24-0  
 619306-25-1 619306-26-2 619306-27-3  
 619306-28-4 619306-29-5 619306-30-8  
 619306-31-9 619306-32-0 619306-33-1  
 619306-34-2 619306-35-3 619306-36-4  
 619306-37-5 619306-38-6 619306-39-7  
 619306-40-0 619306-41-1 619306-42-2  
 619306-43-3 619306-44-4 619306-45-5  
 619306-46-6 619306-47-7 619306-48-8  
 619306-49-9 619306-50-2 619306-51-3  
 619306-52-4 619306-53-5 619306-54-6  
 619306-55-7 619306-56-8 619306-57-9  
 619306-59-1 619306-60-4 619306-61-5  
 619306-62-6 619306-63-7 619306-64-8  
 619306-65-9 619306-66-0 619306-67-1  
 619306-68-2 619306-69-3 619306-70-6  
 619306-71-7 619306-72-8 619306-73-9  
 619306-74-0 619306-75-1 619306-76-2  
 619306-77-3 619306-78-4 619306-79-5  
 619306-80-8 619306-81-9

RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase  
 inhibitors)


RN 619305-38-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinylmethyl)phenyl]- (CA INDEX NAME)




RN 619305-39-4 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN    619305-40-7    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-(2-cyclohexylphenyl)- (CA INDEX NAME)




RN    619305-41-8    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperidinyl)phenyl]- (CA INDEX NAME)




RN    619305-42-9    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 619305-43-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619305-44-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619305-45-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(methylpropylamino)phenyl]- (CA INDEX NAME)




RN 619305-46-3 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[1,1'-biphenyl]-2-yl-3-(3-chlorophenyl)- (CA INDEX NAME)




RN 619305-47-4 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(cyclopentylamino)phenyl]- (CA INDEX NAME)




RN 619305-48-5 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-  
[(phenylamino)carbonyl]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX  
NAME)




RN 619305-49-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(3-methyl-2-butenyl)amino]phenyl]-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 619305-50-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-methylphenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-51-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(2-phenoxyphenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-52-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(phenylmethyl)thio]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-53-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(6-phenoxy-3-pyridinyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-54-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)




RN 619305-55-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(4-phenyl-1-butynyl)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 619305-56-5 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-  
 [(tetrahydro-2-furanyl)methyl]thio]phenyl]- (CA INDEX NAME)




RN    619305-57-6    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[[2-(diethylamino)ethyl]amino]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN    619305-58-7    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1,1-dimethylethyl)phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN    619305-59-8    CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[(2-aminoethyl)amino]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 619305-60-1 CAPLUS


CN D-Phenylalanine, N-[[3-[4-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 619305-61-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-[2-[2-(trifluoromethyl)phenyl]ethyl]phenyl]- (CA INDEX NAME)



RN 619305-65-6 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[[3-[4-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 619305-66-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[(1R)-2-hydroxy-1-phenylethyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 619305-67-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[1,1'-biphenyl]-4-yl-3-(3-chlorophenyl)- (CA INDEX NAME)




RN 619305-68-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(1-naphthalenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619305-69-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-fluoro-4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619305-70-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-[(2-aminoethyl)amino]phenyl]-

3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 619305-71-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-72-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-methyl-5-(1-piperazinyl)phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 619305-73-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-methoxyphenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-74-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-(phenylmethyl)-N-4-piperidiny- (CA INDEX NAME)




RN 619305-75-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-(1-piperazinylcarbonyl)phenyl]- (CA INDEX NAME)




RN 619305-76-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(2-methylamino)ethyl]-1-piperidinyl]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 619305-77-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-methyl-3-(1-piperazinyl)phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 619305-78-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-(2,3-dihydroxypropyl)-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-79-2 CAPLUS

CN Acetic acid, [4-[[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-3-(1-piperazinyl)phenoxy]-, hydrazide (9CI) (CA INDEX NAME)




RN 619305-80-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(methilamino)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-81-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinyl)phenyl]-7-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 619305-82-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-methyl-4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-83-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,5-difluorophenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-84-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3,4-difluoro-2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-85-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(5-phenyl-1-pentynyl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 619305-86-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 619305-87-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)amino]phenyl]-N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




PAGE 1-A




RN 619305-88-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(2-methylpropyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 619305-89-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinyl)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 619305-90-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(3-amino-1-propynyl)phenyl]-3-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 619305-91-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-[4-

(ethylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619305-92-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-methyl-2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619305-93-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-(4-amino-1-piperidinyl)phenyl]-3-[4-[(cyclohexylmethyl)amino]phenyl]- (CA INDEX NAME)



RN 619305-94-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)amino]phenyl]-N-[ (1S)-1-(hydroxymethyl)-2-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 619305-95-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phoxymethyl)phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-96-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]-2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-97-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(2-hydroxyethyl)amino]-1-butyryl]phenyl]- (9CI) (CA INDEX NAME)



RN 619305-98-5 CAPLUS


CN  $\beta$ -Alanine, N-[1-[2-[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]phenyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 619305-99-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)amino]phenyl]-N-[(1R)-1-(hydroxymethyl)-2-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 619306-00-2 CAPLUS

CN Butanoic acid, 4-[[1-[2-[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]phenyl]-4-piperidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 619306-01-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)amino]phenyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 619306-02-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(4-amino-3-fluorophenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-03-5 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[2-[[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 619306-04-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(dimethylamino)-3-fluorophenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-05-7 CAPLUS

CN Glycine, N-[1-[2-[[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]phenyl]-4-piperidiny]-N-(2-methoxy-2-oxoethyl)-, methyl ester (CA INDEX NAME)




RN 619306-06-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-(4-amino-1-piperidinyl)phenyl]-3-[4-[(phenylmethyl)amino]phenyl]- (CA INDEX NAME)




RN 619306-07-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[2-(2-hydroxyethyl)amino]ethyl]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619306-08-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(cyclopropylamino)-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-09-1 CAPLUS

CN Glycine, N-[1-[2-[[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]phenyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 619306-10-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2,5-difluoro-4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-11-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(4-piperidinyloxy)-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 619306-12-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(3-aminopropyl)-1-piperazinyl]phenyl]-3-(3-chlorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 619306-13-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(3-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-14-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(3-hydroxypropyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 619306-15-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-[(aminoacetyl)amino]propyl]-1-piperazinyl]phenyl]-3-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 619306-16-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(aminoacetyl)-1-piperazinyl]phenyl]-3-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 619306-17-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-[(3R,5S)-3,5-dimethyl-1-piperazinyl]phenyl]-3-[4-[(phenylmethyl)amino]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 619306-18-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3R)-3-(diethylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 619306-19-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)amino]phenyl]-N-[3-[4-(ethylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)






RN 619306-20-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-[(3R,5S)-3,5-dimethyl-1-piperazinyl]phenyl]-3-[4-[[ (3-methoxyphenyl)methyl]amino]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

—OMe

RN 619306-21-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-[4-(methylamino)-1-piperidinyl]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 619306-22-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-[3-(aminoiminomethyl)amino]propyl]-1-piperazinyl]phenyl]-3-(3-chlorophenyl)-


, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 619306-23-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-[2-[(aminomethylamino)ethyl]-1-piperazinyl]phenyl]-3-(3-chlorophenyl)]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 619306-24-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(ethylamino)-1-piperidinyl]phenyl]-3-phenyl- (CA INDEX NAME)



RN 619306-25-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[2-[(iminomethylamino)ethyl]-1-piperazinyl]phenyl]]-, monohydrochloride (9CI)


(CA INDEX NAME)



● HCl


RN 619306-26-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinyl)-3-pyridinyl]- (CA INDEX NAME)




RN 619306-27-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(ethylamino)-1-piperidinyl]-5-(trifluoromethyl)phenyl]-3-phenyl- (CA INDEX NAME)




RN 619306-28-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(3-methoxyphenyl)methyl]amino]phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-29-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(diethylamino)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-30-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(1-piperazinylmethyl)phenyl]- (CA INDEX NAME)




RN 619306-31-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-ethylaminophenyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 619306-32-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(cyclopentylamino)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-33-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4,5-difluoro-2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-34-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-fluorophenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-35-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(2-aminoethyl)-1-piperazinyl]phenyl]-3-(3-chlorophenyl)-7-(diethylamino)- (CA INDEX NAME)




RN 619306-36-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(dimethylamino)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-37-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-(1-piperazinylmethyl)phenyl]- (CA INDEX NAME)




RN 619306-38-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-methoxy-2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-39-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(phenylmethyl)amino]phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-40-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,4-dichlorophenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-41-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-42-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-phenyl-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-43-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,4-dichlorophenyl)-N-[2-(4-(ethylamino)-1-piperidiny)]-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 619306-44-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[3-(1-piperazinyl)propoxy]phenyl]-, hydrochloride (10:19) (CA INDEX NAME)



●19/10 HCl

RN 619306-45-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(4-(butylamino)-1-piperidiny)]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)






RN 619306-46-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(pentylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619306-47-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-methylphenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619306-48-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[3-(1-piperazinyl)propoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 619306-49-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-(1-piperazinyl)phenyl]-3-(4-propylphenyl)- (CA INDEX NAME)



RN 619306-50-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[[trans-4-(methylamino)cyclohexyl]oxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 619306-51-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619306-52-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-propyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-53-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-(phenylmethoxy)phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-54-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(4-methyl-1-piperazinyl)amino]phenyl]- (CA INDEX NAME)



RN 619306-55-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-(phenylmethoxy)phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619306-56-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(2-(4-morpholinyl)ethoxy)-2-(1-piperazinyl)phenyl]-, hydrochloride (10:19) (CA


INDEX NAME)



● 19/10 HCl


RN 619306-57-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-methyl-3-[4-(phenylmethoxy)phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-59-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(4-amino-1-butynyl)phenyl]-3-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 619306-60-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[3-[4-(ethylamino)-1-piperidinyl]phenyl]-3-[4-[(phenylmethyl)amino]phenyl]- (CA INDEX NAME)




RN 619306-61-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(3,3-dimethyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-62-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(3-ethyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-63-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(2-hydroxyethyl)amino]-1-propynyl]phenyl]- (9CI) (CA INDEX NAME)




RN 619306-64-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[3-(methylamino)methyl]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619306-65-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(2-methoxyethyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619306-66-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,5-dichlorophenyl)-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-67-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[4-(methylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619306-68-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619306-69-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-(1-piperazinyl)phenyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 619306-70-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]phenyl]-3-[4-[[3-methoxyphenyl)methyl]amino]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




—OMe

RN 619306-71-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-[(3R)-3-amino-1-pyrrolidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619306-72-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-[(cis-4-aminocyclohexyl)oxy]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)

Relative stereochemistry.






RN 619306-73-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619306-74-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[5-fluoro-2-(1-piperazinyl)phenyl]-3-[4-(phoxymethyl)phenyl]- (CA INDEX NAME)




RN 619306-75-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,5-dimethylphenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-76-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-methyl-4-(4-piperidinyloxy)phenyl]- (CA INDEX NAME)




RN 619306-77-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-(1-methylethyl)phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619306-78-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[3-(1-methylethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 619306-79-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[3-chloro-4-(4-piperidinyloxy)phenyl]- (CA INDEX NAME)




RN 619306-80-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-(3-phenylpropyl)-N-4-piperidinyl- (CA INDEX NAME)



RN 619306-81-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylamino)methyl]phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)



IT 619302-82-8P 619302-65-1P 619302-88-4P

619302-89-5P 619302-92-0P 619302-95-3P

619302-98-6P 619303-00-3P 619303-04-7P

619303-08-1P 619303-12-7P 619303-16-1P

619303-22-9P 619303-26-3P 619303-29-6P

619303-33-2P 619303-36-5P 619303-39-8P

619303-40-1P 619303-41-2P 619303-44-5P

619303-48-9P 619303-52-5P 619303-56-9P

619303-59-2P 619303-63-8P 619303-67-2P

619303-69-4P 619303-71-8P 619303-73-0P

619303-74-1P 619303-75-2P 619303-77-4P

619303-79-6P 619303-81-0P 619303-83-2P

619303-85-4P 619303-87-6P 619303-89-8P

619303-90-1P 619303-91-2P 619303-92-3P

619303-94-5P 619303-95-6P 619303-96-7P

619303-97-8P 619303-98-9P 619303-99-0P

619304-00-6P 619304-01-7P 619304-02-8P

619304-03-9P 619304-04-0P 619304-05-1P

619304-06-2P 619304-07-3P 619304-08-4P

619304-09-5P 619304-10-8P 619304-11-9P


619304-12-0P 619304-13-1P 619304-14-2P  
 619304-15-3P 619304-16-4P 619304-17-5P  
 619304-18-6P 619304-19-7P 619304-20-0P  
 619304-21-1P 619304-22-2P 619304-23-3P  
 619304-24-4P 619304-25-5P 619304-27-7P  
 619304-28-8P 619304-29-9P 619304-30-2P  
 619304-31-3P 619304-32-4P 619304-33-5P  
 619304-34-6P 619304-35-7P 619304-41-5P  
 619304-42-6P 619304-46-0P 619304-47-1P  
 619304-48-2P 619304-49-3P 619304-50-6P  
 619304-51-7P 619304-52-8P 619304-53-9P  
 619304-54-0P 619304-55-1P 619304-56-2P  
 619304-57-3P 619304-58-4P 619304-59-5P  
 619304-60-8P 619304-61-9P 619304-62-0P  
 619304-63-1P 619304-65-3P 619304-66-4P  
 619304-67-5P 619304-69-7P 619304-70-0P  
 619304-71-1P 619304-72-2P 619304-73-3P  
 619304-74-4P 619304-75-5P 619304-76-6P  
 619304-77-7P 619304-78-8P 619304-79-9P  
 619304-80-2P 619304-81-3P 619304-83-5P  
 619304-85-7P 619304-86-8P 619304-87-9P  
 619304-88-0P 619304-89-1P 619304-91-5P  
 619304-92-6P 619304-93-7P 619304-94-8P  
 619304-95-9P 619304-96-0P 619304-97-1P  
 619304-98-2P 619305-02-1P 619305-05-4P  
 619305-07-6P 619305-08-7P 619305-09-8P  
 619305-11-2P 619305-13-4P 619305-14-5P  
 619305-15-6P 619305-18-9P 619305-19-0P  
 619305-21-4P 619305-22-5P 619305-24-7P  
 619305-25-8P 619305-26-9P 619305-29-2P  
 619305-31-6P 619305-32-7P 619305-33-8P  
 619305-34-9P 619305-35-0P 619305-36-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)


RN 619302-82-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 619302-85-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619302-88-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 619302-89-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619302-92-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-ethyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619302-95-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-(1-methylpropyl)-3-

[[ (phenylmethoxy)imino]methyl]- (CA INDEX NAME)




RN 619302-98-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-(1-methylpropyl)-3-(2-phenylethenyl)- (CA INDEX NAME)



RN 619303-00-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)




RN 619303-04-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[[2-(1-piperazinyl)phenyl]methyl]-, (2E)-2-butenedioate (2:1) (CA INDEX NAME)

CM 1

CRN 619303-03-6

CMF C24 H23 Cl N6 O




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 619303-08-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[[2-(4-morpholinyl)phenyl]methyl]- (CA INDEX NAME)



RN 619303-12-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-(1-methylpropyl)-2-phenyl- (CA INDEX NAME)



RN 619303-16-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[[2-(4-

morpholinyl)phenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 619303-22-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 2-phenyl-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-26-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 2-phenyl-N-[[2-(1-piperazinyl)phenyl)methyl]- (CA INDEX NAME)



RN 619303-29-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)





RN 619303-33-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-(3-pyridinyl)- (CA INDEX NAME)



RN 619303-36-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[(3R)-3-amino-1-pyrrolidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619303-39-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-3-pyridinyl- (CA INDEX NAME)



RN 619303-40-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-cyclohexyl- (CA INDEX NAME)



RN 619303-41-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3R)-3-(methylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 619303-44-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619303-48-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(4-amino-1-piperidinyl)phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)




RN 619303-52-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-(methylamino)-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 619303-56-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(dimethylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619303-59-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-63-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-fluoro-4-hydroxyphenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-67-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(1-chloro-2-phenylethenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-69-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(phenylacetyl)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 619303-71-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(2-phenylethyl)phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619303-73-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[(1E)-2-phenylethenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 619303-74-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[6-[(phenylmethyl)amino]-3-pyridinyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-75-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(phenylmethyl)amino]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-77-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 619303-79-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(cyclohexylmethoxy)phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-81-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-(3-pyridinylmethoxy)phenyl]- (CA INDEX NAME)



RN 619303-83-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-(3-thienylmethoxy)phenyl]- (CA INDEX NAME)



RN 619303-85-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-[(1E)-2-phenylethenyl]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 619303-87-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(aminoiminomethyl)-1-piperazinyl]phenyl]-3-(3-chlorophenyl)-, hydrochloride (5:7) (CA INDEX NAME)



● 7/5 HCl


RN 619303-89-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(1-naphthalenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619303-90-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-2-thiazolyl- (CA INDEX NAME)




RN 619303-91-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[2-(4-chlorophenyl)ethyl]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619303-92-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[2-(3-fluorophenyl)ethyl]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)






RN 619303-94-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[(1R)-1-(hydroxymethyl)-2-phenylethyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619303-95-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(1-piperazinyl)phenyl]-3-[4-[2-[4-(trifluoromethyl)phenyl]ethyl]phenyl]- (CA INDEX NAME)




RN 619303-96-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 619303-97-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 619303-98-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[2-(4-methoxyphenyl)ethyl]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619303-99-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(5-phenyl-1-pentynyl)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 619304-00-6 CAPLUS


CN Benzenecetic acid,  $\alpha$ -[[[3-[4-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]amino]-, methyl ester, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-01-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-02-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(3,5-dimethyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-03-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(aminoiminomethyl)-1-piperazinyl]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 619304-04-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-[2-(1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)



RN 619304-05-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-(1-piperazinyl)ethyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-06-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-07-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-08-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[[2-(1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)




RN 619304-09-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[[2-(1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)




RN 619304-10-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(2-aminoethyl)-1-piperazinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)




RN 619304-11-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(aminomethyl)-1-piperidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)




RN 619304-12-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-(ethylamino)-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 619304-13-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 619304-14-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-(methylamino)-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 619304-15-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(ethylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-16-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(propylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-17-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[4-(butylamino)-1-piperidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)




RN 619304-18-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(1-methylethyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-19-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(1-methylpropyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-20-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[4-(methylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 619304-21-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[4-(ethylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)






RN 619304-22-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[4-(1-methylethyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-23-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[4-(propylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-24-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[4-(2-propenylamino)-1-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 619304-25-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[4-(butylamino)-1-piperidinyl]phenyl]-3-(4-chlorophenyl)- (CA INDEX NAME)



RN 619304-27-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[(2S)-2-[(2-hydroxyethyl)amino]methyl]-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-28-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(5-phenyl-1-pentynyl)-N-[3-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 619304-29-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenylmethoxy)phenyl]-N-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 619304-30-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[(3R)-3-amino-1-pyrrolidinyl]phenyl]-3-(4-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619304-31-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(2-phenylethyl)phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619304-32-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[(2S)-2-(aminomethyl)-1-pyrrolidinyl]phenyl]-3-(4-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-33-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(diethylamino)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-34-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(2-(dimethylamino)ethyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-35-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(2-naphthalenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619304-41-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(3-hydroxypropyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 619304-42-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[(3S)-3-(ethylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-46-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(2S)-2-(ethylamino)ethyl]amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-47-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(phenylmethyl)amino]phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-48-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(2-methylpropyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-49-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[5-fluoro-2-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619304-50-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(cyclohexylmethyl)amino]phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619304-51-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(1-

piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-52-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-[(4-fluorophenyl)amino]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-53-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(methyl (phenylmethyl) amino)phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-54-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(2-hydroxyethyl)amino)methyl]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-55-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(1-methylethyl)(phenylmethyl)amino]phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-56-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)methylamino]phenyl]-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619304-57-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-(phenoxy)methyl]phenyl]-N-[2-(1-piperazinyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)






RN 619304-58-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 619304-59-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(methylamino)methyl]-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619304-60-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(cyclohexylmethyl)amino]phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-61-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 619304-62-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[3-(methylsulfonyl)amino]propyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 619304-63-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 619304-65-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 619304-66-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3R)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 619304-67-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3S)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-69-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[(3R)-3-[(2-aminoethyl)amino]-1-pyrrolidinyl]phenyl]-3-(3-chlorophenyl)-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CRN 619304-68-6  
CMF C25 H26 Cl N7 O


Absolute stereochemistry.



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 619304-70-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[(3S)-3-[(2-aminoethyl)amino]-1-pyrrolidinyl]phenyl]-3-(3-chlorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 619304-71-1 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(2-aminoethyl)-1-piperidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)




RN    619304-72-2    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[3-(aminomethyl)-1-piperidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)




RN    619304-73-3    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(methylamino)-1-piperidinyl]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN    619304-74-4    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(methylamino)-1-piperidinyl]phenyl]-3-[4-[(phenylmethyl)amino]phenyl]- (CA INDEX NAME)



RN 619304-75-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(methylamino)-1-piperidinyl]phenyl]-3-[4-(2-phenylethyl)phenyl]- (CA INDEX NAME)



RN 619304-76-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(methylamino)-1-piperidinyl]phenyl]-3-[4-[(1Z)-2-phenylethenyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 619304-77-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[4-(methylamino)-1-piperidinyl]phenyl]-3-[4-[(1E)-2-phenylethenyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 619304-78-8 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(1-methylethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 619304-79-9 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[(1-methylethyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 619304-80-2 CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[(2S)-2-(aminomethyl)-1-pyrrolidinyl]phenyl]-3-(3-chlorophenyl)-    (CA INDEX NAME)


Absolute stereochemistry.



RN 619304-81-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(2S)-2-[[2-(hydroxyethyl)amino]methyl]-1-pyrrolidinyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 619304-83-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3S)-3-methyl-1-piperazinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-85-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[[2-(2-hydroxypropyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 619304-86-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[[[(1R)-2-hydroxy-1-methylethyl]amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 619304-87-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[[[(1S)-2-hydroxy-1-methylethyl]amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 619304-88-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(2S)-2-[(methylamino)methyl]-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619304-89-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(2-ethenyl-2-butenyl)oxy]phenyl]-N-[3-[4-(ethylamino)-1-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 619304-91-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(1-piperazinyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 619304-92-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-[[[(2S)-2-hydroxypropyl]amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 619304-93-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(4-piperidinyloxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 619304-94-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-(4-piperidinyloxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 619304-95-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,5-dichlorophenyl)-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-96-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3,5-dichlorophenyl)-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-97-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-[(phenylmethyl)amino]phenyl]-N-[2-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619304-98-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[4-[(1-methylpropyl)amino]-1-piperidinyl]phenyl]- (CA INDEX NAME)



RN 619305-02-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(1-piperazinyl)-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 619305-05-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-(4-chlorophenyl)-N-[2-[(3R)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619305-07-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[4-(propylamino)-1-piperidinyl]phenyl]- (CA INDEX NAME)




RN 619305-08-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-(4-cyanophenyl)- (CA INDEX NAME)




RN 619305-09-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3-[(phenylmethyl)amino]phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-11-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[6-(1-piperazinyl)-3-pyridinyl]- (CA INDEX NAME)



RN 619305-13-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(4-chlorophenyl)-N-[3-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 619305-14-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-[(3S)-3-amino-1-


pyrrolidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619305-15-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(phenylmethyl)aminophenyl]-N-[4-(1-piperazinylmethyl)phenyl]- (CA INDEX NAME)



RN 619305-18-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-[(2S)-2-(aminomethyl)-1-pyrrolidinyl]phenyl]-3-(3-chlorophenyl)-, hydrochloride (10:17) (CA INDEX NAME)

Absolute stereochemistry.




●17/10 HCl

RN 619305-19-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[4-(1-piperazinyl)phenyl]-3-

(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 619305-21-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(3-pyrrolidinyloxy)phenyl]- (CA INDEX NAME)



RN 619305-22-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[4-[(phenylmethyl)amino]phenyl]-N-[4-(4-piperidinyloxy)phenyl]- (CA INDEX NAME)



RN 619305-24-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[2-(2-aminoethyl)-1-piperidinyloxy]phenyl]-3-(3-chlorophenyl)-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 619305-23-6

CMF C26 H27 Cl N6 O






CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 619305-25-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-(4-methoxy-3-(1-piperazinyl)phenyl)- (CA INDEX NAME)




RN 619305-26-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[2-(aminomethyl)-1-piperidinyl]phenyl]-3-(3-chlorophenyl)- (CA INDEX NAME)



RN 619305-29-2 CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(4-chlorophenyl)-N-[4-methoxy-3-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN    619305-31-6    CAPLUS

CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-[(2R)-2-(aminomethyl)-1-pyrrolidinyl]phenyl]-3-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN    619305-32-7    CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-[[trans-4-(ethylamino)cyclohexyl]oxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN    619305-33-8    CAPLUS


CN    Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 619305-34-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[2-[(3R)-3-methyl-1-piperazinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 619305-35-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(4-piperidinylmethyl)phenyl]- (CA INDEX NAME)



RN 619305-36-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-N-[4-(4-piperidinyl)phenyl]- (CA INDEX NAME)



RE.CNT 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:656742 CAPLUS Full-text  
 DN 139:197375  
 TI Preparation of piperidinyl alcohols as chemokine receptor modulators for  
 treatment of diseases such as asthma  
 IN Alcaraz, Lilian; Furber, Mark; Purdie, Mark; Springthorpe, Brian  
 PA Astrazeneca A.B., Swed.  
 SO PCT Int. Appl., 166 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068743	A1	20030821	WO 2003-SE258	20030217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, IJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472822	A1	20030821	CA 2003-2472822	20030217
	AU 2003206554	A1	20030904	AU 2003-206554	20030217
	BR 2003007477	A	20041109	BR 2003-7477	20030217
	EP 1478624	A1	20041124	EP 2003-705600	20030217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1633414	A	20050629	CN 2003-804130	20030217
	JP 2005525341	T	20050825	JP 2003-567874	20030217
	NZ 534296	A	20060127	NZ 2003-534296	20030217
	NZ 541682	A	20060526	NZ 2003-541682	20030217
	CN 1907968	A	20070207	CN 2006-10110091	20030217
	IN 2004DN02041	A	20050401	IN 2004-DN2041	20040715
	MX 2004PA07906	A	20041015	MX 2004-PA7906	20040813
	ZA 2004006509	A	20050915	ZA 2004-6509	20040816
	US 2005107428	A1	20050519	US 2004-504936	20040817
	NO 2004003899	A	20041117	NO 2004-3899	20040917
	IN 2007DN09369	A	20080215	IN 2007-DN9369	20071205
FRAI	SE 2002-465	A	20020218		
	SE 2002-2673	A	20020909		
	CN 2003-804130	A3	20030217		
	NZ 2003-534296	A1	20030217		
	WO 2003-SE258	W	20030217		
	IN 2004-DN2041	A3	20040715		
OS	CASREACT 139:197375; MARPAT 139:197375				
GI					



$\text{CR}^2\text{R}^3(\text{CH}_2)_m\text{CR}^4(\text{OH})\text{CR}^5\text{R}^6(\text{CR}^7\text{R}^8)_n\text{NR}^{32}\text{ZYZR}$

I

AB The invention provides piperidinyl alcs. (shown as I; variables defined below; e.g. N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-(methylsulfonyl)benzamide) for use as modulators of chemokine receptor (especially CCR3) activity for use in, for example, treating asthma. For I: X is CH<sub>2</sub>, O, S(O)2 or NR10; Y is a bond, CH<sub>2</sub>, NR35, CH<sub>2</sub>NH, CH<sub>2</sub>NHC(O), CH(OH), CH(NHCOR33), CH(NHSO<sub>2</sub>R34), CH<sub>2</sub>O or CH<sub>2</sub>S; Z is C(O), or when Y is a bond Z can also be S(O)2; R1 is (un)substituted aryl, (un)substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; addnl. details are given in the claims. Percent inhibition at 3 nM eotaxin of eotaxin-mediated human eosinophil chemotaxis is tabulated for 16 examples of I, e.g. 106 % for N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-1-oxo-1,2-dihydroisoquinoline-4-carboxamide. Histamine H1 receptor binding activity was determined for the same compds., e.g. pKi = 8.4 for N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-1-oxo-1,2-dihydroisoquinoline-4-carboxamide. 49 Example preps. of intermediates and 234 of I are included. For example, to prepare N-[(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-(methylsulfonyl)benzamide (0.055 g), a mixture of 2-(methylsulfonyl)benzoic acid (0.063 g), (2R)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (0.1 g) and N,N-diisopropylethylamine (0.1 ml) in dry DMF (3 mL) was cooled to 0° with stirring; 2-(1H-9-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.13 g) was added and the mixture was stirred at 0° for 1-2 h. The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compds. of the invention. The process comprises (a) reacting 4-hydroxypiperidine with a suitable base in a suitable solvent at room temperature; and (b) heating the mixture so produced and 1,2-dichloro-4-fluorobenzene at 50-90°, or at reflux of the solvent used.


IT 583881-86-1P, N-[(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2,7-dimethylpyrazolo[1,5-a]pyrimidine-6-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidinyl alcs. as chemokine receptor modulators for treatment of diseases such as asthma)

RN 583881-86-1 CAPIUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[(2R)-3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-hydroxypropyl]-2,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2002:695987 CAPLUS Full-text  
 DN 137:232638

TI Preparation of bicyclic diamines as CCR2 and CCR3 chemokine receptor antagonists for treating/preventing diseases associated with monocyte, lymphocyte or leukocyte accumulation

IN Colon-Cruz, Roberto; Didiuk, Mary Theresa; Duffy, Erin Maureen; Garigipati, Ravi Shanker; Lau, Wan Fang; McDonald, Wayne Scott

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 165 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070523	A1	20020912	WO 2002-IB238	20020124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2440803	A1	20020912	CA 2002-2440803	20020124
	AU 2002225290	A1	20020919	AU 2002-225290	20020124
	EP 1368354	A1	20031210	EP 2002-715643	20020124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007952	A	20040727	BR 2002-7952	20020124
	JP 2004529113	T	20040924	JP 2002-569843	20020124
	US 2003008893	A1	20030109	US 2002-93273	20020306
	US 6821964	B2	20041123		
	MX 2003PA08109	A	20031212	MX 2003-PA8109	20030905
	US 2005234090	A1	20051020	US 2004-989764	20041115
PRAI	US 2001-273984P	P	20010307		
	WO 2002-IB238	W	20020124		
	US 2002-93273	A1	20020306		
OS	MARPAT 137:232638				
GI					




I



II

- AB Chemokine receptor antagonists, in particular, bicyclic diamines (shown as I; e.g. N-[2-[5-(2,4-dimethylbenzyl)hexahydropyrrolo[3,4-c]pyrrol-2-yl]-2-oxoethyl]-3-trifluoromethylbenzamide) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compns. and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein. In I, A is a substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C2-C6)alkenyl, substituted or unsubstituted partially saturated or fully saturated (C3-C6)cycloalkyl, substituted or unsubstituted partially saturated or fully saturated 5 to 6 membered heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl group. A is 0-3; w, x, y and z are each independently 0-4 with provisos; p is 0 or 1. L is a linking group selected from -(CH2)q-X-, where X is NH, O, or oxo and q is 0-4, -(S(O)r-(CH2)t-NH-, where r is 0-2 and t is 0-4, -(aryl)-NH-, -(heteroaryl)-NH-, and an amino acid residue where the amino N of said amino acid residue is attached to B and the carbonyl of said amino acid residue is attached to the ring N. B is a substituted or unsubstituted (C1-C6)alkylcarbonyl, arylcarbonyl, (C1-C6)alkoxycarbonyl, aryloxycarbonyl, (C1-C6)alkylsulfonyl, arylsulfonyl, (C1-C6)alkylthiocarbonyl, arylthiocarbonyl, (C1-C6)alkylcarbamoyl, arylcarbamoyl, (C1-C6)alkyl-C(=NH)-, substituted or unsubstituted aryl-C(=NH)-, or a protecting group. Although the methods of preparation are not claimed, several example preps. are included and about 1500 specific compds. are listed with their HPLC retention times and CI-MS mol. wts. In general, the compds. listed in the Examples provided CCR2 activity based on chemotaxis from .apprx.5 to .apprx.100% inhibition at 1  $\mu$ M concentration Compds. II (R = Me) provided higher activity for inhibition of binding to its CCR2 receptor and showed less activity for inhibition of binding to the CCR3 receptor. Whereas, compds. II (R = Cl) provided higher activity for inhibition of binding to the CCR3 receptor and less activity for binding to the CCR2 receptor.
- IT 455912-61-5P, 2,7-Dimethylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid [2-[5-(2,4-dimethylbenzyl)hexahydropyrrolo[3,4-c]pyrrol-2-yl]-2-oxoethyl]amide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of bicyclic diamines as CCR2 and CCR3 chemokine receptor antagonists for treating/preventing diseased associated with monocyte, lymphocyte or leukocyte accumulation)
- RN 455912-61-5 CAPLUS
- CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[5-(2,4-

dimethylphenyl)methyl]hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-oxoethyl]-  
2,7-dimethyl- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



TI 1-(N,N-dimethylamino)-2-(N-phenylcarbamoyl)-1-buten-3-one as a building block for the synthesis of heterocyclic compounds

AU Elmaati, T. A.; Said, S.; Elenein, N. A.; Sofan, M.; Khodeir, N.

CS Faculty of Specific Education, Mansoura University, New Damietta, Egypt

SO Polish Journal of Chemistry (2002), 76(7), 945-952

CODEN: PJCHDQ; ISSN: 0137-5083

PB Polish Chemical Society

DT Journal

LA English

OS CASREACT 137:352926

AB Acetoacetanilide reacted with DMF-DMA to give the enamionone MeCOC(:CHNMe2)CONHPh (I). I, when treated with hydrazines, gives pyrazoles, resp., and with pyrazole derivs. the pyrazolopyrimidines. On the other hand, in reaction of I with benzimidazole and benzimidazole-2-acetonitrile, pyrimidobenzimidazole and the pyridobenzimidazole were formed. I reacts with hippuric acid in boiling acetic anhydride to afford a pyridine derivative. In the reaction of I with malononitrile, cyanoacetamide or malononitrile dimer compds. were formed.


IT 474369-18-1P 474369-21-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(use of (N,N-dimethylamino)(N-phenylcarbamoyl)butenone as a building block for the synthesis of heterocyclic compds.)


RN 474369-18-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-amino-2-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-7-methyl-N-phenyl- (CA INDEX NAME)



RN 474369-21-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-amino-7-methyl-N-phenyl-2-(phenylazo)- (9CI) (CA INDEX NAME)



L10 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2002:487577 CAPLUS Full-text  
 DN 137:63420


TI Preparation of lactone ketolide macrolide erythromycin antibiotics  
 IN Andreotti, Daniele; Arista, Luca; Biondi, Stefano; Cardullo, Francesca;  
 Damiani, Frederica; Lociuero, Sergio; Marchioro, Carla; Merlo, Giancarlo;  
 Mingardi, Anna; Niccolai, Daniela; Paio, Alfredo; Piga, Elisabetta;  
 Pozzan, Alfonso; Seri, Catia; Tarsi, Luca; Terreni, Silvia; Tibasco,  
 Jessica

PA Glaxo Group Limited, UK  
 SO PCT Int. Appl., 215 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050091	A1	20020627	WO 2001-GB5665	20011220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2432429	A1	20020627	CA 2001-2432429	20011220
	AU 2002017277	A	20020701	AU 2002-17277	20011220
	EP 1363925	A1	20031126	EP 2001-271380	20011220
	EP 1363925	B1	20061115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2003002526	A2	20031128	HU 2003-2526	20011220
	CN 1492874	A	20040428	CN 2001-822651	20011220
	BR 2001016431	A	20040622	BR 2001-16431	20011220
	JP 2004531471	T	20041014	JP 2002-551984	20011220
	NZ 526450	A	20050429	NZ 2001-526450	20011220
	AT 345350	T	20061215	AT 2001-271380	20011220
	ES 2275621	T3	20070616	ES 2001-271380	20011220
	IN 2003DN00933	A	20070420	IN 2003-DN933	20030616
	ZA 2003004748	A	20040423	ZA 2003-4748	20030619
	NO 2003002846	A	20030820	NO 2003-2846	20030620
	MX 2003PA05668	A	20041203	MX 2003-PA5668	20030620
	US 2004077557	A1	20040422	US 2003-450893	20031119
	US 2005215495	A1	20050929	US 2005-127701	20050512
	US 2006211636	A1	20060921	US 2006-422122	20060605
PRAI	GB 2000-31309	A	20001221		
	GB 2001-26276	A	20011101		
	GB 2001-26277	A	20011101		
	WO 2001-GB5665	W	20011220		
	US 2003-450893	B1	20031119		
	US 2005-127701	A1	20050512		
OS	MARPAT 137:63420				
GI					



I

AB The present invention relates to lactone ketolides I wherein R is H, CN, substituted alkyl; R1 is alkyl, alkenyl; R2 is H, hydroxy protecting group; R3 is H, halogen, and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body. Thus, (11S,21R)-3-decladineryl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]erythromycin A was prepared and tested as antibacterial agent against *Streptococcus pneumoniae* and *Streptococcus pyogenes* (MIC  $\leq$  1  $\mu$ g/mL).

IT 439105-28-9P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)


RN 439105-28-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[[(3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-9-[[[3,4,6-trideoxy-3-(dimethylamino)- $\beta$ -D-xylo-hexopyranosyl]oxy]-2H-furo[2,3-c]oxacyclotetradecin-3-yl]amino]ethyl]-2,7-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RE.CNT 6      THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:275953 CAPLUS Full-text

DN 136:309851

TI Preparation of diphenylamines and N-nitrosodiphenylamines for treatment of oxidative stress and unavailability of endothelial nitric oxide.

IN Lardy, Claude; Nioche, Jean-Yves; Caputo, Lidia; Decerpit, Jacques; Ortholand, Jean-Yves; Festal, Didier; Guerrier, Daniel

PA Merck Patent G.m.b.H., Germany

SO PCT Int. Appl., 142 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028820	A1	20020411	WO 2001-EP10761	20010918
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	FR 2815030	A1	20020412	FR 2000-12749	20001005
	CA 2424684	A1	20020411	CA 2001-2424684	20010918
	AU 2001089891	A	20020415	AU 2001-89891	20010918
	BR 2001014252	A	20030701	BR 2001-14252	20010918
	EP 1322598	A1	20030702	EP 2001-969732	20010918
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	HU 2003002771	A2	20031229	HU 2003-2771	20010918
	JP 2004521866	T	20040722	JP 2002-532407	20010918
	US 2004063783	A1	20040401	US 2003-398238	20030403
	NO 2003001533	A	20030404	NO 2003-1533	20030404
	MX 2003PA02999	A	20030714	MX 2003-PA2999	20030404
	ZA 2003003369	A	20040730	ZA 2003-3369	20030430
	IN 2003KN00563	A	20050121	IN 2003-KN563	20030502
PRAI	FR 2000-12749	A	20001005		
	WO 2001-EP10761	W	20010918		
OS	MARPAT 136:309851				
GI					



AB Title compds. [I; X, Ra = H, (unsatd.) alipharyl, AY; A = CO, SO2, CONRa, CONRaSO2; T = H, halo, NO2, cyano, (unsatd.) (halogenated) alipharyl optionally interrupted by O and/or S; Y = organic substituent; with provisos], and des-nitroso compds. (II; variables as above), were prepared Thus, a mixture of nicotinoyl chloride hydrochloride, 4-amino-4'-methoxy-N-tert-butoxycarbonyldiphenylamine, and Et3N was stirred in CH2Cl2 to give 100% 4-

nicotinoylamino derivative which was N-deprotected with CF3CO2H to give 95.2% 4-methoxy-4'-nicotinoylamino-diphenylamine. The latter in HOAc was treated dropwise with aqueous NaNO2 to give 88% N-nitroso-4-methoxy-4'-nicotinoylamino-diphenylamine. Tested II inhibited oxidation of human low mol. weight lipoproteins by Cu2+ with IC50 = 1.7-13.4 µM.


IT 409354-39-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diphenylamines and N-nitrosodiphenylamines for treatment of oxidative stress and unavailability of endothelial nitric oxide)

RN 409354-39-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[4-[(4-methoxyphenyl)nitrosoamino]phenyl]-2,7-dimethyl- (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2002:240695 CAPLUS Full-text  
 DN 136:279198  
 TI Preparation of resorcinol derivatives as inhibitors of tyrosinase for use  
 as skin-lightening agents  
 IN Bradley, Stuart Edward; Collington, Eric William; Fyfe, Matthew Colin  
 Thor; Gattrell, William Thomas; Geden, Joanna Victoria; Murray, Peter  
 John; Procter, Martin James; Rowley, Robert John; Williams, Jonathan  
 Gareth  
 PA Pfizer Products, Inc., USA  
 SO PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024613	A2	20020328	WO 2001-IB1677	20010913
	WO 2002024613	A3	20020627		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2423262	A1	20020328	CA 2001-2423262	20010913
	AU 2001084362	A	20020402	AU 2001-84362	20010913
	EP 1318974	A2	20030618	EP 2001-963342	20010913
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001014059	A	20030701	BR 2001-14059	20010913
	JP 2004509154	T	20040325	JP 2002-528629	20010913
	JP 3950046	B2	20070725		
	US 2002137961	A1	20020926	US 2001-953690	20010917
	US 6541473	B2	20030401		
	US 2003190298	A1	20031009	US 2003-386878	20030312
	US 6797731	B2	20040928		
	MX 2003PA02452	A	20030619	MX 2003-PA2452	20030319
PRAI	US 2000-234468P	P	20000921		
	WO 2001-IB1677	W	20010913		
	US 2001-953690	A1	20010917		
OS	MARPAT 136:279198				
GI					






AB Title compds. I [R = cycloalkyl, cycloalkenyl ring substituted by (1) NR1CONR2R3 wherein R1-2 = H, alkyl, arylalkyl; R3 = H, alkyl, arylalkyl, aryl; (2) NR4COR5 wherein R4 = H, alkyl, arylalkyl, OH; R5 = alkyl, aryl, arylalkyl, Oaryl, CF3, heterocycloalkyl, alkylheterocycloalkyl, alkenylheterocycloalkyl, heteroaryl, alkylheteroaryl, alkenylheteroaryl, alkenylaryl, alkenyl-CO-aryl, alkylNR4-CO-aryl, alkyl-CO-aryl, alkylhydroxyaryl, alkyl-X-aryl, alkenyl, benzylhydryl, 5-hydroxyoxoindanyl, tetrahydronaphthalenyl; X = O, SO0-2 or NR1; (3) NR1OCOaryl; (4) :CHCO2R1, etc., with the proviso that the cycloalkenyl ring is not aromatic] were prepared For instance, trans-4-[2,4-bis[(tert- butyldimethylsilyl)oxy]phenyl]cyclohexanol (preparation given) was coupled to N-(tert-butoxycarbonyl)-L-phenylalanine (CH2Cl2, DCC, DMAP) and the resulting ester treated with TFA to afford II. II had IC50  $\approx$  2  $\mu$ M for human tyrosinase. I are useful as skin lightening agents.

IT 405518-29-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug; preparation of resorcinol derivs. as inhibitors of tyrosinase for use as skin-lightening agents)

RN 405518-29-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[cis-4-(2,4-dihydroxyphenyl)cyclohexyl]-2,7-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:788869 CAPLUS Full-text

DN 135:344496

TI Preparation of pyrazolopyrimidine and pyrrolopyridazine derivatives as herbicides

IN Mizukoshi, Takashi; Adachi, Tomoaki; Maeda, Kaneshige; Akiyama, Shigeaki; Watanabe, Shigeomi; Nakahira, Kunimitsu; Oki, Toru; Hamada, Nobuyuki

PA Nissan Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 29 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2001302666	A	20011031	JP 2000-286572	20000921
PRAI	JP 1999-266544	A	19990921		
	JP 2000-36792	A	20000215		
OS	MARPAT 135:344496				
GI					




AB The title compds. I [Z1-Z2-Z3-Z4-Z5-Z1 is a pattern such as C-N-N:C(R4)-C(R5):C, etc.; R1 = H, alkyl, etc.; R2 = H, alkyl; R3 = H, halo, etc.; R4, R5 = H, alkyl, etc.; further details on R4 and R5 are given; X = CO2R10, etc.; R10 = H, alkyl, etc.] are prepared. Many compds. of this invention (at 2.5 g/area) gave  $\geq 90\%$  control of *Scirpus juncoides*. Several compds. of this invention (at 2.5 g/area) caused no damage to rice plants.

IT 371113-64-3P 371113-65-4P 371113-72-3P  
371113-73-4P 371113-74-5P 371113-75-6P  
371113-76-7P 371113-79-0P 371113-80-3P  
371113-81-4P 371113-84-7P 371113-85-8P  
371113-86-9P 371113-90-5P 371113-91-6P  
371113-92-7P 371113-93-8P 371113-95-0P  
371113-96-3P 371113-99-4P 371114-06-0P  
371114-02-2P 371114-03-3P 371114-04-4P  
371114-05-5P 371114-06-6P 371114-07-7P  
371114-08-8P 371114-09-9P 371114-14-6P  
371114-15-7P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolopyrimidine and pyrrolopyridazine derivs. as herbicides)


RN 371113-64-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-2,7-dimethyl-N5-(2-methylpropyl)- (CA INDEX NAME)




RN 371113-65-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-2,7-dimethyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-72-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-7-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-73-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-3-cyano-7-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-74-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-7-methyl-N5-(2-methylpropyl)- (CA INDEX NAME)




RN 371113-75-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-bromo-N6-(3-chloro-2,6-diethylphenyl)-7-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-76-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-bromo-N6-(3-chloro-2,6-diethylphenyl)-7-methyl-N5-(2-methylpropyl)- (CA INDEX NAME)




RN 371113-79-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-3,7-dimethyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-80-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-3,7-dimethyl-N5-(2-methylpropyl)- (CA INDEX NAME)




RN 371113-81-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-N5-ethyl-3,7-dimethyl- (CA INDEX NAME)




RN 371113-84-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-7-(methoxymethyl)-2-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-85-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-3-methoxy-7-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-86-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-N5-ethyl-3-methoxy-7-methyl- (CA INDEX NAME)




RN 371113-90-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2-methylphenyl)-7-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)




RN 371113-91-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-chloro-N-(3-chloro-2-methylphenyl)-7-methyl-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 371113-92-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-ethyl-7-methyl- (CA INDEX NAME)




RN 371113-93-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-chloro-N-(3-chloro-2,6-diethylphenyl)-7-methyl-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 371113-95-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 3-chloro-6-[(3-chloro-2-methylphenyl)amino]carbonyl]-7-methyl-, 2-ethylhydrazide (CA INDEX NAME)





RN 371113-98-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-chloro-N-(3-chloro-2,6-diethylphenyl)-7-[(methylthio)methyl]-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 371113-99-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(3-chloro-2,6-diethylphenyl)-3,7-dimethyl-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 371114-00-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-ethyl-7-[(methylthio)methyl]- (CA INDEX NAME)






RN 371114-02-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2-methylphenyl)-N5-(2-hydroxypropyl)-7-methyl- (CA INDEX NAME)




RN 371114-03-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5,7-dimethyl- (CA INDEX NAME)





RN 371114-04-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-ethyl-N5,7-dimethyl- (CA INDEX NAME)





RN 371114-05-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N5-(3-chloro-2,6-diethylphenyl)-N5-cyclopropyl-7-methyl- (9CI) (CA INDEX NAME)




RN 371114-06-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-(cyclopropylmethyl)-7-methyl- (CA INDEX NAME)




RN 371114-07-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-(2-fluoroethyl)-7-methyl- (CA INDEX NAME)




RN 371114-08-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-(2-hydroxyethyl)-7-methyl- (CA INDEX NAME)




RN 371114-09-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-N5-(2-chloroethyl)-7-methyl- (CA INDEX NAME)




RN 371114-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, 3-chloro-N6-(3-chloro-2,6-diethylphenyl)-7-methyl-N5-(1-methylethyl)- (CA INDEX NAME)



RN 371114-15-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,6-dicarboxamide, N6-(3-chloro-2,6-diethylphenyl)-3-hydroxy-7-methyl-N5-2-propenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1999:753019 CAPLUS Full-text  
 DN 132:12506

TI Preparation of peptides for treating diseases of excessive bone loss or cartilage or matrix degradation as cysteine protease inhibitors  
 IN Bondinell, William Edward; Desjarlais, Renee Louise; Veber, Daniel Frank; Yamashita, Dennis Shinji  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 128 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9959526	A2	19991125	WO 1999-US11266	19990520
	WO 9959526	A3	20000120		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2332531 A1 19991125 CA 1999-2332531 19990520 EP 1067894 A2 20010117 EP 1999-924421 19990520 R: BE, CH, DE, ES, FR, GB, IT, LI, NL JP 2002515411 T 20020528 JP 2000-549192 19990520 US 6518267 B1 20030211 US 2000-700828 20001121 PRAI US 1998-86557P P 19980521 WO 1999-US11266 W 19990520 OS MARPAT 132:12506 GI				



AB The present invention provides peptides bis-aminomethyl carbonyl protease inhibitors I (R1, R2 = alkyl; P = X, Y; R3 selected from the group consisting of: CH2CH(CH3)2, CH2CH2CH3, CH2CH=CH2, or CH2Ph; R4 is selected from the group consisting of alkyl; N-piperazine; N-tetrahydroisoquinoline; substituted alkyl, Ph, benzofuran, benzothiazole; quinoline; naphthyl; and benzoxazole; R5 = Ph and Ph substituted with alkyl, N-piperidine, benzofuran; pyridine; Q = arylacyl) and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K,

pharmaceutical compns. of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention. Thus, (S)-3N-(N-(thianaphthenyl-2-carbonyl)-leucanyl)- amino-1N-(3-(2-(1-oxo-pyridyl)phenylacetyl)-amino-butan-2-one was prepared for treating diseases of excessive bone loss or cartilage or matrix degradation as cysteine protease inhibitor. Determination of cathepsin K proteolytic catalytic activity of these compds. are reported.

IT 251457-50-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptides for treating diseases of excessive bone loss or cartilage or matrix degradation as cysteine protease inhibitors)

RN 251457-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2,7-dimethyl-N-[(1S)-3-methyl-1-[[[2-oxo-3-[[[3-(2-pyridinyl)phenyl]acetyl]amino]propyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Me

L10 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:166589 CAPLUS Full-text

DN 130:209978

TI Preparation of N-aroarylphenylalanine derivatives as vascular cell adhesion molecule-1 (VCAM-1) binding inhibitors

IN Chen, Li; Guthrie, Robert William; Huang, Tai-Nang; Hull, Kenneth G.; Sidduri, Achyutharao; Tilley, Jefferson Wright

PA F.Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9910313	A1	19990304	WO 1998-EP5144	19980813
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2300121	A1	19990304	CA 1998-2300121	19980813
	AU 9893419	A	19990316	AU 1998-93419	19980813
	AU 742928	B2	20020117		
	EP 1005446	A1	20000607	EP 1998-946326	19980813
	EP 1005446	B1	20040225		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	TR 200000481	T2	20000621	TR 2000-481	19980813
	BR 9811988	A	20000905	BR 1998-11988	19980813
	JP 2001514163	T	20010911	JP 2000-507644	19980813
	JP 3727536	B2	20051214		
	AT 260243	T	20040315	AT 1998-946326	19980813
	PT 1005446	T	20040630	PT 1998-946326	19980813
	ES 2214728	T3	20040916	ES 1998-946326	19980813
	ZA 9807602	A	19990504	ZA 1998-7602	19980821
	US 6455550	B1	20020924	US 1998-138353	19980821
	TW 515792	B	20030101	TW 1998-87113767	19980821
	MX 200001743	A	20001211	MX 2000-1743	20000218
	US 2003109459	A1	20030612	US 2002-117616	20020405
	US 6806365	B2	20041019		
	US 2004210051	A1	20041021	US 2004-828771	20040421
PRAI	US 1997-56929P	P	19970822		
	US 1998-94591P	P	19980729		
	WO 1998-EP5144	W	19980813		
	US 1998-138353	B3	19980821		
	US 2002-117616	A3	20020405		
OS	MARPAT 130:209978				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [one of X, X1 = H, halo, lower alkyl and the other = (un)substituted group X6, X7, X10; R1 = H, lower alkyl; n = 0, 1; Het = 5-6 membered heteroarom. ring containing 1-3 heteroatoms N, O, S, or 9-10 membered

bicyclic heteroarom. ring containing 1-4 heteroatoms N, O, S; R19 = (un)substituted lower alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; R18 = H, any group R19; R20 = (un)substituted lower alkyl, aryl, lower alkanoyl; Y = CR22R23R24, 3-7 membered ring Y2; R22, R23 = (un)substituted aryl, heteroaryl, lower alkyl; R24 = H, CN, (un)substituted aryl, lower alkyl, with provisos; R25 = lower alkyl, F-(un)substituted lower alkenyl, R26(CH2)m; R26 = aryl, heteroaryl, N3, CN, OH, NO2, amino, lower alkoxy, lower alkoxy carbonyl, lower alkanoyl, lower alkylthio, lower alkylsulfonyl, lower alkylsulfinyl, etc.; Q = bond, (CH2)pO, (CH2)pS, (CH2)p; m = 0-4; p = 0-3; Z = H, lower alkyl and pharmaceutically acceptable salts and esters thereof, are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing integrin VLA-4. Such compds. are useful for treating diseases whose symptoms and /or damage are related to the binding of VCAM-1 to cells expressing VLA-4. Thus, amidation of 4-amino-N-[(1-phenylcyclopentyl)carbonyl]-L-phenylalanine Me ester (preparation given) with 4-quinolinecarboxylic acid and saponification gave desired title derivative II as its sodium salt. II inhibited VLA-4 binding to immobilized VCAM-1 with IC50 = 2.7 nM in solid-phase dual antibody assay.

IT 220880-17-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-aroylphenylalanine derivs. as vascular cell adhesion mol.-1 (VCAM-1) binding inhibitors)

RN 220880-17-1 CAPLUS


CN L-Phenylalanine, 4-[[[2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl)carbonyl]amino]-N-[[1-[4-(methylsulfonyl)butyl]cyclopentyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1999:166588 CAPLUS Full-text  
 DN 130:196952

TI Preparation of N-alkanoylphenylalanine derivatives as vascular cell  
 adhesion molecule-1 (VCAM-1) binding inhibitors  
 IN Chen, Li; Guthrie, Robert William; Huang, Tai-Nang; Hull, Kenneth G.;  
 Sidduri, Achyutharao; Tilley, Jefferson Wright  
 PA F. Hoffmann-La Roche A.-G., Switz.  
 SO PCT Int. Appl., 135 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9910312	A1	19990304	WO 1998-EP5135	19980813
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2301377	A1	19990304	CA 1998-2301377	19980813
	AU 9892620	A	19990316	AU 1998-92620	19980813
	AU 739511	B2	20011011		
	EP 1005445	A1	20000607	EP 1998-945235	19980813
	EP 1005445	B1	20040526		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000482	T2	20000621	TR 2000-482	19980813
	BR 9811730	A	20000905	BR 1998-11730	19980813
	HU 2000003642	A2	20010228	HU 2000-3642	19980813
	HU 2000003642	A3	20011128		
	JP 2001514162	T	20010911	JP 2000-507643	19980813
	JP 3555876	B2	20040818		
	NZ 502813	A	20021025	NZ 1998-502813	19980813
	RU 2220950	C2	20040110	RU 2000-106434	19980813
	EP 1403247	A1	20040331	EP 2003-27533	19980813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	AT 267801	T	20040615	AT 1998-945235	19980813
	PT 1005445	T	20040930	PT 1998-945235	19980813
	ES 2221197	T3	20041216	ES 1998-945235	19980813
	IL 134550	A	20051218	IL 1998-134550	19980813
	PL 193283	B1	20070131	PL 1998-338857	19980813
	ZA 9807604	A	19990518	ZA 1998-7604	19980821
	US 6229011	B1	20010508	US 1998-137798	19980821
	TW 490458	B	20020611	TW 1998-87113768	19980821
	IN 1998MA01892	A	20050304	IN 1998-MA1892	19980821
	EG 23729	A	20070628	EG 1998-981	19980822
	IN 1998MA01897	A	20070525	IN 1998-MA1897	19980824
	HR 2000000080	A1	20001231	HR 2000-80	20000211
	MX 200001744	A	20001211	MX 2000-1744	20000218
	NO 2000000841	A	20000221	NO 2000-841	20000221
PRAI	US 1997-56718P	P	19970822		
	US 1998-94592P	P	19980729		
	EP 1998-945235	A3	19980813		
	WO 1998-EP5135	W	19980813		

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [one of X, X1 = H, halo, lower alkyl and the other = (un)substituted group X6, X7, X10; R1 = H, lower alkyl; n = 0, 1; Het = 5-6 membered heteroarom. ring containing 1-3 heteroatoms N, O, S, or 9-10 membered bicyclic heteroarom. ring containing 1-4 heteroatoms N, O, S; R18 = lower alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; R19 = (un)substituted lower alkyl, aryl, heteroaryl; R20 = lower alkyl, lower alkanoyl; R19R20 = (CH2)4; Y = group Y1, (un)substituted 5-6 membered monocyclic heteroarom. group containing 1-3 heteroatoms N, O, S, 9-10 membered bicyclic heteroarom. group containing 1-4 heteroatoms N, O, S; R22, R23 = H, lower alkyl, lower alkoxy, lower alkoxyaryl, lower alkylamino, aryl, arylalkyl, NO2, CN, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkanoyl, halo, perfluoroalkyl; both R22 and R23 ≠ H; R24 = H, OH, lower alkyl, lower alkoxy, lower alkylsulfonyl, amino, aryl, NO2, CN, halo, (un)substituted 1-amino-5-tetrazolyl, sulfonamido, carboxamido; R22R24 = fused benzene ring; Z = H, lower alkyl; R31 = H, (un)substituted lower alkyl] and pharmaceutically acceptable salts and esters thereof, are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing integrin VLA-4. Such compds. are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4. Thus, amidation of 4-amino-N-tert-butoxycarbonyl-L-phenylalanine Me ester with 2,6-dichlorobenzoyl chloride, followed by acidic deprotection, amidation with 2-chloro-6-methylbenzoic acid, and saponification gave desired title derivative II. II inhibited VLA-4 binding to immobilized VCAM-1 with IC50 = 0.33 nM in solid-phase dual antibody assay.

IT 220848-10-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-alkanoylphenylalanine derivs. as vascular cell adhesion mol.-1 (VCAM-1) binding inhibitors)

RN 220848-10-2 CAPLUS

CN L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-[[[(2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl)carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI New Azole Antifungals. 2. Synthesis and Antifungal Activity of Heterocyclecarboxamide Derivatives of 3-Amino-2-aryl-1-azoly-2-butanol

AU Bartroli, Javier; Turmo, Enric; Alguero, Monica; Boncompte, Eulalia; Vericat, Maria L.; Conte, Lourdes; Ramis, Joaquim; Merlos, Manuel; Garcia-Rafanell, Julian; Forn, Javier

CS Research Center, J. Uriach Cia. S.A., Barcelona, 08026, Spain

SO Journal of Medicinal Chemistry (1998), 41(11), 1855-1868


CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society


DT Journal

LA English

GI



I



II

AB A series of 92 azole antifungals containing an amido alc. unit was synthesized. The nature and substitution of the amide portion was systematically modified in search of improved antifungal activity, especially against filamentous fungi. The compds. were tested in vitro against a variety of clin. important pathogens and in vivo (po) in a murine candidosis model. Thiazole and thiophene carboxamides carrying both a substituted Ph ring and a small alkyl group were best suited for activity against filamentous fungi. In a subset of these compds., the amide portion was conformationally locked by means of a pyrimidone ring and it was proven that only an orthogonal orientation of the Ph ring yields bioactive products. A tendency to display long plasma elimination half-lives was observed in both series. Two compds., I and 107, representative of the open and cyclic amides, resp., were chosen for further studies. Both candidates showed excellent activity in in vivo murine models of candidosis and aspergillosis, but their long elimination rates and high toxicities were still unsatisfactory. This work describes the SARs found within this series. The next paper displays the results obtained in a related series of compds., the quinazolinones.

IT 18/998-15-EP 205632-18-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and antifungal activity of heterocyclecarboxamide derivs. of 3-amino-2-aryl-1-azoly-2-butanol)

RN 187998-15-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-7-methyl-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 205692-18-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,7-dimethyl-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 45      THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:483984 CAPLUS Full-text

DN 127:171090

TI N-Arylpiperazinyl-N'-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective  $\alpha 1$ -Adrenoceptor Antagonists

AU Elworthy, Todd R.; Ford, Anthony P. D. W.; Bantle, Gary W.; Morgans, David J., Jr.; Ozer, Rachel S.; Palmer, Wylie S.; Repke, David B.; Romero, Magarita; Sandoval, Leticia; Sjogren, Eric B.; Talamas, Francisco X.; Vazquez, Alfredo; Wu, Helen; Arredondo, Nicolas F.; Blue, David R.; DeSousa, Andrea; Gross, Lisa M.; Kava, M. Shannon; Lesnick, John D.; Vimont, Rachel L.; Williams, Timothy J.; Zhu, Quan-Ming; Pfister, Juerg R.; Clarke, David E.

CS Roche Bioscience, Palo Alto, CA, 94304-1397, USA

SO Journal of Medicinal Chemistry (1997), 40(17), 2674-2687

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Novel arylpiperazines were identified as  $\alpha 1$ -adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(Ortho-Substituted phenyl)piperazin-1-yl]propylamines were treated with N,N-di-Me anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a "neg. screen" for the test antagonists. Binding to  $\alpha 1$ -ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides and pyrazolo[3,4-b]pyridines ligands with nanomolar affinity at the  $\alpha 1$ -AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, resp.) and displaying 2-3 orders of magnitude selectivity over the  $\alpha 1D$ -AR.

IT 193975-30-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpiperazinylpropylamino derivs. of heteroaryl amides as adrenoceptor antagonists)


RN 193975-30-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 3-chloro-7-[[3-[4-(4-fluoro-2-methoxyphenyl)-1-piperazinyl]propyl]amino]-N,N-dimethyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 193975-29-0

CMF C23 H29 Cl F N7 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4



RE.CNT 52      THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:226815 CAPLUS Full-text

DN 126:212156

TI Preparation of heteroarylcarboxamides as agrochemical and medical fungicides

IN Bartroli, Javier; Turmo, Enric; Anguita, Manuel

PA J. Uriach & Cia. S.A., Spain

SO PCT Int. Appl., 84 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9705131	A1	19970213	WO 1996-EP3419	19960802
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	ES 2107376	A1	19971116	ES 1995-1564	19950802
	ES 2107376	B1	19980701		
	BR 9606546	A	19980714	BR 1996-6546	19950802
	ES 2112774	A1	19980401	ES 1995-2042	19951020
	ES 2112774	B1	19990516		
	CA 2201478	A1	19970213	CA 1996-2201478	19960802
	AU 9667889	A	19970226	AU 1996-67889	19960802
	EP 783502	A1	19970716	EP 1996-928404	19960802
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10507205	T	19980714	JP 1996-507253	19960802
	US 5888941	A	19990330	US 1997-809815	19970331
	NO 9701471	A	19970530	NO 1997-1471	19970401
PRAI	ES 1995-1564	A	19950802		
	ES 1995-2042	A	19951020		
	WO 1996-EP3419	W	19960802		
OS	MARPAT 126:212156				
GI					



II

AB RCH2CR5(OR4)CR1R2NR3COZ1(CH2)mZ2(CH2)qR6 [I; R = imidazolo or 1,2,4-triazo-1-yl; R1 = alkyl; R2 = H or alkyl; R1R2 = alkylene; R3 = H (halo)alkyl, Ph, etc.; R4 = H; R3R4 = CH2, CH2CH2, CH(OH)CH2, COCH2; R5 = (halo- or CF3-substituted) Ph; R6 = (un)substituted Ph, -heterocyclyl; Z1 = (un)substituted



phenylene or -heterocycliyene; Z2 = bond, O, S00-2, NR6; m,q = 0-2] were prepared Thus, (2R,3R)-3-amino-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol was amidated by 1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid (preparation given) to give title compound (R,R)-II. Data for biol. activity of I were given.

IT 187998-15-8P


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylcarboxamides as agrochem. and medical fungicides)

RN 187998-15-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-7-methyl-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1992:511639 CAPLUS Full-text

DN 117:111639

TI Preparation of pyrimidine derivatives as androgen inhibitors

IN Kiyokawa, Hiroshi; Yamada, Satoshi; Miyajima, Keisuke; Hashimoto, Kinji;  
Inai, Masatoshi; Inoue, Makoto; Tatsumi, Kunihiro; Yamauchi, Takeshi;  
Kurisu, Kazunobu

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 132 pp.


CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9206096	A1	19920416	WO 1991-JP1367	19911007
	W: AU, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9186261	A	19920428	AU 1991-86261	19911007
	AU 639615	B2	19930729		
	EP 503099	A1	19920916	EP 1991-917341	19911007
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 05000948	A	19930108	JP 1991-259198	19911007
	CN 1060844	A	19920506	CN 1991-109738	19911009
	CN 1030768	B	19960124		
	JP 05112571	A	19930507	JP 1991-262099	19911009
	US 5420128	A	19950530	US 1992-854619	19920609
	AU 9338775	A	19930826	AU 1993-38775	19930524
	AU 653103	B2	19940915		
PRAI	JP 1990-270970	A	19901009		
	JP 1990-282745	A	19901019		
	JP 1991-218927	A	19910829		
	WO 1991-JP1367	A	19911007		
OS	CASREACT 117:111639; MARPAT 117:111639				
GI					



I



II


AB Pyrazolopyrimidine derivs. [I; R1 = H, OH; R2 = H, alkoxycarbonyl, alkoxy, halo, alkyl, etc.; R3 = H, OH, alkyl, C3-8 cycloalkyl, etc.; R4 = H, alkyl, alkoxy; R5 = H, (halo)alkyl, alkoxyalkyl], useful in treating prostatic hyperplasia, female hypertrichosis, and male baldness or pimples, are prepared Heating a mixture of 2.97 g pyrazole derivative II and 2.16 g EtOCH<sub>2</sub>C(CO<sub>2</sub>Et)<sub>2</sub> (III) in HOAc at 90-110°, and with 0.21 g addnl. III, gave 1.69 g I (R1 = OH, R2 = CO<sub>2</sub>Et), R3-R5 = H), which showed IC<sub>50</sub> of 2.0 × 10<sup>-6</sup> M against specific binding with 3H-5α-dihydrotestosterone, vs. »1 × 10<sup>-5</sup> M with flutamide.

IT 142664-57-1P 142664-50-6P 142664-61-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as androgen inhibitor)


RN 142664-57-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-hydroxy-N-phenyl-3-[4-(phenylthio)phenyl]- (CA INDEX NAME)




RN 142664-60-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-hydroxy-3-[4-(phenylthio)phenyl]-N-(3,4,5-trichlorophenyl)- (CA INDEX NAME)



RN 142664-61-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(1,1-dimethylethyl)-7-hydroxy-3-[4-(phenylthio)phenyl]- (CA INDEX NAME)



L10 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1991:237536 CAPLUS Full-text

DN 114:237536

TI Pyrazolopyrimidinone cyan photographic coupler and silver halide photographic photosensitive material containing same

IN Shishido, Tadao; Yamakawa, Kazuyoshi; Kobayashi, Hidetoshi

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 34 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 02214858	A	19900827	JP 1989-37067	19890216
PRAI	JP 1989-37067		19890216		
GI					




AB The title coupler is a pyrazolo[1, 5-a]pyrimidine-5(4H)-one derivative I (X = H, a group to be eliminated upon coupling with an oxidized color developing agent; R1, R2, R3 = H, a substituent). In the title material having on a support at least 1 Ag halide emulsion layer, at least 1 of the Ag halide emulsion layers contains the title coupler.

IT 133940-11-1

RL: TEM (Technical or engineered material use); USES (Uses)  
(cyan photog. coupler, for silver halide photosensitive materials)

RN 133940-11-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[3-(2,4-bis(1,1-dimethylpropyl)phenoxy)propyl]-3-chloro-4,5-dihydro-7-methyl-2-(1-methylethyl)-5-oxo- (CA INDEX NAME)



L10 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:17411 CAPLUS Full-text

DN 84:17411

OREF 84:2891a,2894a

TI Thiophosphoric acid esters and pesticidal compositions containing them

IN Scherer, Otto; Mildenerger, Hilmar

PA Hoechst A.-G., Fed. Rep. Ger.

SO Ger., 3 pp.

CODEN: GWXXAW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----		-----	-----	-----
PI	DE 1642260	A	19711202	DE 1967-F52467	19670520
	DE 1642260	B2	19750731		
	DE 1642260	C3	19760311		
PRAI	DE 1967-F52467	A	19670520		

GI For diagram(s), see printed CA Issue.


AB Pyrazolopyrimidinyl thiophosphates I [R = P(S)(OEt)2] were prepared by esterification of I [R = H] with (EtO)2P(S)Cl. Thus, I (R = R1 = H, R2 = CO2CH2C.tplbond.CH) and (EtO)2P(S)Cl gave I [R = P(S)(OEt)2, R1 = H, R2 = CO2CH2C.tplbond.CH]. Similarly prepared were I [R = P(S)(OEt)2, R1, R2 given]: Br, CO2CH2C.tplbond.CH; H, CONMe2; H, CO2Et. Extensive data were given for the effectiveness of I in treatment of mildew.

IT 57615-04-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(esterification of, with thiophosphoryl chlorides)

RN 57615-04-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 2-hydroxy-N,N,5-trimethyl- (9CI)  
(CA INDEX NAME)




IT 57615-01-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and fungicidal activity of)

RN 57615-01-7 CAPLUS

CN Phosphorothioic acid, O-[6-[(dimethylamino)carbonyl]-5-methylpyrazolo[1,5-a]pyrimidin-2-yl] O,O-diethyl ester (CA INDEX NAME)



AB cf. C.A. 52, 2021f. The conversion of 3-amino-5-phenylpyrazole (I) and 3-amino-5-methyl-2-phenylpyrazole (II) to pyrazolopyrimidines, pyrazolotriazines, formamidines (III), hydrazidines (IV), and pyracriazines is described; to elucidate the course of the reaction between III and IV, PhNHCH:NPh (V) is studied. I and BzCH<sub>2</sub>CN in equimolar amts. heated 1 hr. at 140-50° first melt and then solidify; the product is cooled, taken up with EtOH, filtered, and crystallized from EtOH to give 7-imino-2,5-diphenylpyrazolo [2,3-a]-4,7-dihydropyrimidine, m. 275-8°. I and H<sub>2</sub>NC(:NH)NHCN in equimolar amts. are heated 30 min. at 160°, cooled, taken up in EtOH, filtered, and the residue crystallized from AcOH to give 5,7-diimino-2-phenylpyrazolo[2,3-a]-4,5,6,7-tetrahydro-s-triazine (VI), m. 338-40°. VI (0.5 g.) refluxed 2 hrs. with 5 g. Ac<sub>2</sub>O gives a diacetyl derivative, C<sub>15</sub>H<sub>14</sub>O<sub>2</sub>N<sub>6</sub>, m. 246° (EtOH). VI (0.5 g.) is refluxed 2 hrs. with 20 ml. 20% aqueous KOH, neutralized with HCl to pH 6.5, and the precipitate crystallized from AcOH to give a product of uncertain structure, C<sub>11</sub>H<sub>9</sub>O<sub>5</sub>N<sub>5</sub>, m. above 300° (acetyl derivative, C<sub>13</sub>H<sub>11</sub>O<sub>2</sub>N<sub>5</sub>, m. 292-4°). I and (CH<sub>2</sub>CO)<sub>2</sub>NH (VII) in equimolar amts. are heated 40 min. at 300°, cooled, extracted repeatedly with hot alc. to give as residue 3-phenyl-5- succinimidopyrazole, m. 304-5°. Similarly, phthalimide (VIII) gives 3-phenyl-5-phthalimidopyrazole (IX), m. 294-5°. IX (0.5 g.) refluxed 2 hrs. with 5 g. Ac<sub>2</sub>O gives the 1-acetyl derivative, m. 169° (EtOH). II does not react with VII and VIII under the same conditions as I. I and (CH<sub>2</sub>CO)<sub>2</sub>O in equimolar amts. are heated 30-40 min. at 180-200°, cooled, extracted with EtOAc, and the residue crystallized from H<sub>2</sub>O to give N-(3-phenyl-5-pyrazolyl) succinamic acid (X), m. 171-2°. X (0.5 g.) in AcOH treated with 3 drops HCl and a slight excess of 10% aqueous KI in the cold gives the 4-nitroso derivative, green crystals. I (1 g.) is heated with 1 g. (NHCHO)<sub>2</sub> (XI) 20 min. at 150°, cooled, and taken up with and crystallized from hot EtOH to give 3-formamido-5-phenylpyrazole (XII), m. 228-30°. I (1 g.) is heated with 3 g. XI 2 hrs. at 200°, cooled, and extracted with Et<sub>2</sub>O to give 4-(3-phenyl-5-pyrazolyl)-1,2,4-triazole, m. 192° (EtOAc); similarly, II gives 4-(3-methyl-1-phenyl-3-pyrazolyl)-1,2,4-triazole, m. 173-5° (H<sub>2</sub>O). I (1 g.) and 3 g. CH(OEt)<sub>3</sub> (XIII) refluxed 40 min. in 50 ml. EtOH, the product filtered off, and crystallized from EtOH give N,N'-bis(3-phenyl-5-pyrazolyl)formamidine (XIV), 263-5°. II (1 g.) and 1 g. XIII are heated 1 hr. at 130°, 5 g. EtOH and 200 ml. H<sub>2</sub>O added to precipitate an oil which slowly solidifies, the product separated, and crystallized from EtOAc to give N,N'-bis(3-methyl-1-phenyl-5- pyrazolyl)formamidine (XV), m. 65°. XIV (1 g.) in 20 ml. EtOH is refluxed 20 min. with 0.4 g. PhNHNH<sub>2</sub> and H<sub>2</sub>O added to precipitate the phenylhydrazone of XII, yellow-orange, m. 168-70° (dilute aqueous EtOH). XIV and NCCH<sub>2</sub>CONHNH<sub>2</sub> (XVI) are heated 3 min. at 120°, extracted with hot EtOH, cooled, and filtered to give the 3-phenyl-5-pyrazolyl aminomethylenehydrazide of cyanoacetic acid (XVII), m. 185-6° (MeOH). XIV (1 g.) and 1 g. 7-methyl-2-phenylpyrazolo[2,3-a]pyrimidine-5- carbohydrazide (XVIII) are heated at 160° until the mixture softens, cooled rapidly, and MeOH added to give 3-phenyl-5- pyrazolylaminomethylenehydrazide (XIX) of 7-methyl-3phenyl-5-pyrazolo[2,3- a]pyrimidine-5-carboxylic acid (XX), yellow, m. 238-40° (MeOH) (decomposition). XIX (0.5 g.) refluxed 30 min. with 5 g. Ac<sub>2</sub>O, evaporated to half volume, and hot H<sub>2</sub>O added gives on cooling the diacetyl

derivative, C28H24O3N6, m. 283-5° (AcOH). XIX heated 15 min. at 250-60°, the product taken up with 1:1 EtOH-Et2O and crystallized from MeOH gives 7-methyl-2-phenyl-5-[4-(3-phenyl-5-pyrazolyl)-1,2,4-triazolyl]pyrazolo[2,3-a]pyrimidine, m. 212-14°. V and BzNHNH2 in equimolar ams. are heated 5 min. at 160°, cooled, taken up with EtOH and filtered to give BzNHN:CHNPh (XXI) m. 222-4° (EtOH). XXI heated 10-15 min. at 250° and taken up with and crystallized from H2O gives 4,5-diphenyl-1,2,4-triazole, m. 125-7°. V and XVI in equimolar ams. heated 10 min. at 100°, cooled rapidly, taken up with EtOH, and filtered give PhNHCH:NN:(OH)CH2CN (XXII), m. 180-2° (EtOH). XXII (0.5 g.) refluxed 2 hrs. in AcOH, evaporated to dryness and treated with H2O gives 4-phenyl-1,2,4-triazol-3-yl acetonitrile m. 158-60°. V and XVIII in equimolar ams. heated 5 min. at 160-70°, cooled slowly to 100°, cooled completely, taken up in EtOH, filtered, and crystallized from dioxane give the anilinomethylenshydrazide (XXIII) of XX, m. 252-4° (decomposition). XXIII (0.5 g.) heated 20 min. at 280°, the semisolid product taken up in a little alc., filtered, and crystallized from a little MeOH gives 7-methyl-2-phenyl-5-(4-phenyl-1,2,4-triazol-3-yl)pyrazolo [2,3-a] pyrimidine, m. 212-4°. XV (1 g.) heated with 0.05 g. PhNH2 1 hr. at 220° and taken up with a little EtOH gives 3,4-dimethyl-1,6-diphenyl-7,8-pyrazine (XXIV) (pyrazine = C.A. dipyrazolo[3,4-b; 4',3'-e]-1,7-dihydropyridine), m. 205° (EtOH). XVI (1 g.) heated with 0.05 g. PhNH2 2 hrs. at 260°, taken up with alc., filtered, and crystallized from MeOH gives 3,4-diphenyl-7,8-pyrazine (XXV), m. above 300°. XXV is also obtained by heating XII, alone or with I, 2 hrs. at 250-60°. XXV (1 g.) refluxed 1 hr. in Ac2O gives the 1,6-diphenyl derivative, m. 264-5° (AcOH). I (2 g.) heated 6 hrs. at 250°, taken up with EtOH, filtered, and crystallized from AcOH gives bis(3-phenyl-5-pyrazolyl)amine (XXVI), m. 294-5°. XXVI (1 g.) heated 2 hrs. at 260-80° with 1.6 g. V or 4,4'-EtOC6H4NHC:NC6H4OEt gives XXV. Mixts. of I and XII or of III and XII in these conditions give XXIV and XXV, not the unsym. substituted derivs. XXVI (0.5 g.) treated at 300-20° with a large excess of (CH2O)3 in small portions, cooled, taken up with EtOH, and the residue boiled with AcOH gives a very small yield of a substance of uncertain structure, C19H15N5, m. 350° (acetyl derivative prepared but no properties given). XXVI boiled 1 hr. in a large excess of Ac2O gives the 2,2'-diacetyl derivative, m. 242-4°. XXVI (0.5 g.) dissolved in the min. amount of 10% aqueous NaOH and treated with 2 g. BzCl ppts. the 2,2'-di-Bz derivative, m. 227-8°. XXVI (1 g.) and 1 g. AcCH2CO2Et (XXVII) refluxed 2 hrs. in AcOH, the product filtered off, washed with EtOAc, and crystallized from AcOH gives a compound, C22H17ON5, m. 334° (XXVIII) (monoacetyl derivative m. 265-7°). XXVIII is also obtained from 1 g. XXV and 3 g. XXVI heated 1 hr. at 160°. XXVI (0.5 g.) in AcOH treated with 2 g. Br gives C18H13N5Br2 (XXIX), m. 267-8° (AcOH). XXIX heated with 3 moles XXVII 8 min. at 170° gives C18H12N5Br (XXX), m. 217-18° (AcOH). XXIX heated 1 hr. at 170° with excess XXVI gives XXVIII. Bis(5-amino-3-methyl-1-phenyl-4-pyrazolyl)benzimidene heated 1 hr. at 220° gives 3,5-dimethyl-1,4,7-triphenyldipyrazolo[3,4-b; 4',3'-e]-1,7-dihydropyridine, m. 235-7°.


IT 117882-75-4P, Hydrazine, 1-acetyl-2-[[1-(acetyl-3-phenylpyrazol-5-yl)amino]methylene]-1-(7-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-5-ylcarbonyl)-

RL: PREP (Preparation)

(preparation of)

RN 117882-75-4 CAPLUS

CN Hydrazine, 1-acetyl-2-[[1-(acetyl-3-phenylpyrazol-5-yl)amino]methylene]-1-(7-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-5-ylcarbonyl)- (6CI) (CA INDEX NAME)





TI 5-Aminopyrazole derivatives. III. Acids of pyrazopyrimidine, pyrazopyridone, pyrazopyridine, and some derivatives

AU Checchi, Silvio; Papini, Piero; Ridi, Mario

CS Univ. Florence

SO Gazzetta Chimica Italiana (1956), 86, 631-45

CODEN: GCITA9; ISSN: 0016-5603

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. C.A. 50, 10731g. Derivs. of 3-phenyl-5-aminopyrazole (I) were prepared by heating with 1.5 parts reagent to 100°, filtering off the precipitate, and crystallizing from 95% alc.; the materials reacted also in boiling HOAc or simply ground in a mortar at room temperature I reacted with acetoneoxalic (II), oxaloacetic (III),  $\alpha$ -oxalopropionic (IV), and acetonesuccinic ester (V) to give, resp., 3-phenyl-4'-methyl-1,5,2',3'-pyrazo-6-carbethoxy- 2',3'-dihydropyrimidine (VI), m. 156-8°, the 4-oxo-1',2',3',4'- tetrahydro compound (VII), m. 270-2°, the 5'-Me analog (VIII), m. 220-1°, and 3-phenyl-6'-methyl-4'-oxo-1,5:2',3'-pyrazo-5'- carbethoxymethyl-1',2',3',4'-tetrahydropyrimidine (IX), m. 242-4°. Similarly, molar amts. of 1,3-diphenyl-5-aminopyrazole (X) and II refluxed 1 hr. and cooled with EtOAc yielded 1,3-diphenyl-4'-methyl-4,5:5',6'- pyrazo-2'-carbethoxypyridine, m. 163-5°; 1-phenyl-3-methyl-5-aminopyrazole (XI) and II gave the 1-phenyl-3,4'-dimethyl compound (XII), m. 103-5°. X and IV refluxed 2 hrs. in HOAc gave 1,3-diphenyl-3'- methyl-4,5:5',6'-pyrazo-2'-carbethoxy- $\gamma$ -pyridone, m. 202-5°, XI and III gave the 1-phenyl-3-methylpyrazopyridone, m. 110°, and X and IV gave the 1-phenyl-3,3'-dimethyl compound, m. 174-6°. 3-Phenyl-4,6-dimethyl-5-aminopyrazole with V 20 min. at 140° gave 3-phenyl-4,6'-dimethyl-1,2:2',3'-pyrazo-5-carbethoxymethyl-1',2',3',4'- tetrahydropyrimidine (XIII), m. 270-2°. Et esters prepared above were hydrolyzed to the acids by refluxing 30 min. with 50 cc. 10% KOH, filtering, cooling, acidifying, washing the precipitate with hot H<sub>2</sub>O, and crystallizing from alc. or aqueous alc.; from VI, VII, VIII, IX, XII, and XIII were obtained acids (XIV, XV, XVI, XVII, XVIII, and XIX), resp., decompose 225-7°, 323-5°, 290-300°, 314-16°, 194-6°, and 308-10°. The Na salt of XIV, m. above 300°, was obtained by heating 0.5 g. VI 20 min. with 20 cc. 15% NaOH. The imines of XV and XVI were methylated by cold treatment of 0.5 g. in 10 cc. 5% KOH with 1 equivalent Me<sub>2</sub>SO<sub>4</sub> to give the N-Me compds. (XX and XXI), m. 172-5° and 272-4°, resp. Decarboxylation about 20° above the m.p. of XIV, XVI, XVII, XX, and XXI yielded the compds. (XXII, XXIII, XXIV, XXV, and XXVI), m. 95-6°, above 350°, 65-6°, 192-4°, and 246-8°. XXV was also obtained by methylation of XXIII. 4-NO derivs. were prepared by treating 0.5 g. compound in 10 cc. HOAc with 5 drops concentrated HCl, cooling to 35°, and adding an equivalent aqueous KNO<sub>2</sub> [compound and m.p. of derivative (from alc.) given]: VIII, 235°; IX, 239°; XV, 265°; XVI, 243° (yellow from water, green from dioxane); XVII, 259°; and XXVI, 253°. A hydrazide was prepared by heating 0.5-1 hr. at 100° 2 g. VI with 5 g. N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O, taking up, and crystallizing from absolute MeOH; VI gave the hydrazide of XIV, m. 194-5° [monoacetate, m. 271° (HOAc); diacetate, m. 215°, reversible to the monoacetate by boiling with 10% NaOH]. Similarly, the hydrazide of XVIII, m. 179-81° (H<sub>2</sub>O), was prepared from XII (diacetate, m. 254-5°), and the hydrazide of XVI, m. above 330°, from VIII. Reduction of the 4-NO to the 4-NH<sub>2</sub> derivs. was difficult; only that of IX, m. 275-7°, was obtained with Zn in hot HOAc by evaporating the filtrate and crystallizing from alc. and H<sub>2</sub>O. Phenylformylacetic ester with X and I 1 hr. at 100° gave PhN.N:C:Ph.CH:CN:CHCHPhCO<sub>2</sub>Et, m. 118-20°, and HN.N:C:Ph.CH:CN:CHCHPhCO<sub>2</sub>Et, 178-80° (mono-Ac derivative, m. 123-4°; pyrolysis product, N:CH.CHPh.CO.N:C:CH.CPh: N, after 20 min. at 200°, m. 320°).

IT 107621-62-5P, Hydrazine, 1,2-diacyl-1-(7-methyl-2-


phenylpyrazolo[1,5-a]pyrimidin-5-ylcarbonyl)-

RL: PREP (Preparation)


(preparation of)

RN 107621-62-5 CAPLUS

CN Hydrazine, 1,2-diacetyl-1-(7-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-5-ylcarbonyl)- (6CI) (CA INDEX NAME)




=> d l2; d l6; d his; log y  
L2 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.  
L2 QUE ABB=ON PLU=ON L1

L6 HAS NO ANSWERS  
L5 STR



Structure attributes must be viewed using STN Express query preparation.  
L6 QUE ABB=ON PLU=ON L5

(FILE 'HOME' ENTERED AT 18:24:42 ON 20 MAR 2008)

FILE 'REGISTRY' ENTERED AT 18:25:00 ON 20 MAR 2008

L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 50 S L2  
L4 3086 S L2 FUL  
L5 STRUCTURE UPLOADED  
L6 QUE L5  
L7 41 S L6 SAM SUB=L4  
L8 769 S L6 FUL SUB=L4  
L9 2317 S L4 NOT L8

FILE 'CAPLUS' ENTERED AT 18:27:56 ON 20 MAR 2008

L10 41 S L9

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	227.29	449.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-32.80	-32.80

STN INTERNATIONAL LOGOFF AT 18:32:40 ON 20 MAR 2008